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Abstract 
Toxoplasma gondii is a widely distributed protozoan parasite, estimated to infect 
25-50% of the global human population. While most infections are asymptomatic, 
AIDS-associated toxoplasmic encephalitis causes a high level of morbidity and 
mortality and this is a particular problem in sub-Saharan Africa, where HIV affects a 
substantial part of the population. Despite the scale of the problem, virtually 
nothing has been known about the T. gondii strains present in Africa. The work 
presented in this thesis showed for the first time that all the three main clonal 
lineages of T. gondii are present and cause disease in African HIV-patients, and that 
genotype II was the most common in Uganda. Subsequent isolation of eight strains 
revealed that the T. gondii parasites in Uganda are highly similar to the strains 
found in Europe and North America, but over 1,200 novel mutations were identified 
and many of these were indicative of positive selection of genes active in the 
interface with the host. An important finding was the discovery of a rare natural 
recombinant strain, which possessed genetic elements from both genotype II and III 
and displayed an intermediate in vivo growth rate, compared with the genuine type 
II and III strains from the same area. Whole genome sequencing of this isolate 
revealed that sexual recombination may be more frequent than previously thought, 
but that selective pressures appear to favour a conserved genetic composition. The 
studies included in this thesis provide novel insight into the genotype and 
phenotype of T. gondii strains from Africa, and describe for the first time the 
genomics of a natural recombinant T. gondii strain. 
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Chapter 1 Introduction 
1.1 The parasite, Toxoplasma gondii 
1.1.1 History and classification 
Toxoplasma gondii is an obligate intracellular protozoan parasite that infects a 
wide range of warm-blooded animals, including humans (Dubey and Beattie, 1988). 
It was first identified in 1908, by two separate research groups. Alfonso Splendore 
at the Bacteriological Institute in Sao Paolo found the parasite in a rabbit, but 
misidentified the protozoan as a species of Leishmania (Splendore, 1908). Charles 
Nicolle and louis Mancaeux at the Pasteur Institute in Tunis discovered the parasite 
in the North African rodent Ctenodactylus gundi which, although misspelt, gave the 
parasite its species name (Nicolle and Manceaux, 1908). Initially they named the 
parasite Leishmania gondii, but in 1909 the genus Toxoplasma was introduced 
(Nicolle and Manceaux, 1909). The name refers to the crescent morphology of the 
organism; toxon means crescent-shaped in Greek and plasma means form (Hill et 
aI., 2005). In the following decades, several species of Toxoplasma were named 
(levine, 1977), but all of these were later reclassified as T. gondii or moved to other 
genera including Hammondia, Atoxoplasma and Isospora. T. gondii was first 
recognised as a human pathogen in the 1930s, when it was shown to cause 
encephalitis in neonates (Wolf et aI., 1939), but the life cycle of the organism as well 
as transmission routes remained largely unknown until cats were identified as the 
definitive hosts in the late 1960's (see section 1.1.2). 
Toxoplasma belongs to the phylum Apicomplexa, an ancient phylum that may 
date back as long as 1 billion years, based on analysis of small subunit rRNA (Sogin 
and Silberman, 1998). The phylum consists of several thousands of species, nearly 
all of which are obligate intracellular parasites (levine, 1988), the main exception 
being the early branching extracellular Gregarines (leander, 2008). Many important 
human and veterinary pathogens are found within the Apicomplexa, including 
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Plasmodium, the causative agent of malaria; Cryptosporidium, which causes 
gastrointestinal disease; Eimeria, an important pathogen in poultry; and Theileria 
and Babesia, which can cause fatal disease in cattle. An overview of the relationship 
between Toxoplasma and other Apicomplexa and their taxonomic placement in 
relation to other protozoan parasites and major organism groups is shown in a 
cladistic tree in Figure 1-1. 
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Figure 1-1. Cladogram placing Toxoplasma in the tree of life. Toxoplasma belongs to the phylum 
Apicomplexa and is a coccidian parasite closely related to Neospora and Sarcocystis spp. The tree is 
abstracted from the NCBI taxonomy database (http://www.ncbLnlm. nih.gov/Taxonomy/). 
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The type characteristics of the phylum Apicomplexa are seen in organelles 
adapted to allow intracellular invasion, including the apical complex and a range of 
secretory organelles (Dubremetz et aL, 1998). However, apicomplexan parasites 
differ in many other important aspects of their biology, including host and tissue 
specificity, intracellular location, organelle content, transmission route and both 
sexual and asexual development (Plattner and Soldati-Favre, 2008). Two remarkable 
traits that set Toxoplasma apart from the majority of apicomplexan parasites are 
the capacity to invade and propagate in almost any cell type in a wide range of host 
species as well as its ability of direct transmission between intermediate hosts, thus 
circumventing the sexual cycle. Most parasites are highly specific, for example there 
are dozens of species of Plasmodium with a definite intermediate host range (Rich 
and Ayala, 2003) and among the hundreds of Eimeria species, seven are exclusively 
specialized to chickens, each targeting a discrete area of the gut (Morris and Gasser, 
2006). T. gondii on the other hand, has been isolated from hundreds of different 
host species all over the world (Tenter et aL, 2000), and has even been shown to 
invade, but not persist in fish cells (Omata et aL, 2005), even though cold-blooded 
animals are not within the known host range. The ease with which T. gondii is 
cultivated both in vivo and in vitro, and the possibility of genetic manipulation, has 
made it a favourite model organism for investigation of the cellular and molecular 
biology of the phylum (see 1.1.3). 
1.1.2 Life cycle 
T. gondii has a complex life cycle. Asexual replication can take place in a wide 
range of mammals and birds, while the sexual cycle, which results in shedding of 
environmentally resistant oocysts, only takes place in the epithelial cells of the small 
intestine of feline hosts (for a life cycle overview, see Figure 1-2). The understanding 
of the T. gondii life cycle began to unfold when J.K.A. Beverley proved successive 
congenital transmission in mice (Beverley, 1959) and G. Desmonts showed that 
consumption of raw meat was an important route of infection in humans 
(Desmonts et aL, 1965). W.M. Hutchison provided the first indication that cats were 
important for transmission in 1965 (Hutchison, 1965), and two years later he 
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proposed that T. gondii was transmitted inside the eggs of the cat nematode 
Toxocara cati (Hutchison, 1967). In the years to follow, several different groups 
- showed that T. gondii transmission in cats was independent of the worm 
(summarized in Frenkel, 1973), and the T. gondii oocyst was finally described in 
1970 by J.P. Dubey, N.lo Miller and J.K. Frenkel (Dubey et aI., 1970). Subsequently, a 
number of other species were investigated, but only felids including bobcats, 
ocelots and cougars, were found to shed oocysts (Dubey and Beattie, 1988). 
Figure 1-2. life cycle of Toxoplasma gondii. (a) Felids are the definitive hosts and excrete T. gondii 
oocysts, which contaminate soil, water and vegetation . (b) Parasites ingested by intermediate hosts 
undergo initial rapid division and dissemination as tachyzoites, before transformation into 
bradyzoites in tissue cysts, which can persist for the lifetime of the host. (c) In order to return to the 
sexual cycle the parasites inside tissue cysts need to be eaten by a member of the cat family. (d) 
Intermediate hosts can become infected th rough bradyzoite-infected meat. (e) The tachyzoite stage 
can pass through the placenta and cause abortion or infected progeny; this is known as vertical 
transmission . 
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In addition to the highly infectious sporozoites inside oocysts, T. gondii 
appears in two other infectious stages: rapidly dividing tachyzoites (tachy=fast) and 
slowly multiplying bradyzoites (brady=slow) in tissue cysts (Frenkel, 1973). Felids 
normally become infected upon ingestion of bradyzoites in the tissue of their prey, 
where the parasite containing tissue cysts are most commonly found in muscle and 
neural tissue (Dubey, 1997a). The cysts are ruptured as they pass through the 
digestive tract and enter the epithelial cells of the cat small intestine, where asexual 
proliferation is followed by a sudden switch to sexual stages. The sexual cycle was 
first described in 1972 by Dubey and Frenkel, who discovered five successive stages, 
named A-E, in the cat ileum (Dubey and Frenkel, 1972). The parasites multiply by 
endodyogeny, endopolygeny and schizogony, and then form gametocytes which 
develop either into 10-30 biflagellar microgametes, containing a nucleus and a 
mitochondrion, or into a single macrogamete which confers the apicoplast 
organelle (Ferguson et aI., 2005; Speer and Dubey, 2005). like other apicomplexan 
parasites, T. gondii is haploid throughout the life cycle, apart from the transient 
zygote stage (Cornelissen et aI., 1984). The actual fertilization and zygote formation 
has never been observed, and it has been suggested that oocyst formation may to 
some extent occur by parthenogenesis (Ferguson, 2002). However, it is clear that 
sexual reproduction does occur, as shown by experimental studies on 
recombination (Pfefferkorn and Pfefferkorn, 1980; Sibley et aI., 1992). Experimental 
infections of cats with a single parasite clone resulted in oocyst production, which 
showed that mating types are not predetermined (Pfefferkorn et aI., 1977; 
Cornelissen and Overdulve, 1981), but the mechanism behind the development of a 
particular parasite to either micro- or macrogamete remains unknown. 
Following fertilization in the cat gut, millions of immature oocysts are shed 
with the faeces. Unsporulated oocysts contain a single primary sporoblast, which 
undergoes development outside of the host into two sporocysts, each containing 
four sporozoites (Ferguson and Dubremetz, 2007). The sporulated oocyst can 
survive in soil and water for several months, even years under cool and moist 
conditions (Dubey, 1998b). The oocyst wall protects the highly infectious 
sporozoites from environmental stresses, but enzymes in the gastrointestinal tract 
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destroy the oocyst and sporocyst walls when it enters the digestive system of an 
intermediate host (Dubey et aL, 1998). Studies of the route of infection in mice 
show that sporozoites invade epithelial cells and then differentiate into rapidly 
dividing tachyzoites, which spread throughout the body via the blood-and lymph 
system (Barragan and Sibley, 2003). In tissue culture, this initial differentiation to 
the tachyzoite stage takes place within 24 hours post-invasion (Speer et aI., 1995) 
and in the presence of a functioning immune system the tachyzoites convert into 
bradyzoites within 1-2 weeks (Dubey and Frenkel, 1976; Di Cristina et aL, 2008). The 
parasites can remain latent in intracellular tissue cysts for extended periods, 
possibly for the lifetime of the host, although cyst rupture and reinvasion is likely to 
occur from time to time (Weiss and Kim, 2000), and if an infected animal is eaten by 
a cat the sexual cycle starts all over again. 
Horizontal transmission between intermediate hosts occurs when an animal 
or human eats raw or undercooked meat containing tissue cysts and the course of 
events is essentially the same as upon oocyst ingestion; the cyst wall is digested by 
the gastric enzymes, the bradyzoites invade epithelial cells and transform into the 
tachyzoite stage (Dubey, 1997c). Although tachyzoites are often used for 
subcutaneous and intraperitoneal infection in laboratory mice, this stage is highly 
sensitive to both pepsin and trypsin digestion and the oral infectivity rate is low 
(Dubey, 1998a). Tachyzoites are, however, important in vertical transmission, 
where they can pass from mother to foetus through the placenta (Dubey, 1987), 
either following a recent infection or after reactivation of a latent infection, with 
conversion from bradyzoites to tachyzoites. Only primary infections are considered 
important in immunocompetent pregnant women (Foulon et aL, 2000), but 
sporadic cases of congenital transmission have been reported in 
immunocompromised women with previously documented T. gondii infection 
(Bachmeyer et aI., 2006; Cruz et aL, 2007) and also as a result of superinfection with 
an atypical strain (Elbez-Rubinstein et aI., 2009). In host species that are more 
sensitive to T. gondii infections, congenital transmission may be highly prevalent 
and even occur over successive generations as shown in experimental infection and 
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natural populations of mice (Beverley, 1959; Marshall et aL, 2004) and sheep 
(Duncanson et aL, 2001; Morley et aI., 2008). 
1.1.3 Cellular and molecular biology 
The biology of T. gondii has been well studied, partly as a pathogen in its own 
right, but also as a model for other Apicomplexa since it is easily cultured and 
amenable to genetic manipulation (Kim and Weiss, 2004). Tachyzoites and 
bradyzoites can be obtained in vivo as well as in vitro, while sporozoites can only be 
acquired from cats. Ultrastructurally these stages are similar: approximately 7 by 2 
~m, crescent-shaped or nearly elliptic, without cilia or flagella and with a pointed 
conoid tip, the apical complex (Figure 1-3), which contains a polar ring from which 
the microtubular cytoskeleton extends and through which secretory proteins are 
released during invasion (Dubey et aL, 1998). 
Micronemes 
__ ~~PHiI 
Rhoptries 
I I 
1 ~m 
Figure 1-3. Morphology and major organelles of T. gondii. At the top right is the apical complex and 
nearby several small micronemes can be seen. The rhoptries extend from the apical end and their 
bulb appears partly hollow, which is typical of tachyzoites. Dense granules are seen both towards the 
anterior and posterior end . Nucleus, Goigi apparatus and Endoplasmic reticulum (not shown) are 
universal eukaryotic organelles present in T. gondii. Transmission electron microscopy (TEM) picture 
of strain Me49, for methodology see 4.2.8. 
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Bradyzoites can often be visually distinguished from tachyzoites by the 
posterior location of the nucleus, high number of amylopectin granules and 
electron-dense rhoptry organelles (Dubey et aL, 1998). In addition, the life stages 
can be differentiated by the detection of stage-specific proteins, notably the surface 
antigens (Smith, 1995). This group of proteins includes the major tachyzoite surface 
antigens SAGl and SAG2, which are highly immunogenic (Grimwood and Smith, 
1996) as well as specific bradyzoite antigens including BAGl and SRS9, against 
which antibodies are not found in natural infections (Kim and Boothroyd, 2005). 
SAGl was early identified as important in host cell invasion (Grimwood and Smith, 
1992) and allelic variants of SAG1 and 2 have been used extensively to differentiate 
between mouse-virulent and avirulent T. gondii strains (Howe and Sibley, 1995; 
Howe et aL, 1996). In total, more than 160 members of this family (called SRS 
genes, which is short for SAG1-related sequences) have been identified through 
bioinformatic analysis and their short, intronless genes are found in tandem arrays 
on most chromosomes (Jung et aL, 2004 and Figure 1-4). SRS proteins are important 
in the initial host cell attachment (Robinson et aL, 2004) and it has been 
hypothesized that the variability of the SRS superfamily render the invasion of a 
wide range of cell types possible (Lekutis et aI., 2001; Jung et aI., 2004). 
Furthermore, these genes are believed to be highly important for immune evasion 
and persistence in the host (Kim et aL, 2007). 
Other important protein families in T. gondii originate from three kinds of 
secretory organelles: the club-shaped rhoptries, the small rod-shaped micronemes 
and the electron-dense, globular dense granules (Figure 1-3). The protein families 
associated with these organelles are called Raps (rhoptry proteins), RONs (rhoptry 
neck proteins), MICs (microneme proteins) and GRAs (dense granule proteins), from 
the common nomenclature proposed by Sibley, Pfefferkorn and Boothroyd (Sibley 
et aL, 1991). Surface and secretory proteins are essential in the invasion process, 
which is further discussed in section 1.1.4. Several members of these protein 
families have attracted a lot of interest in recent years, since they appear to be 
crucial for the extreme differences in mouse-virulence seen among different strains 
of T. gondii. 
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Rhoptry proteins (both ROPs and RONs) are specific for apicomplexan 
parasites, and many have enzymatic activity (Dubremetz, 2007). They are released 
during invasion and several ROPs migrate to the parasitophorous vacuole 
membrane or into the host cell cytosol and even nucleus, where they interfere with 
the host cell gene expression (Boothroyd and Dubremetz, 2007). ROP18 is a highly 
polymorphic serine-threonine kinase, which causes phosphorylation of an unknown 
parasite protein (Sinai, 2007), and has been shown to be a major determinant of 
mouse-virulence through bioinformatic analysis and transfection of recombinant 
proteins, (Saeij et aI., 2006; Taylor et aL, 2006). Other ROP-proteins that have been 
implicated in virulence include ROP2, ROPS and ROP16 (EI Hajj et aI., 2006; Saeij et 
aL, 2006; Bradley and Sibley, 2007) and further structural characterization of these 
proteins and the mechanisms behind their role in pathogenesis is in progress (Qiu et 
aL, 2009). 
Several of the GRA proteins, derived from the dense granule organelles, are 
highly polymorphic and variation in the GRA6 gene sequence has been used 
extensively for differentiation between genotypes at the DNA level (Fazaeli et aI., 
2000; Su et aL, 2006; Zia-Ali et aL, 2007), while peptides from GRA3, 6 and 7 have 
been used in serotyping assays (Kong et aL, 2003; Sousa et aL, 2008). The GRA 
proteins are released post-invasion and have been shown to interact with a number 
of host proteins, and while the exact function of each one remains to be elucidated, 
they appear to be important for the persistence of infection and inhibition of host 
cell apoptosis (Ahn et aI., 2006) and nutrient acquisition (Coppens et aL, 2006). In 
addition, the dense granule isozymes NTPase I and II are essential in the purine 
salvage pathway (Sibley et aL, 1994; Carruthers, 1999). 
MIC proteins are key molecules in the invasion process by recognition of sialic 
acids on the host cell surface, which establishes the first attachment and initiates 
the penetration (Blumenschein et aL, 2007; Hager and Carruthers, 2008). Knock-out 
experiments have also shown that some MIC proteins, including MIC1, 2 and 3, are 
major determinants of virulence (Huynh and Carruthers, 2006; Ismael et aL, 2006). 
The distribution of SRS, ROP, GRA and MIC genes across the 14 chromosomes of the 
haploid T. gondii genome is shown in Figure 1-4. 
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Figure 1-4. Distribution of major protein families over the 14 chromosomes (la-XII). No special 
clustering is seen except for the SRS proteins, which are often found in tandem arrays and frequently 
towards the subtelomeric regions. Th is picture summarizes local ization searches for genes with 
keywords "SAG or SRS", "Rap or RON", "GRA" and "MIC" in the Toxoplasma genome database 
(ToxoDB v.4.3) and does not include genes with high sequence homology that have not been 
assigned to these groups by the administrators. 
T. gondii contains two endosymbiontic organelles, a mitochondrion and a 
multimembrane plastid, the apicoplast (see Figure 1-5). The single mitochondrion is 
large and elongated, enveloped by double membranes with abundant cristae 
(Mather and Vaidya, 2008) . As in other Apicomplexa, the mitochondrial genome has 
been reduced to ~6 kb, but T. gondii is unusual since it contains numerous copies of 
mitochondrial derived sequences in the chromosomal DNA (Ossorio et aI., 1991). 
Due to the difficulties introduced by these gene multiplications, the T. gondii 
mitochondrial genome is still rather poorly characterized, and the sequence is not 
yet available in the Toxoplasma genome database (ToxoDB). However, similar to the 
situation in Plasmodium and Theileria, the reduced mitochondrial genome of 
Toxoplasma is believed to encode three proteins (cytochrome c oxidase' and "', 
and apocytochrome b), which participate in the electron transport chain, plus a 
small number of unique rRNAs (Feagin, 2000). 
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The apicoplast is an organelle found in nearly all apicomplexan parasites, with 
the exception of Cryptosporidium (Goodman and McFadden, 2007). It is enclosed by 
four membranes, a remnant from its origin as a secondary endosymbiont; originally 
a prokaryotic cyanobacterium was engulfed by an algal predecessor, which in turn 
was ingested by the ancestor of the Apicomplexa (Stoebe and Maier, 2002; Moore 
et aL, 2008). Gene transfer to the nucleus has left a much reduced genome (~35 kb, 
average chloroplast genome sizes are ~150-200 kb), and the organelle has lost its 
photosynthetic function (Obornik et aL, 2009). In addition to RNAs and proteins 
required for translation and transcription of the organellar genome, the apicoplast 
genome encodes proteins essential for the biosynthesis of fatty acids, isoprenoids 
and haeme (Foth and McFadden, 2003). Several nuclear-encoded proteins are 
targeted to both the apicoplast and mitochondrion, which collaborate in the haeme 
biosynthesis and possibly additional metabolic pathways (Obornik and Green, 2005; 
Pi no et aL, 2007) and these organelles are located in close proximity to each other 
(Figure 1-5). 
Figure 1-5. Morphology of the endysymbiotic organelles. The elongated single mitochondrion is 
close to the multi-membrane enclosed apicoplast, since they share at least one metabolic pathway. 
TEM picture of strain Me49, by Irene Bontell. 
Since its recent discovery, just over a decade ago (McFadden et aL, 1996; 
Kohler et aL, 1997), the apicoplast has emerged as an important drug target since it 
possesses metabolic pathways of prokaryotic origin. Not only could the presence of 
this organelle explain the action mechanisms of known parasiticidal drugs like 
c1indamycin and spiromycin, but it has also led to development of new drugs 
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currently in the clinical trial phase (Waller and McFadden, 2005; Wiesner et aI., 
2008). 
Due to the straight-forward propagation and manipulation of T. gondii, a vast 
amount of biological data has been generated and this is increasingly being made 
available at the Toxoplasma genome database ToxoDB at www.toxodb.org (Gajria 
et aI., 2008). Currently this database contains three annotated genomes, each 
spanning approximately 61 Mb divided on 14 chromosomes. In addition other data 
types have been added, including transcriptomic, proteomic, epigenomic data and 
metabolic pathway reconstructions, providing an excellent platform for hypothesis 
testing on the system biology level (Kim and Weiss, 2008). 
1.1.4 Invasion, stage conversion and egress 
Invasion of host cells is an active process that is largely conserved throughout 
the phylum, beginning with the parasite moving across the cell surface using a 
gliding motility without visible conformational changes (Heintzelman, 2006). The 
movement is driven by actin and myosin structures in the glideosome, a complex 
located between the outer plasma membrane and the inner membrane complex 
(Opitz and Soldati, 2002), and motility has been shown to be essential for active 
invasion (Soldati-Favre, 2008). Entry into the host cell is normally completed within 
15-20 s and can be divided into several steps mediated by different groups of 
proteins, which are outlined in Figure 1-6 (Carruthers and Boothroyd, 2007). 
Apicomplexan parasites have a strong polarity in their cell structure and both 
move and invade with the apical end leading. During invasion the parasite 
reorientates upon attachment so that the apex is opposed the host cell membrane 
(Sasono and Smith, 1998). SAG proteins are involved in the early attachment stage 
(Grimwood and Smith, 1996) where they, and subsequently the MIC proteins, 
anchor the parasite to sialylated oligosaccharides on the host cell membrane 
(Besteiro et aI., 2009). Thereafter the moving junction (MJ) is formed by the 
micronemal protein Apical Membrane Antigen 1 (AMA1) and RONs 2, 4, 5 and 8 
(Besteiro et aI., 2009). 
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Figure 1-6. Overview of the invasion process and mediating proteins. Invasion consists of several 
sequentia l steps media ted by different groups of proteins : initial revers ible attachm ent to surface 
receptors (SAGs), apical attachment (MICs), formation of the moving junction (MJ) by rhoptry neck 
proteins and the microneme protein AMA1, rhoptry discharge (ROPs) and invasion when the parasite 
apical end creates an invagination in the host cell membrane and squeezes into a confined vacuole 
(PV) . Th e schemat ic is adapted from Carruthers and Boothroyd, 2007. 
The moving junction is a conserved feature of invasion in the Apicomplexa, a 
ring formation through which the parasite squeezes into the cell. It serves as 
support for the parasite during invasion and efficiently excludes transmembrane 
host cell surface proteins from the parasitophorous vacuole (PV) (Mordue et aI., 
1999). Although the PV membrane mainly consists of host cell membrane, it is 
different from phagosomal vacuoles and does not acidify or fuse with Iysosomes, 
(Sibley et aI., 1985; Black and Boothroyd, 2000). On the contrary, it provides an 
optimal compartment for parasite growth and soon after formation, it associates 
with host mitochondria and endoplasmic reticulum to facilitate the salvage of 
nutrients (Magno et aI., 2005). 
Within the PV, the tachyzoites replicate by endodyogeny, with a rep licat ion 
time of approximately 6-10 hours. The division process begins with the format ion of 
two apical membranes in the middle of the mother cell, followed by organellar 
division between the two daughter cells, which mature inside the orig ina l ce ll 
(Radke et aI., 2001). The division within a tachyzoite vacuole is normally 
synchronous, resulting in 2n parasites, but occasionally the formation of three or 
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more daughters within a mother cell has been observed (Hu et aL, 2002). Host cell 
apoptotic pathways are inhibited by T. gondii (Goebel et aI., 2001), which can grow 
in a safe haven until more space is required. Exit from the host cell, egress, is an 
active event, much like invasion, and is triggered by an increased calcium 
concentration (Arrizabalaga and Boothroyd, 2004), and in in vitro tachyzoite 
cultures this normally occurs after 2-3 days. The host cell then undergoes lytic 
necrosis and the parasites are immediately ready to invade new cells, and this rapid 
propagation results in extensive tissue destruction. If this rapid propagation of 
tachyzoites is not restrained in vivo, it soon results in demise of the host. 
Bradyzoites, on the other hand, can persist in a clinically latent state for extended 
periods, thereby increasing the probability of successful transmission. 
In vitro, stage conversions from tachyzoites to bradyzoites can be induced by • 
stresses like heat shock, chemical induction or high or low pH (Soete et aL, 1994). In 
vivo, pro-inflammatory cytokines, most notably IFN-y, are important inducers of 
stage conversion and for keeping the infection under control (Yano et aI., 2002). 
However, spontaneous stage conversion can occur and recent evidence suggests 
that the cellular environment in brain and muscle may trigger bradyzoite 
development (Ferreira da Silva et aI., 2008). In mice, bradyzoites start to appear 
around six days post-infection (Sahm et aI., 1998) and, although tissue cysts are 
most commonly found in muscle and neural tissue, they can persist in a wide range 
of organs including heart, lung, liver, spleen, lymph nodes and the small intestine 
(Yano et aL, 2002). Young tissue cysts can contain as few as two bradyzoites and 
have a diameter of only 5 Jlm, while a mature cyst may contain thousands of 
parasites and reach a diameter of 50-70 Jlm or more (Weiss and Kim, 2000 and 
Figure 1-7). 
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Figure 1-7. T. gondii bradyzoites in tissue cyst. Picture of a mature t issue cyst, containing hundreds 
of bradyzoi tes. The cyst was isolated from the brain of a laboratory mouse at JP Dubey's lab and the 
parasi te st rain origina ted fro m a chicken from Costa Rica (P ictu re : Irene Bontell) . 
Bradyzoites multiply in a slow and asynchronous fash ion, using both 
endodyogeny and endopolygeny (formation of > 2 daughters w ithin the mother 
cell), and if a tissue cyst is disrupted, bradyzoites can reinvade neighbouring cells 
without intermediate transformation to the tachyzoite stage (Dzierszinski et aI., 
2004), thus efficiently evading the specific immune response directed against 
tachyzoite surface antigens (Kim and Boothroyd, 2005) . Reactivation of chron ic 
toxoplasmosis, when bradyzoites revert to the tachyzoite stage, can rap idly lead to 
local tissue destruction as well as dispersal of parasites throughout the body. 
Reactivated toxoplasmosis is a problem in hosts with a weakened immune defence, 
including transplant patients and people with the acquired immunodefi ciency 
syndrome (AIDS), and the mechanisms behind this stage conversion is further 
discussed in section 1.2.3. 
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1.2 The disease, toxoplasmosis 
T. gondii is highly prevalent in humans, domestic animals, wild birds and 
mammals virtually all over the world (Tenter et aL, 2000), but clinically severe 
disease is relatively rare. Two main types of pathogenicity are seen in T. gondii 
infections: tissue damage due to an overwhelming immune response (in the acute 
phase) or unimpeded parasite growth in the brain due to a deficient cellular 
immune response (reactivation of chronic infection). The outcome of infection is 
largely dependent on the host immune defence and is highly variable between 
different host species. Australian marsupials and lemurs from Madagascar evolved 
in areas without felines, only encountering T. gondii in recent times and these 
animals are highly susceptible to acute toxoplasmosis (Dubey et aL, 1988; Spencer 
et aL, 2004). In mice, the genotype of the parasite strain is a major determinant of 
infection severity (see 1.3.1), while rats are largely resistant and develop disease 
only after high doses of inoculation (Dubey and Frenkel, 1998). Among domestic 
animals, sheep are the most sensitive with a high level of abortions due to 
congenital toxoplasmosis (Morley et aL, 2008), while goats, pigs and cattle are more 
resistant to disease, but nevertheless important for transmission (Dubey and 
Beattie, 1988). Humans have an intermediate sensitivity to T. gondii (Innes, 1997); 
the large majority of infections are controlled by the immune system, but clinical 
symptoms of various severity can occur under certain circumstances, as described 
in this chapter. 
1.2.1 Toxoplasmosis in immunocompetent adults 
Acquired T. gondii infections are generally asymptomatic or cause a mild, non-
specific disease that does not require medical treatment, but around 10-20% report 
with enlarged or swollen lymph nodes, while infrequent symptoms include 
myocarditis, pneumonia, hepatitis and encephalitis (Montoya and liesenfeld, 2004), 
but most infections go unnoticed into the persistent bradyzoite stage. 
In recent years, several studies have shown that presumed innocuous chronic 
T. gondii infections may alter host behaviour, either through histopathological 
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changes or secretion of neuromodulators (Webster, 2007). Experiments in mice 
have shown that T. gondii infection specifically eliminated their natural fear of cat 
odour (Vyas et aL, 2007), and correlations between T. gondii infection and mental 
disorders including schizophrenia, has been reported in human populations (Flegr, 
2007; Mortensen et aL, 2007). Although the precise mechanisms remain to be 
elucidated, the presence of two aromatic amino acid hydroxylases in the genome of 
T. gondii and the recent evidence of I-dopa production (Gaskell et aL, 2009) 
suggests that dopamine biosynthesis could be one way through which T. gondii can 
manipulate its host (Henriquez et aL, 2009). 
1.2.2 Congenital toxoplasmosis 
Congenital infection is the major complication of T. gondii infection in Europe 
and the United States, with incidence rates of up to around 10 cases per year in a 
population of one million (Jones et aL, 2003; Havelaar et aL, 2007; Benard et aL, 
2008). Women who are exposed to T. gondii for the first time during pregnancy may 
transmit the infection to the foetus, which due to its immature immune response 
may suffer from severe sequelae including ocular and/or mental impairment, 
hydrocephalus, epilepsy or intrauterine death (Jones et aL, 2003). The risk of 
transplacental transmission is higher towards the end of the pregnancy, but the risk 
of severe sequelae is highest during the first trimester (Dunn et aL, 1999), and there 
is also a risk that infected children who are asymptomatic at birth develop 
symptoms such as chorioretinitis later in life (Frenkel, 1974; Delair et aL, 2008). 
Following the initial exposure, protective immunity is developed and subsequent 
pregnancies are normally not affected (Foulon et aL, 2000). Screening of all 
pregnant women is performed in France, Germany, Italy and Denmark (Benard et 
aI., 2008) and combinatory treatment consisting of pyrimethamine, sulfadiazine and 
folinic acid can significantly reduce the severity of symptoms in infected babies 
(Foulon et aI., 1999). 
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1.2.3 Toxoplasmosis in immunocompromised hosts 
Individuals with deficient cell-mediated immunity are highly susceptible to T. 
gondii and may develop acute toxoplasmosis immediately after initial infection, or 
as a result of reactivation of latent parasites in tissue cysts. This patient group 
includes transplant recipients and people taking immunosuppressive drugs, as well 
as those suffering from immune deficiency diseases. The largest group consists of 
HIV-infected individuals that are further discussed in section 2.1.3. Toxoplasmic 
encephalitis (TE) is the most common manifestation, but reactivation may also 
occur in eyes, heart, lungs or other organs (Rodgers and Harris, 1996; Eza et aI., 
2006). 
In reactivated toxoplasmosis, conversion from bradyzoites to tachyzoites 
occurs several weeks before symptoms appear (Reiter-Owona et aI., 2000) and 
therefore little is known about the direct trigger mechanism. However, a recent 
study (Takashima et aI., 2008), detected tachyzoites inside tissue cysts in brains of 
mice with recent reactivation, thus showing that stage conversion followed by 
active egress and transmission is one starting point of reactivation, but accidental 
cyst rupture followed by stage conversion is another possibility (Frenkel and 
Escajadillo, 1987; Luft and Remington, 1992). The ability of the immune defence to 
prevent dissemination through killing of extracellular parasites depends on the 
proinflammatory cytokine IFN-y (Suzuki et aI., 1989) and depletion of IFN-y 
producing C04+ and C08+ T-cells in chronically infected mice leads to severe 
encephalitis and death (Gazzinelli et aI., 1992). IFN-y induces several different 
parasite control mechanisms, including NO production (Gazzinelli et aI., 1993), 
tryptophan starvation (Pfefferkorn, 1984), iron deprivation (Oimier and Bout, 1998) 
and production of reactive oxygen intermediates (Murray et aI., 1985). Cerebral or 
disseminated toxoplasmosis in immunocompromised patients cause severe disease 
symptoms including mental confusion, blindness, aphasia, paralysis and death, but 
with the right diagnosis and treatment parasite replication and tissue damage can 
be diminished. For more on diagnosis and treatment, see 2.1.4. 
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1.2.4 Ocular toxoplasmosis 
T. gondii has a predilection for the central nervous system (CNS) including the 
eyes, where it can cause acute inflammation and lasting retinal scars that may lead 
to impaired vision or blindness. Ocular toxoplasmosis can be a result of acquired T. 
gondii infection or a late manifestation of congenital toxoplasmosis, and the disease 
is highly prevalent in some regions of Brazil, where it affects up to 17% of the 
population (Glasner et aL, 1992). The reason for the high prevalence of 
symptomatic disease in that region may be due to oocyst transmitted infections 
from contaminated drinking water (Bahia-Oliveira et aL, 2003), but it has also been 
shown that strains from this area have unusual genotypes (Khan et aI., 2006b). 
1.2.5 Outbreaks of clinical toxoplasmosis 
A number of waterborne toxoplasmosis outbreaks have been reported and 
the most well-documented took place in British Columbia, Canada, where infection 
was traced to a drinking water reservoir and the symptoms included fevers, 
headache, swollen lymph nodes and a high level of retinal lesions (Bowie et aL, 
1997). The reservoir was later found to be frequented by cats and cougars (Aramini 
et aL, 1999), but no isolates were retrieved and the genotype of the strain causing 
the outbreak remains unknown. Other outbreaks have occurred in Atlanta, where a 
cat had shed oocysts in a riding stable (Teutsch et aL, 1979), in American soldiers 
drinking river water in Panama (Sulzer et aI., 1986) and more recently at a boarding 
school in Turkey (Doganci et aL, 2006) and ocular toxoplasmosis related to a 
municipal water supply in India (Palanisamy et aL, 2006). The overt clinical 
symptoms in otherwise healthy individuals during these outbreaks may be due to a 
high dose of ingested oocysts, since this stage is known to be more virulent in 
intermediate hosts compared with bradyzoites (Dubey, 2006). 
In addition, there are several reports of severe and fatal toxoplasmosis in 
immunocompetent humans in French Guiana, who suffer from high fever, 
chorioretinitis, respiratory distress and multiorgan failure (Darde et aL, 1998; Carme 
et aL, 2002; Bossi and Bricaire, 2004; Demar et aL, 2007). The source of infection is 
often unknown, but a number of these cases have been linked to the consumption 
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of wild game from the Amazon region (Carme et aI., 2002). Genetic characterization 
of strains from this area has shown an abundance of highly atypical genotypes, and 
it is likely that the T. gondii strain type is an important determinant of the infection 
outcome in otherwise healthy people in French Guiana (Ajzenberg et aI., 2004). 
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1.3 Diversity of Toxoplasma gondii strains 
1.3.1 Phenotypic and genetic differences between strains 
Different T. gondii strains display significant variation in their growth rate in 
vivo and in vitro, and have long been classified as 'virulent' or 'avirulent' based on 
their pathogenicity in mice, as determined by the LDSO (the dose resulting in 50% of 
the mice dying). Interestingly, nearly all isolated strains can readily be classified as 
virulent (LDSO ::: 1) or avirulent (lDSO > 1000), and intermediate phenotypes are 
rarely seen, although they can arise through experimental crosses (Grigg et aL, 
2001a; Su et aI., 2002). In the 1990's, genetic analysis through enzyme digestion and 
peR-based methods demonstrated that all virulent strains of T. gondii constitute a 
single clonal lineage (Sibley and Boothroyd, 1992a), while the avirulent strains 
comprise two genetic groups (Howe and Sibley, 1995). 
The three clonal lineages are called I, II and III; type I strains are uniformly 
lethal, while types II and III show a dose- and stage dependent disease spectrum 
and normally form a chronic, subclinical infection in mice (Sibley et aL, 2002). The 
mechanisms behind the increased virulence of type I strains are not fully 
understood, but they have been shown to have a higher growth rate (Kaufman et 
aL, 1959) and enhanced migratory ability (Barragan and Sibley, 2003) compared 
with avirulent strains. Mordue et al (2001) showed that a high inoculum (lOs 
parasites) of a type II-strain resulted in similar tissue burdens (::::106 parasites/g) as a 
low inoculum (102 parasites) of a type I-strain. These infections resulted in 
comparable levels of the cytokines IFN-V and IL-18, which caused lethal liver and 
lymphoid damage. After a low inoculum (102 parasites) of the same type II-strain, 
the tissue burden peaked after 8-10 days, but the immune system managed to 
control the infection and transform it to a latent state with moderate, non-
damaging cytokine levels (Mordue et aL, 2001), which implies that rapid 
proliferation is an important virulence factor. 
Although type I strains and are less prone to form tissue cysts in mice and in 
cell culture (Smith, 1995), they have been shown to do so in rats (Lecomte et aI., 
1992), and the virulence of different strains is not an absolute quantity, but 
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depends on the host. No definitive correlations have been established between the 
genotype of the infecting strain and clinical severity in humans, since other factors 
such as immune status, co-infections and infectious dose are important as well. 
However, type I strains have been found to be overrepresented in cases of 
congenital toxoplasmosis in Spain (Fuentes et aI., 2001) as well as among American 
HIV-patients (Khan et aI., 2005a), and atypical genotypes which fall outside this 
classification appear to be more prevalent among patients with ocular 
toxoplasmosis (Grigg et aL, 2001b). 
1.3.2 Genotyping markers 
Studies of the genetic diversity of T. gondii were first performed using a panel 
of enzymes that gave polymorphic digestion patterns of tachyzoite proteins (Darde 
et aL, 1988). Twelve groups, named zymodemes Z1-Z12, were identified over the 
years, where Z1, Z2+Z4 and Z3 were later found to correspond to genotype I, II and 
III respectively, while Z5-Z12 were found in a small number of isolates, mostly from 
French Guiana (Darde et aL, 1992; Cristina et aI., 1995). Sibley and Boothroyd 
showed in 1992 that all virulent T. gondii strains had nearly identical digestion 
patterns using nine PCR-RFlP markers, and a few years later Howe and Sibley (1995) 
identified and named the archetypal lineages I, II and III. Since then a large number 
of genotyping studies have been based on one or multiple PCR-RFlP markers, one 
of the most frequently used assays is the separate amplification and digestion of the 
5' and 3' end of the SAG2-gene (Howe et aL, 1997), which rapidly differentiates 
between the three archetypal lineages. Several other PCR-RFlP markers have also 
been developed (Su et aL, 2006) and the method has sometimes been 
complemented by direct sequencing of polymorphic regions in order to increase 
the resolution beyond the three clonotypes (lehmann et aL, 2000; Khan et aI., 
2005a; Zakimi et al., 2006). 
Other genotyping methods include random amplification of polymorphic DNA 
(RAPD) and microsatellite analysis. In RAPD, short non-specific primers generate a 
pattern of amplicons of variable length, which can be seen as a "genetic fingerprint" 
of the strain (Williams et aL, 1990), and this method has been shown to readily 
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differentiate virulent from avirulent T. gondii strains and also been used for 
mapping the genetic relatedness between strains (Guo et aL, 1997). Microsatellite 
sequences consist of short tandem repeats (2-6 bp) which are known to mutate 
rapidly due to DNA polymerase slippage, and since each marker can contain 
numerous alleles, microsatellite analysis provide higher resolution than single SNP 
typing methods. Analyses of T. gondii strains using 5-6 different microsatellite 
markers confirmed previous classification into type I, II, III or atypical, but in 
addition revealed significant intra-lineage variation, particularly within genotype II 
(Blackston et aL, 2001; Ajzenberg et aL, 2004). 
1.3.3 Genotype distribution 
The classification of strains into lineage I, II and III were principally based on 
isolates from humans or domestic animals in Europe and North America, where 
type II is the predominant lineage and atypical or recombinant strains are 
remarkably rare. For example, four different studies of parasites from human 
infections in France detected a total prevalence of 10% type I strains, 83% type II, 
5% type III and only 1.4% atypical strains (Ajzenberg et aL, 2002; Costa et aL, 1997; 
Honore et aL, 2000; Howe et aL, 1997), also see Figure 1-8 and Appendix 1. 
Interestingly, the proportion of strains appears to be very different among wild 
animals from the same continents; type II is still the most widespread, but atypical 
genotypes are much more prevalent. Notably, new clonal lineages have been 
detected in Californian sea otters and these may represent an adaptation to that 
specific environmental niche, where transmission appears to involve accumulation 
in filter-feeding invertebrates (Miller et aL, 2004). The profile of strains is highly 
divergent in South America, where typing with conventional PCR-RFLP markers 
usually reveal a mixture of type I and type III alleles, while type II strains are 
completely absent from most areas (Dubey et aL, 2003a). Figure 1-8 summarizes 
the distribution of different T. gondii genotypes, as it was known at the beginning of 
this work (for references and details on the studies, see Appendix 1). 
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Europe and North 
America, humans 
and domestic 
animals (N=740) 
Europe and North 
America, wild 
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Central- and South 
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and domestic 
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Figure 1-8. T. gondii genotype distribution in different hosts and geographic regions. The 
prevalence of different genotypes differs between humans and animals from Europe/North America 
compared with Central/South America . Atypical/recombinant indicates strains that do not fall in one 
of the three archetypal lineages, while mixed means infection with more than one genotype. These 
graphs summarize published studies up until early 2006, which were largely based on single-locus 
SAG2-genotyping. For details and references, see Appendix 1. 
Extended sampling and the use of multiple genotyping markers have recently 
revealed a multitude of new genotypes in South America, and many strains 
previously classified as type I or III based on SAG2 typing were shown to contain a 
mixture of type I and III alleles and have been reclassified (Dubey et aI., 2008). 
Furthermore, it has been shown that some of these /latypical" strains are actually 
clonal expansions, for example four clonal lineages called Sri-IV are highly prevalent 
in Brazil (Pena et aI., 2008). Data from other regions has been practically non-
existent until a few years ago and is still missing from Oceania, Central Asia and 
most of Africa . In Asia, multi-locus typing have recently revealed clonal type I in 
Korea (Quan et aI., 2008) and types II and III in Iran (Zia-Ali et aI., 2007), while clonal 
expansions of novel genotypes have been found in Sri Lanka, Vietnam and China 
(Dubey et aI., 2007a; Dubey et aI., 2007b; Dubey et aI., 2007d) . The large amount of 
new data has recently led to a better understanding of the diversity and population 
structure of T. gondii and advanced theories for the timing and events that led to 
the rise of the three archetypal lineages. This is discussed further in the introduction 
to Chapter 4. 
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At the beginning of the work that led to this thesis, only one report had been 
published on T. gondii genotypes in Africa. That study used SAG2-typing and 
showed the presence of type II (14%) and III (86%) strains in 20 chickens and one 
duck from Egypt (Dubey et aL, 2003b). In 2005 another paper showed that all three 
lineages (6% I, 24% II and 70% III) were present in 17 chickens from Congo, Mali, 
Burkina Faso and Kenya (Dubey et aI., 2005b), and these have recently been shown 
by multilocus typing to be highly similar to the archetypal lineages (Velmurugan et 
aL, 2008). In addition, four strains had been genotyped from symptomatic cases in 
individuals of mostly unspecified African origin and in all these cases, atypical 
strains were detected (Ajzenberg et aL, 2004; Khan et aL, 2005a). No study had 
investigated the T. gondii genotype in relation to disease in African HIV-patients. 
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1.4 Aims 
Toxoplasma gondii is an opportunistic pathogen in AIDS-patients, causing 
severe encephalitis with fatal outcome. Most HIV-infections occur in sub-Saharan 
Africa, but very little is known about the importance of AIDS-associated 
toxoplasmosis in Africa or the T. gondii strains present there. The general aim of this 
thesis was to characterize T. gondii strains from Uganda genotypically and 
phenotypically, which is important in relation to AIDS and also for a better 
understanding of the global population structure. 
More specifically, the first aim was to assess the importance of T. gondii as an 
opportunistic pathogen in Ugandan HIV-patients and to determine the genotypes of 
disease-causing parasites. The next aim was to explore the abundance of different 
strain types generally present in this region, using material from asymptomatic 
animals. A key objective was to retrieve Ugandan T. gondii isolates and this was 
achieved from chickens, with eight different strains finally recovered. The isolation 
success enabled phenotypic experiments where the aim was to compare the in vivo 
and in vitro growth in relation to genotype. In vitro culturing made detailed genetic 
analysis feasible, and the identification of an unusual recombinant strain led to the 
whole genome sequencing of a type II/III strain. In this last study the aims were to 
elucidate the genetic composition of this strain, to identify novel mutations and 
genes under selective pressure, and to assess the level of divergence compared 
with the type II and III reference strains. 
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Chapter 2 Infection with Toxoplasma gondii is highly prevalent in 
Ugandan HIV-patients and all three lineages cause disease 
2.1 Introduction 
T. gondii has emerged as one of the most common and detrimental 
opportunistic pathogens in HIV/AIDS patients. Normally kept in a quiescent state by 
the cell-mediated immune defence, parasites may reactivate and cause extensive 
tissue damage and death when the immune system is compromised. Based on the 
seroprevalence rates, around ten million people in sub-Saharan Africa are co-
infected with HIV and T. gondii and are thus at risk of developing toxoplasmic 
encephalitis, unless properly diagnosed and treated. This chapter investigates the 
prevalence of latent and reactivated toxoplasmosis among HIV-patients in Uganda 
and discusses the diagnosis of this disease in a resource-poor setting. 
2.1.1 HIV and opportunistic diseases in Africa 
The human immunodeficiency virus (HIV) is a relatively new pathogen for 
humans, but closely related simian viruses are naturally present in many species of 
African primates (Holmes, 2001). Based on molecular evidence, the transmission to 
humans is believed to have happened in central Africa about 100 years ago 
(Worobey et aI., 2008). According to the latest comprehensive report from WHO, 
the HIV-viruses have killed at least 25 million people over the years, and the 
epidemic is now causing around 2 million annual deaths worldwide and 33 million 
people are currently infected (UNAIDS, 2008). In the past thirty years, HIV has 
spread throughout the world, but the worst affected region is sub-Saharan Africa, 
where AIDS is the leading cause of death in adults (Egger and Boulle, 2008). Two 
thirds of all infected people live in sub-Saharan Africa (Table 2-1), and this is also the 
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region where most children are affected: 90% of HIV-infected children and over 75% 
of all AIDS orphans live in Africa (UNAIDS, 2008). 
Table 2-1. Global overview of HIV-infections in 2007. Data summary by continent, with specifics for 
Uganda shown in bold text. The data was retrieved from "Report on the global AIDS epidemic" by 
UNAIDS!WHO (UNAIDS, 2008). 
Adult Infected 
Total number Deaths in prevalence children Orphans 
of infections Z007 (15-49 y) (0-14 y) (0-17 y 
Global 33,000,000 2,000,000 0.8% 2,000,000 15,000,00C 
~ub-Saharan Africa 22,000,000 1,500,000 5.0% 1,800,000 11,600,00C 
Uganda 940,000 77,000 5.4% 130,000 1,ZOO,00C 
East Asia 740,000 40,000 0.1% 7,800 NA 
pceania 74,000 1,000 0.4% 1,100 NA 
~outh and South-East Asia 4,200,000 340,000 0.3% 140,000 NA 
East Europe and Central Asia 1,500,000 58,000 0.8% 12,000 NA 
rvvestern and Central Europe 730,000 8,000 0.3% 1,300 NA 
North Africa and Middle East 380,000 27,000 0.3% 26,000 NA 
North America 1,200,000 23,000 0.6% 4,400 NA 
~aribbean 230,000 14,000 1.1% 11,000 NA 
Latin America 1,700,000 63,000 0.5% 44,000 NA 
The research effort on HIV/AIDS has been immense. Since the HIV virus was 
identified in 1983 (Barre-Sinoussi et aL, 1983), over 100,000 scientific articles with 
major topic "HIV" or "AIDS" have been published, but no definitive cure or vaccine 
has yet been developed. Treatment and immunization attempts are greatly 
aggravated by the extraordinary genetic variety of HIV, even within a single patient 
(Saag et aL, 1988), and over 200 known mutations are associated with drug 
resistance (Shafer and Schapiro, 2008). HIV is a retrovirus, consisting of a single-
stranded RNA sequence of approximately 9200 nt. Two distinct viruses have been 
discovered: the more aggressive HIV-l, which originates from chimpanzees (Gao et 
aL, 1999) and HIV-2, which has a prolonged pre-patent period and is mainly present 
in West Africa, where its original host is the sooty mangabey (Clavel, 1987). Many 
different genotypes of HIV-l have been identified and while subtype B is the most 
common in Western Europe and USA, much more variation is seen in Africa 
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(Hemelaar et aI., 2006). Subtype C is responsible for most cases in Southern Africa, 
but in Uganda, sUbtype 0 is the most common, followed by subtype A and a small 
proportion of subtype C (Nakasujja et aI., 2005; Hemelaar et aL, 2006). The 
importance of the HIV clades for clinical outcome is largely unknown, but recent 
studies comparing disease progression in African patients infected with subtypes A, 
C and 0 show that infections with recombinant subtypes and clade 0 have a faster 
progression to severe disease and death (Vasan et aL, 2006; Sacktor et aL, 2007; 
Kiwanuka et aL, 2008). 
The primary host cell target for the HIV-virus are CD4+ T-Iymphocytes (CD4-
cells), and after invasion double-stranded DNA is synthesized and integrated into 
the host DNA as a provirus. A clinically latent period follows, when the virus slowly 
but continuously replicates and adapts to the host immune system and builds up an 
ineradicable reservoir (Chun and Fauci, 1999). During the prepatent period the 
number of CD4-cells gradually declines and the patient develops AIDS, which is 
defined as "all HIV-infected persons who have less than 200 CD4+ T-lymphocytes/1l1 
of blood, or a CD4+ T-Iymphocyte percentage of total lymphocytes of less than 
14%" (CDC, 1993). In addition, there are a number of AIDS-defining diseases. Some 
of these, like AIDS dementia, are caused directly by the HIV-virus and are poorly 
understood, but most are caused by opportunistic pathogens. The risk of 
opportunistic illnesses increases as the CD4-count (number of CD4-cells per III 
blood) declines and the relative importance of different pathogens depend on their 
prevalence in each region. Tuberculosis is the biggest threat to HIV-patients in many 
parts of the world (Havlir et aI., 2008), but a wide range of bacterial, viral, fungal 
and protozoal infections can cause severe disease and deaths in immunosuppressed 
individuals (Table 2-2). In Uganda, tuberculosis, cryptococcal meningitis, 
toxoplasmic encephalitis and Kaposi's sarcoma are among the main problems 
associated with HIV infection, but other common reasons for seeking medical care 
include chronic diarrhoea, bacterial meningitis, pneumonia, oral candidiasis and 
herpetic ulcers (Nakasujja et aL, 2005). 
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Table 2-2. Overview of common opportunistic pathogens of HIV-patients. (Data from Jung and 
Paauw, 1998; Holmes et aI., 2003; Davaro and Thirumalai, 2007). 
Bacterial infections Main disease location(s) CD4-counta 
'Mycobacterium tuberculosis Pulmonary, neurological <500 
'flalmonella, Shigella, Campylobacter spp. Gastrointestinal <sao 
~treptococcus, Haemophilus, Staphylococcus, 
egianella spp. Pulmonary, sepsis Variable 
'Mycobacterium avium complex Multi-organ <100 
Treponema pal/idum (syphilis) Neurological <350 
lViral infections 
Herpes viruses Kaposi's sarcoma, skin, retina Variable 
~ytomegalovirus Neurological, retina Variable 
Hepatitis C virus liver Variable 
Epstein-Barr virus Lymphomas Variable 
Protozoal infections 
Toxoplasma gondii Neurological, retina <200 
rryptosporidium spp. Gastrointestinal <200 
sospora belli Gastrointestinal <200 
Microsporidia spp. Multi-organ <200 
Fungal infections 
Pneumocystis jirovecii Pulmonary <250 
Aspergillus spp. Pulmonary, multi-organ <50 
Irryptococcus neoformans Neurological <200 
';Iistoplasma capsulatum Multi-organ <SO 
'f:andida albicons Esophagus, oral <100 
alndicates at which stage of immunodeficiency HIV-patients are considered to be at risk of disease 
with the respective pathogens. 
2.1.2 Epidemiology and transmission of T. gondii 
T. gondii is the most common protozoan infection in humans world-wide, and 
since it is mostly post-natally acquired the seroprevalence increases with age 
(Frenkel, 1973). The prevalence may vary depending on food habits, water supply, 
climate and the presence of felines, and high seroprevalence rates of T. gondii 
infections have been reported from diverse population groups such as the Inuit in 
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northern Canada (59.8%) (Messier et aL, 2008), strict vegetarians in India (47%) 
(Hall et aL, 1999), and pregnant Parisian women (67.3%) (Jeannel et aL, 1988). In 
Europe and USA, meat consumption is believed to be the main transmission route, 
and countries such as France and Serbia with a tradition of eating raw or 
undercooked meat have very high seroprevalence rates (Baril et aL, 1999; Bobic et 
aL, 2007). In other places, including the United Arab Emirates (Abu-Zeid, 2002), 
India (Yasodhara et aL, 2004) and Mexico (Alvarado-Esquivel et aL, 2006), 
seroprevalence was linked to residential area and socioeconomic status, and risk 
factors included poor housing and close contact with animals. Several studies from 
Brazil, where ocular toxoplasmosis is common, have shown that the seroprevalence 
rate is associated with socioeconomic status and drinking unfiltered water (Bahia-
Oliveira et aL, 2003; de Amorim Garcia et aL, 2004; de Moura et aL, 2006). In 
addition, many of these studies reported an increasing seroprevalence with age, 
and a large population based study from the Netherlands, including> 7000 samples, 
found an increase from 1% in the> 1-year old to 79% in the 75-79 year age group, 
with the steepest increase between 25 and 44 years of age (Koortbeek et aI., 2004). 
In Africa, the prevalence of T. gondii-infection is highly variable, both between 
and within countries (Figure 2-1 and Appendix 2), with reported rates ranging from 
4% in a Tanzanian Muslim village (Gille et aL, 1992) to 83.5% among pregnant 
women in Antananarivo, Madagascar (Lelong et aL, 1995). Apart from the 
previously mentioned life-style factors, climatic conditions appear to be important, 
with a general trend of lower human seroprevalence in dry compared with humid 
areas, which probably reflects the reduced oocysts survival time in arid climates. For 
example, a study from the Ivory Coast shows a prevalence of 55-70% in humid, 
tropical areas and only 36% in the pre-desert zone (Dumas et aL, 1989), and the 
corresponding figures in Senegal were 58% and 27% (Dumas et aL, 1990b). The 
compilation of T. gondii seroprevalence studies from Africa shown in Figure 2-1 also 
supports a climatic effect, where the humid regions in West Africa and Madagascar 
have the highest prevalence, while drier areas in the Northern and Southern parts 
have a lower rate of infection. 
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Figure 2-1. T. gondii seroprevalence in Africa. Compilation of seroprevalence studies on African 
adults between 1975 and 2006 (countries for which no data was available are uncoloured, 
references in Appendix 2) . The insert shows the annual rainfall with darker blue indicating a higher 
amount of precipitation (UNEP, 2009). The highest T. gondii prevalence was found in West Africa and 
Madagascar, which have a humid climate, while a lower prevalence was found in most of Northern 
and Southern Africa . 
The relative contribution of the different transmission routes may vary 
between different communities; oocysts transmission has been suggested as the 
major source of T. gondii infection in Somalia (Ahmed et aI., 1988), Congo (Candolfi 
et aI., 1993) and Gabon (Duong et aI., 1992), while meat was found to be more 
significant in Sudan (Abdel-Hameed, 1991). Both routes were considered important 
in Nigeria (Uneke et aI., 2005) and the Ivory Coast (Adou-Bryn et aI., 2004). Since 
there are no direct methods to determine the route of acquisition, these studies are 
based on analyses of the prevalence in different age groups and/or questionna ires. 
One seroprevalence study had been executed in Uganda before the start of the 
work in this thesis, which showed a seroprevalence of 27% in the general 
population and 34% among HIV-patients, but no analysis of transmission or risk 
factor was performed (Zumla et aI., 1991). 
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2.1.3 Toxoplasmosis in HIV-patients 
Toxoplasmosis in the CNS and retina was first associated with AIDS patients, 
including some of African origin, in the early 1980's (Pitchenik et aL, 1983; Schuman 
and Friedman, 1983; Clumeck et aI., 1984). It was later discovered that around 25-
50% of patients coinfected with HIV and T. gondii eventually develop TE (Luft and 
Remington, 1992), usually after the CD4-count has dropped below 200 (Jung and 
Paauw, 1998). The risk increases with advanced AIDS, and a Scottish study revealed 
that 48% of all HIV and T. gondii seropositive patients in Edinburgh with a CD4-
count below 50 had developed cerebral toxoplasmosis (Laing et aI., 1996). 
Many diverse factors have been investigated in relation to the risk of TE in 
HIV-patients, including gender and route of HIV-infection. However, only a few risk 
factors have repeatedly been found to be significantly associated with the 
development of TE: low CD4-count, positive serology and absence of T. gondii 
prophylaxis and anti-retroviral treatment (Dunlop et aL, 1996; Meisheri et aL, 1997; 
Nascimento et aL, 2001; Antinori et aL, 2004; Nissapatorn et aL, 2004). The clear 
association with positive T. gondii serology strongly suggest that reactivation of 
latent infection is a major cause of disease. For example, in the Norwegian study 
the seroprevalence in 698 HIV-patients was 17.8%, but among the 19 patients who 
developed TE, 18 (95%) had positive serology (Dunlop et aI., 1996). However, in 
places where the yearly acquisition rate is high recent infections may be more 
important, and superinfection with a different parasite strain has been shown to 
cause disease in immunosuppressed patients (Ghosn et aL, 2003). The risk of 
reactivation may also increase through additional impairment of the immune 
function due to concurrent infections. A case-control study from Ethiopia showed 
that helminth infections, which induce a very strong anti-inflammatory response, 
facilitate the reactivation of latent tuberculosis (Elias et aL, 2006), and the same 
may be true for toxoplasmosis, which like tuberculosis require a pro-inflammatory 
response to be kept in the latent state. 
Since the introduction of highly active antiretroviral therapy (HAART) in 1996, 
the mortality among AIDS-patients has decreased dramatically. As treatment 
became available, the mortality caused by opportunistic infections was reduced 
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more than 5-fold between 1994-97 in a US cohort consisting of patients starting 
with a CD4-count below 100 (Palella et aL, 1998), and today carefully optimized 
antiretroviral treatment enables patients to lead normal lives (Rosen-Zvi et aL, 
2008). With the correct treatment, immune reconstitution including recovery of T. 
gondii specific responses, can be achieved in most AIDS-patients and if the CD4-
count is kept > 200 for three months the patients may be considered for 
discontinuation of T. gondii prophylaxis (Furco et aL, 2008). In the western world, 
toxoplasmosis and other opportunistic pathogens are no longer major causes of 
CNS related disease in HIV-patients, but the problem remains where HAART is not 
available (Smith et aL, 2008). 
2.1.4 Diagnosis and treatment 
Differential diagnosis of HIV-associated opportunistic diseases can be very 
difficult, and the diagnosis of TE in Uganda relies mainly on clinical signs plus 
neuroradiological findings for patients who can afford computer tomography (CT). 
TE clinical symptoms include headache, convulsions, paresis and mental confusion, 
which is a similar spectrum as that seen for other opportunistic infections in the 
CNS, such as cerebral tuberculosis and neurosyphilis, rendering differential 
diagnosis difficult (Modi et aL, 2004). CT-scans of TE abscesses show large, 
necrotizing lesions, which are often surrounded by several smaller foci (Offiah and 
Turnbull, 2006) and suspected TE can be verified by response to specific treatment, 
but this method requires at least two weeks follow-up (Dupon et aL, 1995; Raffi et 
al.,1999) 
A number of serological methods have been developed for specific detection 
of anti-To gondii IgG antibodies, for example the Sabin-Feldman dye test (Sabin and 
Feldman, 1948), agglutination tests (Fulton and Turk, 1959; Mitchell and Green, 
1960) and enzyme-linked immunosorbent assays (Walls et aI., 1977). IgG-antibodies 
arise about 2 weeks post-infection and normally persist at detectable levels 
throughout life, even though the production may be reduced in immunodeficient 
individuals. Since IgG-detection assays cannot distinguish between latent and active 
infections, serial measurement of IgG and IgM-antibody levels is used for diagnosis 
- 34-
of active toxoplasmosis in immunocompetent people (Montoya, 2002; Lappalainen 
and Hedman, 2004). However, IgM is often undetectable in HIV-patients and direct 
detection of live parasites or of T. gondii-DNA outside tissue cysts is required for 
diagnosis in immunocompromised hosts (Bastien, 2002; Joseph et aI., 2002). The 
gold standard for detection of TE is histological examination of brain biopsies 
(Dupouy-Camet et aI., 1993), but this is an invasive procedure which poses a health 
risk for the patient. Direct detection can also be achieved through isolation of the 
parasite in mice or cell culture, but these methods are expensive and time-
consuming. peR detection of parasite DNA is rapid, inexpensive and has the 
possibility of high throughput. Cerebrospinal fluid or peripheral blood can be used 
for detection of active toxoplasmosis, and one of the most common targets is the 
35-fold tandem repeat "Bl" (Burg et aI., 1989). 
A range of anti-parasitic agents is available, which inhibit different stages of 
tachyzoite growth through interference with the folate metabolism (Fung and 
Kirschenbaum, 1996) or through inhibition of the purine salvage pathway (Gherardi 
and Sarciron, 2007; Hyde, 2007). However, no regimen is able to eradicate the 
intracellular bradyzoites and in order to prevent reactivation medication must 
continue as long as the CD4-count stays below 200 (Miro et aI., 2006). In Uganda, 
Septrin (co-trimoxazole, trimethoprim + sulfamethoxazole) and Fansidar 
(pyrimethamin + sulfadoxin) are used for treatment of toxoplasmosis in HIV-
patients, and these drugs are readily available as they are also used to treat malaria. 
Both drugs exploit the inability of the parasite to salvage folic acid from the 
environment by inhibition of the folate synthesis pathway, and the diet should 
therefore be complemented with extra folic acid. Treatment of TE usually results in 
a markedly improved clinical condition within 14 days (Amogne et aI., 2006), but 
unfortunately these drugs can cause adverse effects such as rash, anaemia and 
leukopenia (Fung and Kirschenbaum, 1996). 
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2.1.5 Aims 
The aims of this study were to determine T. gondii seroprevalence and rate of 
active toxoplasmosis in Ugandan HIV-patients, and to find out which parasite 
genotypes were present. Furthermore, we wanted to investigate the relationship 
between the laboratory results (serology and PeR-detection) and the clinical 
phenotype (level of immunosuppression and disease symptoms) in order to assess 
the current situation of toxoplasmosis in Ugandan HIV-patients and identify 
indicators of reactivation that can facilitate diagnosis. 
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2.2 Materials and Methods 
2.2.1 Study site 
Uganda is a relatively small, landlocked state in east Africa, traversed by the 
equator and with an elevation range between 621 and 5,110 m. The rapidly growing 
population of about 31 million people consist of around 20 ethnic groups, which can 
be divided into the Nilotic people of the North and the Bantu people of the South. 
Half of the population are children up to 15 years of age, around 35% live below the 
poverty line, infant mortality is 6.6% and the life expectancy is around 52 years (CIA, 
2006). In the capital, Kampala, 67% have access to clean water but only 7% to 
sewerage and in many other places these figures are even lower (National Water 
and Sewerage Corporation, 2006). The HIV rate is estimated to be around 5.4% in 
the 15-49 age group, but somewhat higher in urban areas (Nakasujja et aI., 2005; 
UNAIDS, 2008) and other common infections include tuberculosis, malaria and a 
range of helminth infections (Kolaczinski et aI., 2007). 
2.2.2 Study populations and sample collection 
Patients were recruited from Mulago Hospital, which is the largest 
government referral hospital in Uganda and the main teaching hospital of Makerere 
University. Mulago Hospital is situated close to central Kampala and most patients 
derive from a lower socioeconomic urban population. Inclusion criteria for this 
study were positive HIV-serology (or previously documented infection) and 
willingness to participate after being informed about the purpose of the study. The 
samples were collected on different occasions from two different wards, and have 
therefore been divided into five groups, G1- G5 (Table 2-3). 
The first samples (Gl) were collected in March-April 2005 from patients with 
known HIV-infection who presented at Mulago with neurological symptoms 
(N=130). For the next sampling round (G2) in Jan-Feb 2006, this category of patients 
was not accessible, instead blood was collected from patients who had recently 
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tested positive for HIV (N=130). G3 consisted of patients from that same HIV-testing 
clinic in February 2007 (N=45). Blood samples and clinical data from patient groups 
4 and 5 (N=254 and 116 respectively) were collected by Dr Erima Bernard during 
2006, who also performed the T. gondii IgG agglutination test for G4 patients. The 
G4 samples, like G1, originated from symptomatic patients ("Sympt"), whereas G5, 
like G2 and G3, consisted of patients from the HIV-testing clinic ("HIV-test"). In 
total, 675 patients were included in the study. Their average age was 33.5 years and 
the overall male to female ratio was 1:1.51. 
Peripheral blood samples (0.5-5 ml) were obtained with sterile, disposable 
needles by qualified health workers and collected in EOTA-tubes. Physicians at 
Mulago Hospital performed medical examinations, while laboratory personnel at 
the hospital carried out the HIV-ELISA and C04-count assays. The current study 
formed part of the medical evaluation of these patients, but was not the sole 
objective for taking blood specimens, why it was not always possible to obtain full 
clinical records and C04-counts. However, in order to obtain a good sample size for 
the laboratory investigation, a" HIV-positive patients were included, but naturally 
only those with the appropriate records were taken into account for each test. 
Therefore, the numbers of patients vary between tests, and the exact group size for 
every test is stated for a" results separately. 
Table 2-3. Overview of the five patient groups and the corresponding data sets. 
Mean age Clinical CD4-
Group N Collection- Patientsb Sex (M:F) ±SD Data C count C 
Gl 130 2005 Sympt 1:1.06 36.4±8.8 Partial No 
G2 130 2006 HIV-test 1:1.98 31.8±9.3 No Partial 
G3 45 2007 HIV-test 1:1.87 32.5±6.7 Yes No 
G4 254 EB,2006 Sympt 1:1.33 34.2±9.3 Yes Yes 
G5 116 EB,2006 HIV-test 1:1.76 32.9±10.1 Yes Yes 
- Samples from patient groups G1-G3 were collected on three occasions, from 2005 to 2007 (Irene 
Bontell), G4 and Gs were collected by Dr Erima Bernard in 2006. 
bSamples were obtained from one ward where patient sought care because of neurological signs 
("Sympt"), or from a HIV-testing clinic ("HIV-test"). 
CUnfortunately, clinical data and CD4-counts were only available for a subset of patients 
- 38-
2.2.3 T. gondii serology (Taxa-Screen DA) 
Blood samples were incubated at 4D( overnight in order to separate the blood 
components, and the following day serum and buffy coat were separated and 
stored at _20D( until used. Toxo-Screen DA (BioMerieux) is a commercial test for 
detection of T. gondii IgG in serum through direct agglutination with formalin-
treated T. gondii parasites of the RH-strain . Non-specific agglutination is suppressed 
by the addition of 2-mercapthoethanol, which denatures IgM antibodies by 
breaking the disulfide bonds. All reagents are supplied with the kit; antigen, diluents 
(coloured albumin buffer), 2-mercaptoethanol, positive and negative controls (goat 
serum from one animal with known titre and one uninfected animal), powdered 
PBS and round-bottom 96-well plates with self-adhesive sheets. Serum samples 
including controls were diluted in PBS to 1:20, and 25 III serum dilution, 25 III 0.2M 
2-mercaptoethanol and 50 III antigen solution were dispensed in each well. The 
plates were covered with adhesive sheets and incubated at room temperature for 
6-24 hours. Plates were read by visual examination and interpreted according to the 
manufacturer's instructions: positive if agglutination of antibody and antigen had 
formed a mat covering about half of the well base and negative if antigen had 
sedimented at the bottom (Figure 2-2). 
Figure 2-2. T. gondii direct agglutination test (Toxo-Screen DA). The uppermost row and first two 
wells on the second row had negative reactions, where the antigen had sedimented at the bottom; 
the other wells had positive reactions, where antibodies and antigen have formed a sprawl ing 
complex. 
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Serial dilutions were not performed since the value of this has not been 
established in HIV-patients, and because of cost and limited availability of reagents. 
However, samples tested in duplicate at the same and different time points always 
showed the same result and the controls were always valid. The test result is 
therefore a binomial yes or no, rather than a serological titre. Indecisive results 
were very rarely seen, and could always be resolved by a repeated testing. 
2.2.4 DNA-extraction 
DNA was extracted using the QIAamp DNA-kit (Qiagen) according to the 
instructions for the Blood Mini Spin-protocol. Briefly, 200 III of buffy coat was mixed 
with 20 III Proteinase K and 200 III lysis buffer and incubated at 56°C for 20-40 
minutes, until the cells had undergone lysis. Thereafter, 200 III of pure ethanol was 
added; the mixtures were vortexed and transferred to spin columns and centrifuged 
for 1 minute in a benchtop microfuge at 8,000 rpm. Following two washing steps 
the DNA was eluted for 5 minutes using 200 III elution buffer and the resulting DNA 
extracts were stored at -20°C. 
2.2.5 Diagnostic and genotyping PCRs 
A nested PCR-protocol was used for detection of T. gondii-DNA, based on the 
original method from 1989 targeting the 35-fold repetitive Bl-gene (Burg et aI., 
1989). Basic genotyping, which classifies strains into one of the three archetypal 
lineages (I, II or III), was performed through PCR-RFLP on both ends of the SAG2-
gene (Howe et aI., 1997). Total reaction volume was originally 50 III with 20 III DNA 
template for the Gl-samples, but this was later reduced to 20 III with 5 III template 
DNA. The mastermix was made of 4 III GoTaq 5* buffer, 2 III dNTPs (2mM), 1 III 
forward + reverse primer (10 IlM) and 1 III GoTaq polymerase (Promega). For the 
nested PCR, 1 III of the product from the first round was used as template. Primers 
and restriction enzymes are listed in Table 2-4. 
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Table 2.4. Primers and restriction enzymes used for detection and genotyping of T. gondii. 
Gene (chrom) Forward primer" Reverse primer" Length Rest. enz. b 
B1 (IX) ext GGAACTGCA TCCGTTCATGAG TCTTTAAAGCGTTCGTGGTC 194 
int TGCATAGGTTGCAGTCACTG GGCGACCAATCTGCGAATACACC 97 N/A 
SAG2 ext, 5' GCTACCTCGAACAGGAACAC GCATCAACAGTCTTCGTTGC 335 
(VIII) int, 5' GAAATGTTTCAGGTTGCTGC GCAAGAGCGAACTTGAACAC 242 Sau3AI 
ext, 3' TCTGTTCTCCGAAGTGACTCC TCAAAGCGTGCATTATCGC 327 
int, 3' ATTCTCATGCCTCCGCTTC AACGTTTCACGAAGGCACAC 222 Hhal 
-B1 primers from Burg et ai, 1989 and SAG2 primers and enzymes from Howe et ai, 1997. 
bSau3AI digests amplicons with the type III allele (186+56 bp), while Hhal digests products with the 
type II allele (169+53 bp). 
DNA quality and absence of PCR-inhibitors were controlled by a PCR protocol 
generating a 121-bp product from the human ~·globin gene (Primers: 
ACCACCAACTTCATCCACGTTCACC (F) and CTTCTGACACAACTGTGTTCACTAGC (R)). 
This amplification was, however, not performed for groups G4 and G5, since the 
amount of DNA was limited. The PCR cycling program consisted of an initial 
denaturation step at 95°C for 3 min, followed by 35 cycles of denaturation at 94°C 
(45 s), assay specific annealing temperature (30 s), and elongation at 72°C (1 min). 
All programs ended with a final elongation step of 72°C for 7 min. Annealing 
temperatures were: B11st round: 55°C, Bl nested: 52°C, SAG2-3' and SAG2 5' 1st: 
560C, SAG2-3' and SAG2 5' nested: 59°C. Amplified fragments were separated on 1-
2% agarose gels stained with ethidium bromide, and were visualized under UV-light. 
T. gondii DNA from cultured RH parasites was used as positive control and the 
sensitivity and specificity of the assays were tested through serial dilutions, ranging 
from 0.1-100 genome equivalents of parasite DNA (Figure 2-3), with DNA from 
human foreskin fibroblasts (HFFs) and water as negative controls. All methods were 
shown to reliably detect the equivalent of 10 DNA copies, while lower 
concentrations were often, but not always, discovered. 
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Figure 2-3. Sensitivity testing of peR assays used for T. gondii detection. Parasites of the RH strain 
were harvested from cell culture and counted in a haematocytometer. DNA was extracted from a 
volume containing 106 parasites, and serial la-fold dilutions were made. Extracts of uninfected HFF-
cells and water were used as negative controls (short bands visible for Bl are primer-dimers) . 
Fragment lengths are indicated by a 100 bp-marker, where the 500 bp is the brightest band . 
2.2.6 Quantitative real-time peR 
Quantitative real-time PCR (O-PCR) was used on a subset of samples in order 
to estimate the parasite density in blood samples from patients with reactivated 
disease. Primers (GCTCCTCCAGCCGTCTIG (F), TCCTCACCCTCGCCTICAT (R)) and a 
TaqMan minor groove binder probe (6-FAM-AGGAGAGATATCAGGACTGTA) directed 
against the approximately 300-fold repetitive fragment AF146527 (Homan et aI., 
2000) were designed by Dr. Daniel Palm at the Swedish Institute for Infectious 
Disease Control (SMI) and purchased from Applied BioSystems. ROX was used as a 
passive reference and the program utilized consisted of 2 minutes at 50°C and 10 
min 95°C, followed by 45 cycles of 95°C (15 s) and 60°C (1 min). Each sample was 
run in duplicate and the dilution series used to generate the standard curve was in 
triplicate. The standard curve consisted of a 10-fold dilution series, ranging from 
0.1-1000 parasites per ~I, plus three wells with no template control (H 20), and this 
was included on each plate. 
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2.2.7 Statistical analysis 
Most graphs and calculations were performed in Microsoft Excel, including the 
chi-square and t-tests, which were used to test for statistically significant 
differences between groups. The box-plot diagram was generated with the 
statistical software R (www.r-project.org). 
2.2.8 Isolation in cell culture 
Attempts were made to isolate T. gondii strains from seropositive HIV-patients 
directly into cell culture at Makerere University. For more information on standard 
cell culture techniques and reagents, see section 4.2.2. The same HFF cells and cell 
culture medium components that were used in leeds (see 4.2.2) were brought and 
cultures were set up at Makerere. 200 ~I buffy coat from seropositive patients was 
mixed with 10 ml pre-warmed (37"q fresh DMEM medium and added to a 
confluent HFF monolayer. The parasites were allowed 24 hours to invade and the 
following day fresh medium was added. Cultures were monitored under an inverted 
microscope several times a week and medium was changed every 2-3 days. 
All cell culture pipetting work was performed in a sterile hood at the 
Department of Biochemistry, the cultures were kept in a 37"C, 5% CO2 incubator at 
the Department of Bacteriology and the inverted microscope was located at the 
Infectious Disease Institute at Mulago. The cultures were transported between 
these sites in a clean container with closed lid, but contamination proved difficult to 
avoid. The isolation attempt in cell culture probably failed because of the lack of 
appropriate facilities at Makerere University at the time. Space limitations in the 
incubator resulted in the culture flasks being shuffled around and once all ended up 
in a vertical position, resulting in 90% of the cells dying. While some cultures 
survived, yeast and bacterial contamination was a major problem, and although T. 
gondii like organisms were observed no isolates were retrieved from human blood 
using this method. 
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2.2.9 Isolation in mice 
Twenty-one seropositive blood samples from group G3 were brought from 
Uganda to Sweden in EDTA-tubes kept in cold boxes. The buffy coat (approximately 
200 Ill) was mixed 50:50 with sterile PBS, and the mixture was inoculated 
subcutaneously into two mice per sample within 2-4 days after the drawing of 
blood. The mouse work was performed at the section for Experimental Biomedicine 
at SMI, where technical personnel performed inoculations, bleedings, daily animal 
care and putting the mice to death using the anaesthetic isofluorane. The animals 
were monitored daily for disease symptoms and bled for serology (Toxo-Screen DA, 
as in 2.2.3) after six weeks. Seropositive mice were sacrificed and dissected, and the 
brain was used for inoculation in cell culture and parasite quantification using real-
time PCR (for further details on trypsin digestion, inoculation in cell culture and 
quantification of parasites in mouse organs, see 4.2.4 and 4.2.5). 
As with direct isolation in ce"-culture, mouse-isolation of T. gondii from 
human blood proved difficult. Three mice infected with blood from seropositive 
HIV-patients from G3, were positive by serology at a titre of 1:25. Two of these mice 
were inoculated with blood from the same patient (H07-29), a 26-year old female 
suffering from photophobia, while the last mouse was infected with blood from a 
33-year old female reporting with fever and headache (H07-31). Inoculation of 
these mouse brain homogenates in culture did not result in any parasite growth, 
but after a second mouse passage (1:3) three out of six mice infected with H07-29 
were positive by Q-PCR detection, but not by serology. The parasite densities were 
very low, however, at 110, 290 and 515 parasites per gram and the subsequent 
transfers to cell culture were unsuccessful. Sma" quantities of these brain 
homogenates have been cryopreserved for future reference and possibly renewed 
isolation attempts, but were not further used in this study. 
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2.3 Results 
2.3.1 Patient demographics, CD4-counts and symptoms 
Five different groups of samples (G1-G5) were obtained from two different 
wards over a period of three years (summary in Table 2-3, section 2.2.2) . The 
patients in groups G1 and G4 ("Sympt" ) had a previous diagnosis of HIV and came to 
the hospital to seek care for neurological symptoms, while the samples in groups 
G2, G3 and GS ("HIV-test" ) were collected from patients who came to test their HIV-
status. The symptomatic patients were slightly older (on average 34.6 years) and 
had a more equal gender distribution (M:F, 1:1.28) than the people coming for HIV-
testing, who were 32.3 years on average and predominantly female (M :F, 1:1.91). 
The male patients of both categories were older than the females and more than 
90% were aged 45 or younger. The age distribution by sex and patient category is 
shown in Figure 2-4 and the full dataset used for the analysis in this chapter is 
provided in Appendix 3. 
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Figure 2-4. Cumulative age distribution by gender and patient category. The graph shows the 
proporti on of patients up to a given age, in five-year intervals. The symptomatic patients were older 
than those who attended the cl inic for a first HIV-test, and the men were on average a few years 
older than the female pat ients. The majority of all patients were between 25 and 45 years old . 
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The normal range of CD4-positive cells in healthy individuals is around 700-
1000 CD4-cells/~1 (Mair et aI., 2008), while the average CD4-count from the current 
study was 334 for "HIV-test" patients and only 145 for the "Sympt" category. This 
difference between the patient groups was highly significant, as determined with 
the chi-square test (P < 10-1O). A cumulative plot (Figure 2-5) of the CD4-counts in 
these groups showed that 75% of the HIV-test group and over 90% of the 
symptomatic patients had CD4-counts below 500, thus being in the risk zone of 
several opportunistic diseases. One of the CDC definitions for AIDS is a CD4-count 
below 200, and this applied to 74.8% of the symptomatic patients, and 48% of the 
individuals in this group had severe immunodeficiency with a CD4-count below 50. 
The corresponding numbers for the "HIV-test" category was 42.5% below 200 and 
13.4% under 50 CD4-cells /~I. No significant differences were seen between males 
and females, either within each group or in the cohort as a whole (P > 0.05, two-
sided t-test). 
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Figure 2-5. CD4-count in different patient categories. The graph shows the cumulative value in 
blocks of 50, thus the first dot show the percentage of patients with a CD4-count between 0-50, the 
next dot the percentage of patients with a CD4-count between 0-100 and so on. Nearly two th irds of 
all patients (24 7/388) had advanced immunodeficiency, with CD4-counts of 200 or less and 86% 
(334/388) had levels below 500 (indicated by vertical lines) . The symptomatic patients had a 
significantly lower average level compared with the HIV-test group (P < 10-1°). 
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Commonly reported symptoms that were included in the analys is were fever, 
severe or recurrent headaches, vomiting, mental confusion, photophobia, w eakness 
or paresis (mostly half-sided) and convulsions. Other clinical signs included rash, 
oral thrush, coughs, diarrhoea and neck pain. Patients with a severely comprom ised 
immune status (C04 $ 50) had a considerably worse clinical picture compared to 
those with a moderate immunosuppression (C04 > 200), and had significantly 
higher prevalence of fever, headache, vomiting and mental confusion (P < 0.001). 
The pat ients with intermediate C04-levels, between 51 and 200, had an 
intermediate level of fever, headache and mental confusion. However, the re were 
no significant differences in the level of photophobia, paresis or convuls ions 
between the three groups. The percentage of patients with each of the seven 
symptoms and the significant differences between groups are shown in Figure 2-6. 
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Figure 2-6. Prevalence of clinical symptoms in HIV-patients at different CD4-levels. The patients 
were divided into three groups based on their CD4-count : 0-50 (N=140), 51-200 (N=99) and 201 and 
higher (N =131). The percentage of patients suffering from each symptom was calculated for the 
three groups and pai r wise statist ical comparisons were made between all t hree groups using the 
chi-square test. Signif icance levels are indicated in the figure, where one star means P <0.05, two 
stars P <0.01 and three stars P <0.001. (F=fever, HA=headache, V=vomiting, MCF=mental confusion, 
PP=photophobia, PA=paresis or weakness, CV=convulsions) . 
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2.3.2 T. gondii seroprevalence 
Sera from 675 HIV-positive Ugandans were tested for T. gondii specific IgG-
antibodies using a direct agglutination test. Three hundred and eighty two patients 
were found to be seropositive, which gives a total infection rate of 56.6% in this 
population (full result list in Appendix 3). A comparison of the seroprevalence rate 
between patient groups with different levels of immunosuppression showed a 
tendency towards a higher infection rate in the patients with the lowest C04-
counts; 65.0% in the C04 0-50 group, 58.5% in 51-200, and 55.0% in the C04 >200 
group, but these differences were not significant. There was, however, a 
significantly higher (P < 0.005) seroprevalence of T. gondii infection in the 
symptomatic patients in G1 and G4 (61.7%) compared with the HIV-test patients in 
G2, G3 and G5 (49.8%). Positive T. gondii serology was associated with a higher 
prevalence of headache (P < 0.05, chi-square), but no further significant differences 
were found regarding the clinical symptoms (Figure 2-7). 
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Figure 2-7. Prevalence of clinical symptoms in seropositive and seronegative patients. Patients with 
a positive serology ("lgG+", N=382) were more likely to suffer from severe or recurrent headaches, 
compared with the seronegative patients (" lgG-", N=293) at the P <0.05 level indicated by one star in 
the graph). Apart from that, the clinical picture was highly similar in the two groups. (F=fever, 
HA=headache, V=vomiting, MCF=mental confusion, PP=photophobia, PA=paresis or weakness, 
CV=convulsions). 
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2.3.3 Diagnostic peR 
Samples were first screened by nested Bl-PCR, and thereafter amplified at 
both ends of the SAG2-gene (Figure 2-8). The Bllocus was more sensitive and many 
samples that had been freeze-thawed or stored for long periods were difficult to 
amplify with SAG2, although they were repeatedly positive for the 35-fold repeated 
B1 target. 
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~ 
Figure 2-S. Gel picture of nested Bl-PCR. This screening revealed seven positive and 20 negative 
samples. The final five samples on the second row constitute the controls; DNA from uninfected 
human fibroblasts, T. gondii strains of type I (RH). II (Me49) and III (VEGj, and finally distilled water. A 
100 bp-marker is used and the B1 product is 97 bp. 
The highest prevalence of active infection was found among the symptomatic 
patients in Gl, where T. gondii DNA was detected in 30 out of 130 patients (23.1%). 
In the HIV-test groups G2 and G3, the total PCR-prevalence was significantly lower 
at 14.9% (P<0.02). In total, the reactivation rate among the seropositive patients in 
these groups was 26 .1%, while fewer than 10% of the seronegative patients had 
active T. gondii infections (Table 2-5). 
Table 2-5. Seroprevalence and reactivation rate of T. gondii in groups Gl-G3. 
PCR-positive Reactivation rate % 
N IgG+ IgG- % pos Seropos Seroneg Seroneg Seropos Total 
G1 130 70 60 53.8 22 8 13.3 31.4 23 .1 
G2 130 70 60 53 .8 14 6 10.0 20.0 15.4 
G3 45 21 24 46.7 6 0 0.0 28 .6 13.3 
Total 305 161 144 52.8 42 14 9.7 26.1 lS.4 
The number and percentage of seropositive and PeR-positive patients is shown for each group (G1-
G3) . The seroprevalence varied between 46.7%-53.8%. As expected most PeR-positive patients also 
had antibodies, but for G1 and G2 a total of 14 IgG-negative, PeR-positive patients were found. 
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The DNA samples from groups G4 and G5 were difficult to amplify, probably 
due to degradation caused by repeated freezing / thawing, which made the 
screening results unreliable, and only two samples were found positive by nested 
SAG2-PCR. Q-PCR screening of 137 samples from G4 resulted in 11 positives (8%), 
which had an average quantity of 0.097 (range: 0.002-0.3) copies of T. gondii DNA 
per PCR reaction tube. In total, 68 of the 675 HIV-patients investigated in this study 
were PCR-positive (for a complete list, see Appendix 3). 
Positive serology was strongly associated with reactivation; 73.5% of the PCR-
positive patients were seropositive, compared with 54.9% of the PCR-negative 
patients (P<O.OOl, chi-square test). Yet, T. gondii DNA was detected in the blood of 
18 seronegative individuals, meaning that more than one in four Ugandan HIV-
patients with active toxoplasmosis did not have detectable levels of specific IgG-
antibodies. The lack of specific antibodies may be explained by the reduced capacity 
of antibody production in patients at an advanced stage of immunosuppression, 
and a closer look at the 12 PCR-positive patients for which CD4-counts were 
available is consistent with this assumption (Figure 2-9). 
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Figure 2-9 Box-plots showing the distribution of CD4-counts in different patient groups. Each box 
depicts the inter-quartile range with median values marked as a line. Range shows last value within 
1.5 IQR, and outliers are marked by dots. 'All' includes all patients with a CD4-count (N=388, median 
109.5), 'lgG+' seropositive patients (N=229 median 90), 'PCR+' all PCR-positive patients regardless of 
serological status (N=12 median=75), and 'PCR+/lgG-' PCR-positive patients with negative serology 
and known CD4-count (N=4 median 15.5). 
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Four PCR-positive / seronegative individuals were found in the lower end of 
the scale, with counts of 0, 3, 28 and 73 C04-cells/IlI, while the eight patients with 
positive PCR and positive serology had counts of 7, 45, 75, 94, 166, 175, 237, 336 
and 532. The distribution of C04-counts in the patients with active toxoplasmosis 
was compared with that of all seropositive patients and the general study 
population in Figure 2-9. Although there appears to be a trend towards lower C04-
count in patients with positive PCR, the differences did not reach significance. 
The correlation between clinical symptoms and active toxoplasmosis was 
investigated through pair wise comparison of the PCR-positive and PCR-negative 
patients. Headache was the only symptom significantly associated with reactivation 
(P<O.Ol), and there was support on the P<0.05 level that fever was less common 
among patients with toxoplasmosis. However, the predictive value of these 
symptoms in clinical practice remains low, as headache and fever are highly 
prevalent in both patient groups. The proportion of patients presenting with each 
symptom in the respective groups are shown in Figure 2-10. 
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Figure 2-10. Prevalence of clinical symptoms in PCR-positive and PCR-negative patients. Headache 
was the most common symptom, and it was associated with reactivation, affecting 92% of the peR-
positive patients. On the contrary, fever was more common in the PCR-negative group, but was 
nevertheless the second most common symptom in the PCR+ group, with a prevalence of 44%. 
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2.3.4 Genotyping 
Classification of the 30 PCR-positive samples from G1 was achieved through 
restriction enzyme digestion of the SAG2 products. Separate amplifications of the 5' 
and 3' end of the gene is necessary for accurate typing into the canonical three 
lineages and therefore only partial typing was possible for three samples where the 
3'-end amplification was unsuccessful. SAG2-genotyping was attempted on the 
other patient groups but gave inconclusive results. 
All three SAG2-types were found in this cohort of Ugandan HIV-patients. Type 
II was the most common, comprising 60% of the strains (18/30) followed by type I 
at 20%. Three cases of type III infections (10%) were detected and the remaining 
three strains were classified as being either type I or II, but not III. The sample set 
was too small for statistical analysis of the risk factors associated with reactivation 
of a particular genotype, but this data, shown in Figure 2-11, demonstrates that the 
three lineages are all present in Uganda and able to cause disease in HIV-patients. 
1 type I 
6 type II 
1 type III 
5 type I 
12lype II 
2lype III 
3 non-III 
Figure 2-11. Overview of serology, PeR-results and SAG2 genotyping for Gl. Genotyping showed 
that representatives of the three clonal lineages were present, and that type II was the most 
common lineage. The genotype distribution was similar among seropositive and seronegative 
patients. 
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2.4 Discussion 
2.4.1 High seroprevalence and slow increase with age 
The total seroprevalence rate for T. gondii among 675 Ugandan HIV-patients 
was found to be 56.6%. This is similar to the levels of exposure in neighbouring 
countries; 54% in Kenya (Griffin and Williams, 1983), 50% in Rwanda (Gascon et aL, 
1989) and 50% in Kinshasa, DRe (Dumas et aL, 1990a). Two serological studies have 
previously been performed in Uganda: in 1966 a seroprevalence of 11.7% was 
reported among healthy blood donors aged 15-25 years (ludlam and Somers, 
1966), and in 1991 the prevalence in HIV-negative and symptomatic HIV-positive 
individuals was found to be 27% and 34% respectively, using the Sabin-Feldman dye 
test (lumla et aI., 1991). However, the overall prevalence in the latter HIV-positive 
population was 45% using a latex agglutination test, but the authors judged the dye 
test to be more reliable (lumla et aI., 1991). In a study from Kenya the same year, 
other authors found that the agglutination test was more sensitive and more 
specific than the dye test, and this study showed a seroprevalence of 54% in HIV-
patients from Nairobi (Brindle et aL, 1991). Based on the above results it appears 
that the T. gondii incidence is increasing over time in Uganda, but other factors like 
differences in study populations (age, place of origin, HIV-infection etc) or 
sensitivity of the test may also be of importance. Gender-related differences in T. 
gondii seroprevalence have been found in some populations and been traced to 
handling of animals and meat, either at work or in the household (Arene, 1986; 
Abdel-Hameed, 1991; Youssef, 1993). However, gender did not appear to be a 
significant factor for the prevalence of infection or reactivation in Uganda; the 
seroprevalence was 1.1% higher in men, but this difference was not statistically 
significant. 
The majority of T. gondii infections in Uganda appear to be acquired at a 
relatively young age, since only a slow increase in seroprevalence with age was seen 
in this study population. An interesting finding was the considerably higher 
seroprevalence among the symptomatic patients compared with the ones who 
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came to the hospital for HIV-testing (Figure 2-12). Between 20 and 40 years of age 
this difference was in the order of 10-20 percentage units, but in the older age 
groups (41-45 and 46 and above) the seroprevalence among the symptomatic 
patients declined. Although speculative, one feasible explanation is decreased 
survival to this age among those who are severely immunocompromised and 
simultaneously infected with T. gondii. 
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Figure 2·12, Seroprevalence in different age groups in symptomatic and HIV-test patients, An 
increase with age was seen in the 'HIV-test' group, but among the symptomatic patients, the 
prevalence declined in the older age groups. The age is shown in 5-year intervals, where 25 means 
21-25,30 means 26-30 and so on. 
Taking the high rate of active toxoplasmosis in the symptomatic patients into 
account, this sample set is likely to be skewed towards people who are infected, 
which implies that their main reason for seeking care was the symptoms caused by 
toxoplasmosis. The same may be true also for a smaller fraction of the HIV-test 
patients and, hence, while we have shown that T. gondii is a common and 
important infection in HIV-patients in Uganda, the seroprevalence rate reported 
here cannot be assumed to faithfully mirror the infection rate in the general 
population. 
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2.4.2 Reactivation is common and occurs in seronegative patients 
Sixty-eight patients, corresponding to 15.2% of the screened samples, were 
found to have active toxoplasmosis through PCR-detection of parasites in the 
peripheral blood. However, the real reactivation rate may be somewhat higher, 
since the DNA in G4 was scarce and degraded and only showed a reactivation rate 
of 8% in symptomatic patients. In groups GI-G3, the total reactivation rate was 
18.4%, but among individuals with positive T. gondii serology it reached 26.4%. 
Studies investigating HIV-associated toxoplasmosis in other parts of the world 
have shown similar rates of reactivation. A prospective study from France showed 
that 25.4% of patients with positive T. gondii serology and a CD4-count below 100 
developed TE within 12 months (Oksenhendler et aL, 1994), and a 27% reactivation 
rate was found among seropositive Danish AIDS-patients (Garly et aI., 1997). 
However, during the last decade the introduction of highly active antiretroviral 
treatments has decreased the occurrence of toxoplasmosis and many other 
opportunistic diseases in AIDS-patients in Europe (Gray et aL, 2003). Studies on HIV-
patients from sub-Saharan Africa report a variable degree of toxoplasmosis. Several 
studies from West Africa consider toxoplasmosis among the most common causes 
of death among AIDS-patients (Lucas et aI., 1993; Millogo et aL, 2000), while it 
appears to be infrequent «1%) in South Africa (Hari et aL, 2007; Modi et aI., 2007). 
This difference could partly be due to methodological differences; Lucas et al 
performed autopsies, which are likely to detect the majority of TE cases, Millogo et 
al looked at response to treatment, which may lead to an overestimate of the 
number of cases. The South African studies on the other hand used serology, clinical 
presentation and to some extent CT-scans, which may not be sufficient to detect all 
cases of active toxoplasmosis. The predominance of different subtypes of HIV in 
these regions might have some influence, but HIV-clade was not found to be 
significantly associated with disease presentation in the literature summary 
presented by Modi et al (2007). Consistent with the regional differences in 
seroprevalence shown in Figure 2-1, the T. gondii seroprevalence in the study 
population of Hari et al was only 8%, and it does appears that the prevalence of T. 
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gondii and other infectious diseases in a population is the principal factor behind 
the opportunistic infections seen in HIV-patients. 
Two medical dissertations at Makerere University have investigated the 
prevalence of HIV-associated opportunistic infections of the central nervous system 
in Ugandan patients. D. Wamala studied 44 post-mortem samples and found that 
cryptococcal meningitis was the most common cause of death (33%) followed by 
cerebral tuberculosis (16%), bacterial infections (16%) and toxoplasmosis (13%) 
(Wamala, 1998). K. R. Byanyima, on the other hand found toxoplasmosis to be the 
most important opportunistic infection. She investigated 105 symptomatic HIV-
patients, whose main clinical symptoms were headache (76.2%), fever (67.6%), 
focal neurological signs (63.8%), convulsions (37.1%), reduced consciousness 
(30.5%), vomiting (27.6%) and photophobia (12.4%). The final diagnosis was based 
on clinical presentation, CT-scans, laboratory tests for tuberculosis and 
Cryptococcus, response to therapy and in some cases post mortem examination. In 
the Byanyima study, toxoplasmosis was the most common disease, affecting 29 
patients (27.6%), followed by cryptococcal (N=18), bacterial (N=9) and tuberculous 
(N=4) meningitis, and viral encephalitis (N=4) (Byanyima, 1998). 
An unexpected finding in the current study was the high proportion of 
patients who were PCR-positive in spite of negative serology. The absence of 
specific antibodies has sometimes been considered as a diagnostic signal which 
eliminates the risk of reactivated toxoplasmosis (Raffi et aL, 1999), but several other 
research groups have found active infections in T. gondii-seronegative HIV-patients 
(Porter and Sande, 1992; Laing et aL, 1996; Joseph et aL, 2002). In some cases this 
might be explained by recent infection, but considering the low acquisition rate in 
these age groups and the very advanced stage of immunosuppression among the 
symptomatic patients (22.4% had a CD4-count of 10 or lower), a more plausible 
explanation in this particular cohort is that the severe immune deficiency prohibited 
production of detectable antibody levels. 
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2.4.3 Diagnosis of latent and active toxoplasmosis in Uganda 
Active T. gondii infection can cause a wide range of different symptoms, and 
the clinical outcome of reactivated infection in the brain is directly linked to the site 
of parasite proliferation and host cell necrosis. In vivo imaging results suggest that 
parasites use the capillary system to spread within the brain, and the preferred sites 
of growth are the parietal cortex and frontal lobes, where many cognitive functions 
are located (Dellacasa-Lindberg et aL, 2007), but all types of brain cells can be 
infected (Suzuki, 1999) and differential diagnosis between HIV-associated 
neurological diseases cannot be based on clinical presentation alone. Local 
reactivation in the brain is followed by dissemination to other organs, including 
lungs and liver, and by this stage, which can last up to two weeks after the first 
symptoms, parasites start to become detectable in peripheral blood (Takashima et 
aL, 2008). 
Currently, there are no simple ready-to-use tests for detection of TE in AIDS-
patients and expensive methods like brain scanning are not feasible in resource-
limited settings. A study from Peru revealed that 82% of clinically important AIDS-
related diseases remained undiagnosed until the post mortem investigation (Eza et 
aL, 2006), which illustrates the need for reliable diagnostic tools. The IgG-
agglutination test used in this study is robust and easy to perform even in less 
equipped laboratories, and although there is a risk of false negative results in 
patients with advanced immunosuppression, positive serology is useful for 
identifying patients at risk of reactivation. PCR, although sensitive and specific in 
controlled tests, is not trivial to perform on clinical samples where the amount of 
parasite DNA is very small in comparison with the host DNA. In this study, Q-PCR 
quantification showed that the parasite density in the blood of HIV-patients with 
reactivated toxoplasmosis was really on the limit of detection. However, rapid 
processing of samples without freeze-thawing, increased amount of template DNA 
and the use of a mUlti-copy target sequence increases the likelihood of detection. 
In conclusion, serology is useful for identification of patients at risk of 
reactivation, but can be unreliable in individuals with a very low level of CD4-cells. 
T. gondii serology ought to be performed on all patients at the time of HIV-testing 
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and patients who are seronegative should be advised on how to avoid becoming 
infected, while positive patients should be advised to seek care if they get severe 
recurrent headaches. PCR should be used at the suspicion of TE and has a good 
positive predictive value, but a negative result does not rule out active 
toxoplasmosis since local reactivation may occur some time before parasites are 
detected in the blood. Even in the absence of positive serology or PCR, HIV-patients 
should be considered for T. gondii prophylaxis if their CD4-count drops below 100 
and they suffer from severe headaches. 
2.4.4 Three lineages are present and cause reactivation 
SAG2-genotyping data was retrieved from the 30 PCR-positive samples in the 
first cohort and showed that all three clonal T. gondii genotypes were present and 
caused disease in Ugandan HIV-patients. The most common lineage in this study 
was genotype II, which was responsible for 60% of cases, followed by type I and 
type III, and the genotype distribution was thus reminiscent of that seen in humans 
and domestic animals in Europe and North America, and clearly distinct from the 
pattern in South America (Figure 1-8). The absence of genetic data on T. gondii 
strains generally present in Uganda, prohibited comparisons of the strain 
distribution in symptomatic vs. asymptomatic infections that could show whether 
certain genotypes are more prone to reactivate in AIDS-patients. 
Single-locus typing is insufficient for detection of recombinant or atypical 
strains, but although attempts were made with the PCR-RFLPs described in 3.2.9, it 
proved difficult to obtain more genetic information from these samples. PCR-
screening of blood samples is an unbiased method for surveying the strain 
distribution in a human population, but in order to characterize strains more 
thoroughly a starting material with a higher parasite density is necessary, ideally 
isolates propagated in vitro. The wish for extended genotyping possibilities and 
desire to obtain T. gondii genotype information on the general strain distribution in 
the same part of Uganda led on to the next study, where free-range chickens were 
used as a sentinel species for circulating strains. 
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2.S Conclusions 
The high seroprevalence rate of T. gondii in Uganda is alarming in light of the 
AIDS epidemic. Extrapolation of the data from this study to the rest of the country 
implies that around 500,000 people in Uganda are co-infected with HIV and T. 
gondii and therefore at risk of developing TE. The high rate of reactivation in this 
study emphasizes the urgent need for implementation of better diagnosis of 
toxoplasmosis, using a combination of serology, clinical diagnosis, PeR-detection 
and response to chemotherapy. Strains belonging to all the three major lineages of 
T. gondii were present in the study population, but the scarcity of parasite DNA in 
the clinical samples did not allow for thorough genetic analysis. Therefore, further 
studies exploring the genotypes and phenotypes of Ugandan T. gondii strains are 
needed in order to find out if and how they differ from the archetypal lineages. The 
next chapter applies multilocus genotyping to tissue samples and mouse isolates 
from Ugandan chickens. 
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Chapter 3 Multiple Toxoplasma gondii infections are common in 
Ugandan chickens, providing opportunities for sexual recombination. 
3.1 Introduction 
Three highly conserved genetic lineages of T. gondii are predominant in 
humans and animals in Europe and North America, and the work presented in 
Chapter 2 indicated that the same three genotypes are present and cause disease in 
Ugandan HIV-patients. The importance of AIDS-associated toxoplasmosis highlights 
the need to understand the population structure and genetic composition of T. 
gondii in Africa, and the following study utilizes samples from free-range Ugandan 
chickens to assess the diversity of T. gondii through multi-locus genotyping. 
3.1.1 Chicken as indicator species 
Different strains of T. gondii display highly divergent levels of virulence in 
laboratory mice, and the parasite genotype may be important for the disease 
progression in humans (see section 1.3.1). In individuals suffering from acute 
toxoplasmosis, it is possible to isolate parasites or perform direct genotyping from 
blood or cerebrospinal fluid. In asymptomatic infections, however, the parasites are 
hidden inside tissue cysts and DNA cannot easily be obtained, making it difficult to 
assess the general parasite strain distribution in a region. Since T. gondii is a 
zoonotic parasite without defined host barriers (Sibley, 2003), genetic analysis of 
strains present in animals provides an opportunity to estimate the prevalence of 
different parasite genotypes present in a region. 
The domesticated chicken (Gallus domesticus) was chosen as sentinel species 
by Prof. J. P. Dubey to facilitate a direct comparison of the T. gondii strains present 
in the same host species but in different geographic locations. Free-range chickens 
are ideal for this purpose since they are common worldwide and often stray on or 
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around human settlements, where they feed from the ground. This behaviour 
makes them excellent indicators of oocyst contaminated soil and water, a major 
route of transmission to humans (Bahia-Oliveira et aI., 2003; Dubey, 2004). In 
addition, consumption of infected chicken meat provides a route of direct 
transmission from chickens to humans. Chickens are popular food animals, and 
even though meat is generally eaten well cooked in Uganda, handling practices may 
allow for cross contamination of pathogens from raw to cooked chicken meat 
(Wanyenya et aI., 2004). Isolation and genotyping of T. gondii in chickens thus 
provides important background information on strains that may infect humans, 
either through oocysts contaminated food/water or through bradyzoites in meat. 
Collectively, these traits in combination with the general availability and low cost 
make free-range chickens the ideal model for estimation of the T. gondii strain 
distribution in different parts of the world. Importantly, chickens are largely 
resistant to overt toxoplasmosis and rarely have symptoms (Dubey et aI., 2007c), 
thus sampling of chickens can be considered an unbiased survey of the T. gondii 
population, compared with typing of parasites from human blood samples, which 
only reveal disease-causing strains. 
3.1.2 T. gondii in chickens from different global regions 
A large number of studies have investigated the seroprevalence and genotype 
distribution of T. gondii in chickens from different parts of the world. Nearly all of 
them have been performed in the same laboratory (the lab of Prof. J. P. Dubey, 
USDA, Beltsville, USA) using the same techniques, and are therefore suitable for 
direct comparisons. However, the earlier studies, up until 2005, generally relied on 
SAG2-typing only. The marker kit was later expanded to include 5 RFLP markers and 
thereafter expanded further to 10-11 different markers. The number of markers 
used influences the possibility of detecting atypical or recombinant strains, and 
therefore some of the early studies classified a large number of isolates as clonal 
even though they were probably not. For example, many Brazilian strains, from 
chickens as well as other sources, were initially classified as type I or III based on 
SAG2, but it has later been shown that the population structure in Brazil is very 
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different from the clonal lineages seen in Europe (see 1.3.3). Many Brazilian strains 
have a mixture of type I and III alleles and a recent retyping of 151 strains 
recognised as many as 58 different genotypes in Brazilian chickens, half of which 
were found only once, while a few genotypes were spread over wide geographic 
areas (Dubey et aL, 2008). The first study on T. gondii strains in chickens from sub-
Saharan Africa was performed in 2005, resulting in ten isolates from Congo, Kenya, 
Mali and Burkina Faso, which were typed using SAG2 (Dubey et aL, 2005b). This 
study was later expanded with isolates from Nigeria and Ghana to include a total of 
20 isolates, and all samples including the previous ones were retyped using 10 PCR-
RFLP markers (Velmurugan et aL, 2008). The three samples from Ghana (2) and 
Nigeria (1) had atypical genotypes with a mixture of alleles, while the rest of the 
samples appeared to be clonal (with some exceptions for the apicoplast marker), 
and the predominant genotype was type III (Dubey, 2005, Velmurugan, 2008). 
Taken together, these chicken studies provide important background 
information about the diversity and distribution of T. gondii genotypes that are 
present in different geographic locations and may cause disease in humans. The 
overall T. gondii seroprevalence in chickens, as determined through a modified 
agglutination test (see 3.2.4), varied from around 25% in sub-Saharan Africa and 
Asia to nearly 50% in Central- and South America, and the variation in isolation 
success from seropositive samples ranged from less than 10% from Asian chickens 
to 80% in seropositive chickens from Central- and South America (Table 3-1). The 
difference in isolation success rate depends largely on the transport time and 
temperature conditions, and batches with severely degraded tissues rarely yield 
viable isolates (J. P. Dubey, personal communication). Table 3-1 provides a summary 
of the genotypes of T. gondii found in chickens from different parts of the world, 
and details of all included studies sorted by geographic region are listed in Appendix 
4. 
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Table 3-1. Summary of chicken genotyping studies across the world. 
N" Seroposb Isolates' Typeld Type lid Type md Atypicald Multipled 
Europe and 1284 
411 114 0 94 18 2 0 
North America (32%) (28%) (0%) (82%) (16%) (2%) (0%) 
Central- and 1508 
714 568 125 28 141 267 7 
South America (47%) (80%) (22%) (5%) (25%) (47%) (1%) 
ASia 524 
143 13 0 5 6 2 0 
(27%) (9%) (0%) (38%) (46%) (15%) (0%) 
North Africa and 262 
117 44 0 20 24 0 0 
Middle East (45%) (38%) (0%) (45%) (55%) (0%) (0%) 
Sub-Saharan Africa 311 
75 20 1 3 13 3 0 (24%) (27%) (5%) (15%) (65%) (15%) (0%) 
a Number of chickens used for determination of seroprevalence. 
bTotal number of seropositive chickens (seroprevalence) 
C Number of isolates retrieved (isolation success rate of seropositive chickens). 
d Number (%) of isolates classified as type I, II, ,", atypical or multiple infections. 
The data presented summarize studies performed by Dubey et ai, and details of all studies and the 
references are listed in Appendix 4. 
3.1.3 T. gondii in rats and mice 
Mice and rats are considered important reservoirs for T. gondii in nature 
(Webster, 1994; Murphy et aL, 2008), and rodents are a direct source of infection of 
the definitive hosts. Although mice and rats are normally not sources of direct 
transmission to human hosts, the strains circulating in rodents may enter the 
human/domestic animal cycle through the domestic cat. Mice are more susceptible 
to overt toxoplasmosis compared with rats, and are able to transmit the infection 
vertically from generation to generation without reinfection (Beverley, 1959). Rats, 
on the contrary, are highly resistant to acute toxoplasmosis, even type I strains 
cause chronic infections, often with a low parasite burden (Lecomte et aI., 1992; 
Dubey et aL, 1999). 
The seroprevalence of T. gondii in wild-caught mice (Mus musculus) and rats 
(Rattus narvegicus and Rattus rattus) have not been extensively studied, but the 
accumulated knowledge has recently been reviewed (Dabritz et aL, 2008). 
Generally, a low seroprevalence (0.0-2.1%) was found in mice, while the results in 
rats were more variable with several studies reporting an infection rate of 20% or 
more. However, recent peR-screening of rodents in the UK has showed a high 
prevalence (>40%) in both mice and rats (Marshall et aI., 2004; Hughes et aI., 2006). 
Although T. gondii was originally isolated in an African rodent, no recent reports 
have been published regarding the importance of rodents as a reservoir for T. 
gondii in Africa. 
3.1.4 Aims 
The main objective of this study was to assess the general distribution of T. 
gondii genotypes in Uganda and put this in relation to the genotypes previously 
found to cause disease in HIV-patients in the same region (Chapter 2). This was 
achieved through screening and multilocus genotyping of tissues from free-range 
chickens and wild-caught rodents from residential areas in and around Kampala. 
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3.2 Materials and Methods 
3.2.1 Free-range chickens 
Between Sep 4th_6th 2006, 85 free-range chickens were purchased from four 
different areas in and around Kampala (see Figure 3-3 in the results section). The 
locations were Gayaza, a suburban area north of the city (N=25), Buloba, a suburb in 
the west (N=21), Mukono, a rural village in the east (N=19) and the Mulago area, 
close to the city centre (N=20). The chickens were brought to the Veterinary Faculty 
of Makerere University where they were bled from the wing vein and thereafter 
killed. Age estimates were based on the length of the tarometatarsus and the size 
of the comb, and the chickens were divided into four different age groups. Group 1: 
6-9 months (N=27), 2: 10-13 months (N=13), 3: 14-17 months (N=32) and 4: ~18 
months (N=13). The bleeding, killing and age categorization was mainly executed by 
veterinary doctors William Muyombya and Maria Nakamya at the Veterinary 
Department of Makerere University. 
The chest cavity of each chicken was opened and the heart removed using a 
sterile, disposable scalpel. The head and heart were placed in separate, pre-labelled 
zip-lock bags and kept at 4°C. The blood was allowed to clot, first for Ih in room 
temperature and then overnight at 4°C, and thereafter centrifuged for 5 minutes at 
13,000 rpm. Approximately 1 ml of serum was transferred to screw-cap tubes and 
stored at -20°C. 
3.2.2 Wild-caught mice and rats 
Ten walk-in traps with bait were placed in different homesteads in the Mulago 
area in central Kampala. The traps were checked every morning for five days in 
September 2006. Five mice (Mus musculus) and nine rats (Rattus rattus) were 
trapped and brought to the Veterinary Faculty of Makerere University on the day of 
capture. The traps were placed in a container with tight lid, in which chloroform-
drenched cotton was used to euthanize and kill the animals. The intact bodies were 
placed in zip-lock bags in refrigerators until transported on cold packs to USDA, 
- 65-
Beltsville. One rat and four mice were trapped and put to death in the same manner 
during two weeks in January 2007, but since the number was so small, they were 
not sent away, but processed at Makerere (serology only, no bioassay). Dr. William 
Muyombya was in charge of the rodent catching and euthanization. 
3.2.3 Transport 
Chicken heads, hearts and sera, and the intact bodies of the rodents were 
placed on cold packs in polystyrene boxes, brought as checked-in luggage from 
Kampala to Washington DC. The import was cleared in customs according to US 
regulations. All samples were in good condition upon arrival and the sample 
processing at USDA began within 3-6 days of the death of the animals. 
3.2.4 T. gondii serology (MAT) 
The Modified Agglutination Test (MAT) has been developed in the lab of Prof. 
J. P. Dubey and exploits the same principles as the Toxo-Screen DA test (section 
2.2.3). Antigen solution was mixed fresh for each test (96 wells) and consisted of: 
2.5 ml antigen diluting buffer, 35 III 2-mercaptoethanol, 50 III Evans blue dye 
solution and 100 III antigen (formalin-fixed whole parasites). The control in this 
study was serum from a pig with a known titre of 1:200, used in 8 serial dilutions 
(1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 1:1,600 and 1:3,200). The reaction was 
considered valid if the control serum gave a positive result for the first four and a 
negative result for the last four dilutions. Twenty-five III of antigen solution was 
mixed with 25 III serum dilution and incubation at 37"C over night was followed by 
visual inspection and interpretation. As for Toxo-Screen DA, a positive reaction lead 
to the formation of a faint mat consisting of bound antibodies and antigen, while a 
negative reaction resulted in accumulation of antigen in the bottom of a well visible 
as a distinct dot or ring. 
All chicken sera were first tested for dilutions 1:5, 1:10, 1:20 and 1:40. Sera 
that were positive at 1:40 were further diluted and tested for 1:80, 1:160, 1:320 and 
1:640. For safety reasons, the rodents were not bled while alive, but killed and 
transported intact. During dissection, their chest cavity was opened and a few drops 
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of 0.85% saline solution were added, the drawn mixture was spun at 10,000 rpm for 
5 min, and the supernatant was used for serology. The serology was performed with 
the help of with Dr. Oliver Kwok at USDA. 
3.2.5 Bioassay and isolation in mice 
Bioassay in mice was used to isolate live parasites from rodent and chicken 
samples and to assess the mouse-virulence of the parasite strains, and a schematic 
overview of the process is presented in Figure 3-1. Chickens were divided into three 
groups based on their serological titre. Seronegative samples were pooled in three 
groups of 15 and bioassayed in cats (one cat per group), samples with a titre of 1:5 
or 1:10 were pooled in groups of five and bioassayed in mice (four mice per pool), 
while samples with a titre of 1:20 or higher were inoculated into four mice each. 
First, pepsin digestion was performed on chicken brains and hearts, in order to 
increase the concentration of parasites and release bradyzoites from tissue cysts. 
Chicken heads were opened with sterile scissors and bone-cutters, the brain was 
taken out and mixed together with the heart from the same individual in a sterile 
blender with saline (0.85% NaCI), until homogenized. For individual samples 50 ml 
saline was added, for pooled samples from 3-5 chickens 100 ml saline was used. 
After homogenization an equal volume of prewarmed (37"C) pepsin solution- was 
added, and the samples were incubated in a 37·C water bath for 45 minutes. 
Filtration through double layers of gauze removed undigested tissue, and cell 
sedimentation was achieved through centrifugation for 10 min at 2,000 g. The 
supernatant was discarded and the bottom phase resuspended in approximately 20 
ml of 1.2% sodium bicarbonate (NaHC03) with neutral red as a pH indicator (added 
until orange in colour), mixed and spun for 10 min at 2,000 g. The supernatant was 
discarded and the pellet resuspended in 5 ml of saline with 1000 u penicillin and 
100 Ilg streptomycin per ml. Four outbred, female Swiss-Webster mice were 
infected subcutaneously with one ml of this suspension, and 400 III was used to 
extract DNA for direct parasite strain typing. Mice were bled for MAT-serology from 
• 100 ml pepsin solution: 1 g NaCl, 2.80 ml 6N HCI, 0.52 g porcine pepsin and sdH20 up to a final 
volume of 100 ml was mixed. Enzyme is activated at 37"C. 
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the tail vein six weeks post-inoculation, sacrificed through cervical dislocation and 
dissected in a sterile hood. Brains were used for light microscopy examination, 
subpassage in mice, cryopreservation and genotyping of infecting parasites. Prof. J. 
P. Dubey, Dr. Natrajan Sundar, Ms. Katherine Hopkins and Ms. Lucia Bandini 
performed the bioassay work at USDA, including mouse serology, microscopy and 
cryopreservation. 
3.2.6 Cryopreservation of T. gondii from mouse brains 
Brains of infected Swiss-Webster mice were ground in sterile mortars with 1 
ml PBS until homogenized. The homogenate was transferred to a 15 ml tube with 1 
ml freshly made, pre-warmed pepsin solution. This mix was incubated for 45-60 s 
and thereafter neutralized with NaHC03 neutral red until orange, whereby the tube 
was filled up with sterile filtered PBS and centrifuged at 3,000 g for 10 minutes. The 
supernatant was discarded and the pellet dissolved in cryomedium (OM EM with 
25% DMSO and 8% BSA), and aliquoted in 1.5 ml cryovials that were placed in -20'C 
for 2-3 hours, then -80'C over night before final transfer to liquid nitrogen for long-
term storage. The cryopreservation of these samples at USDA was performed by Dr. 
Natrajan Sundar. 
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Figure 3-1. Sample processing overview for Ugandan chickens. Samples were divided into t hree 
groups based on thei r serology titre, and thereafter bioassayed. Genotyping was perform ed directly 
on ch icken tissues as well as tissues from infected mice. Three possible clin ical outcomes in infected 
mice are highl ighted in yellow and negative endpoints in blue. 
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3.2.7 Bioassay in cats 
Cats are the definitive hosts for T. gondii and sensitive to oral infection with 
bradyzoites in meat. Tissues from seronegative chickens were chopped finely and 
mixed with the cats' normal food, which they ate ad libido. All cat faeces between 
days 3-10 were collected and examined for oocysts through faecal flotation. If no 
oocysts had been found after 10 days, cats were considered uninfected. 
litter was collected and dissolved in water, filtered through double layers of 
• gauze and poured into a 50 ml tube. This was filled up with 2M sucrose; tubes were 
shaken vigorously and centrifuged for 10 min at 2,000 g. The oocysts have a lower 
density (1.11 g/cm3) compared with the sucrose solution (1.8 g/cm3) and do 
therefore float at the top of the tube, and one drop of the supernatant was 
therefore used for microscopic examination. Approximately 1 ml of the top layer 
was transferred to 50 ml tubes containing 10 ml of 2% sulphuric acid, which 
accelerates sporulation and prevents fungal growth. The mixture was put on a 
shaker at room temperature for two weeks. If no oocysts were found through 
microscopic examination during this time, all samples from the same cat taken on 
different days were pooled, neutralized and fed orally to mice. Mice are sensitive to 
oral infection with oocysts and a single infective oocyst present in the samples is 
likely to be detected this way. Ms. Katherine Hopkins at USDA took care of the cats 
and performed all of the oocyst isolation work. 
3.2.8 DNA-extraction 
A commercial kit (QIAgen DNeasy, Animal Tissue protocol) was used for DNA-
extraction. For direct genotyping from chickens, the pellet from 400 III brain-heart 
pepsin digest homogenate (section 3.2.5) was used as template. For genotyping of 
parasites isolated through mouse bioassay, DNA was extracted from 200 Ilg brain 
(by Dr. Natrajan Sundar) and sent to leeds University, where genotyping was 
performed. 
• 20 litre batch of 2M sucrose solution: 13 kg sucrose was boiled with water, then 100 ml of phenol 
was added to prevent fungal growth. 
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Briefly, 180 ~I tissue lysis buffer and 20 ~I Proteinase K was added to the 
pellet/brain tissue and mixed by vortexing. This was incubated in a water bath at 
55'C, for 3 hours. Thereafter, the procedure was the same as for the human blood 
samples (see 2.2.4). 
3.2.9 Genotyping PCRs 
Five different PCR-RFlPs were used for molecular detection and genotyping of 
T. gondii, both directly from chicken and rodent tissues and from infected 
laboratory mice. The reactions amplified the loci SAG1, SAG2 (5' and 3' -end), SAG3, 
BTUB and GRA6, according to a published method (Dubey et aI., 2006a). Primers 
and restriction enzymes are listed in Table 3-2. 
Table 3-2. Primers and enzymes used for detection and genotyping. 
Gene Fragment lengths· 
(Chrom) Forward primer length Rest. enz. Type I Type II Type III 
SAG 1 ext GTICTAACCACGCACCCTGAG (F) 476 bp Sau961, 334 293 293 
(VIII) AAGAGTGGGAGGCTCTGTGA (R) Haell 56 97 97 
int CAATGTGCACCTGTAGGAAGC (F) 390 bp 
GTGGTICTCCGTCGGTGTGAG (R) 
SAG2-5' ext GCTACCTCGAACAGGAACAC (F) 335 bp Sau3AI 242 242 186 
(VIII) GCATCAACAGTCTICGTIGC (R) 56 
int GAAATGTTICAGGTIGCTGC (F) 242 bp 
GCAAGAGCGAACTIGAACAC(R) 
SAG2-3' ext TCTGTICTCCGAAGTGACTCC (F) 327 bp Hhal 222 169 222 
(VIII) TCAAAGCGTGCATIATCGC (R) 53 
int ATICTCATGCCTCCGCTIC (F) 222 bp 
AACGTTICACGAAGGCACAC (R) 
BTUB ext TCCAAAATGAGAGAAATCGT (F) 527 bp Taql, 220 191 127 
(IX) AAATIGAAATGACGGAAGAA(R) BsiEI 118 127 118 
int GAGGTCATCTCGGACGAACA (F) 411 bp 73 93 93 
TIGTAGGAACACCCGGACGC (R) 73 
GRA6 ext ATTTGTGTTTCCGAGCAGGT (F) 546 bp Msel 258 183 161 
(X) GCACCTICGCTIGTGGTT(R) 86 161 97 
int TTTCCGAGCAGGTGACCT (F) 344 bp 86 
TCGCCGAAGAGTIGACATAG(R) 
SAG3 ext CAACTCTCACCATTCCACCC (F) 311 bp Ncil 100 226 162 
(XII) GCGCGTIGTIAGACAAGACA(R) 64 64 
int TCTIGTCGGGTGTTCACTCA (F) 226 bp 62 
CACAAGGAGACCGAGAAGGA(R) 
aA double digest of SAG1 amplicons with Sau961 and Haell can differentiate type I from II/III, and also 
detect an unusual allele "u-1" if both enzymes cut the product (237+97+56 bp), see Figure 3-8. 
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All the six external primer pairs were run together in a mUltiplex PCR-reaction. 
The total reaction volume was 25 Ill : 20 III H20, 2.5 III 10*PCR-buffer (New England 
SioLabs), 0.5 III dNTPs (10mM), 0.1 III of each primer (50 pM/ Ill), 0.1 III Taq 
polymerase (New England SioLabs, 5 U/ Ill) and 1 III DNA-template. The 
amplification program for the external multiplex PCR was 9s·C for 4 min followed 
by 25 cycles of 94·C (30 s), S5·C (1 min) and 72·C (2 min). One III of the product was 
used as template for the nested PCRs, where each locus was amplified separately. 
The mastermix and PCR-program for the nested rounds was the same as above but 
with the following exceptions: 21111 H20 was added since only two instead of twelve 
primers were used, the annealing temperature was increased to 60·C for all 
reactions, and the number of cycles was increased to 35. 
SOObp 
~ 
BTUB 
SOObp 
) 
SAG3 
Figure 3-2. Sensitivity testing of the genotyping PCRs for BTUB and SAG3. BTUB had lower 
sensitivity, needing around 10 copies of parasite DNA for detection, and it was also the marker 
yielding the lowest number of positive results when applied to chicken and rodent samples. A 100-bp 
size marker was used, and the short fragments seen at the bottom are primer-dimers. 
Restriction enzyme digests were performed in 20 III reaction volumes, 
consisting of 12.6 III H20, 2 III buffer, 0.2 III BSA, 0.1 III enzyme and 5 III PCR-
product. The reactions were incubated for 1 hour at 37·C, except for the STUB-gene 
where the temperature was 60·C for the double digest BsiEI and Taql. Enzymes 
were from New England BioLabs, except Hhal that was from Promega, and the 
corresponding buffers were enclosed with the enzymes. Fragments were visualized 
on 2% agarose gels under UV-light. 
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3.2.10 Sequencing and sequence analysis 
PCR-amplicons selected for sequencing were purified using the QIAgen PCR 
purification kit, which removes buffer components, primers and free nucleotides. 
The elution volume was 30 Ill, of which 10 III was used for each sequencing 
reaction, together with 4 III of the appropriate primer. Technical personnel at the 
University of leeds performed the sequencing reaction using an ABI377 DNA 
Sequencer machine (Applied BioSystems). 
Chromatograms and automatic reads generated by the sequencer were 
viewed and manually controlled and edited in the BioEdit Sequence Alignment 
Editor software (http://bioedit.software.informer.com/). BLAST searches at NCB I 
Blast (http://blast.ncbLnlm.nih.gov/Blast.cgi) and ToxoDB (www.toxodb.org) were 
used to retrieve sequences for the same loci from different strains and alignments 
were made directly in BioEdit or in ClustalW (http://www.ebLac.uk/ 
Tools/clustalw2/index.html). Successfully sequenced amplicons were submitted to 
GenBank (Accession numbers EF585673-EF585715). 
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3.3 Results 
3.3.1 Serological screening of T. gondii in chickens and rodents 
Eighty-five free-range chickens were obtained from four different areas in 
around Kampala : Gayaza (N=25), Buloba (N=21), Mukono (N=19) and Mulago 
(N=20), see Figure 3-3. 
DE t REP. 
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N=21 ! N=20 
Mulago 
"'P9 
Figure 3-3. Map of sampling areas. Twenty chickens originated from the Mulago area, close to the 
city centre, 21 and 25 came from sub-urban settings in Buloba and Gayaza respectively, while the 
last 19 were obtained from rural areas around Mukono. The map is taken from the CIA factbook 
(https:/ Iwww.cia.gov/library/publications/the-world-factbook/geos/ug.html) . 
Forty chickens were seropositive at a MAT-titre of 1:5 or higher, giving a total 
seroprevalence of 47%. There was a significant difference in total seroprevalence 
among the chickens from Buloba compared with those from the other locations 
(P<O.OOl, chi-square test). The two positive chickens from Buloba both had a low 
titre (1:5 or 1:10), while 20 chickens, originating from Gayaza (N=6), Mukono (N=6) 
and Mulago (N=8) had a titre of 1:20 or higher. The prevalence of negative, low-titre 
(1:5-1 :10) and high titre (~1:20) chickens from different locations are shown in 
Figure 3-4. 
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Figure 3-4. Chicken serology results, by place of origin. The highest seroprevalence was found in 
chickens from the Gayaza area, but Mulago had the highest number of chickens with a titre of at 
least 1:20. Chickens from Buloba had the lowest prevalence, with only two low-titre seropositive 
chickens. 
The full range of MAT-titres was; 1:5 (N=9), 1:10 (N=l1), 1:20 (N=5), 1:40 
(N=12), 1:80 (N=l), 1:160 (N=l), 1:320 (N=l), and a table listing all the site of origin, 
sex, age categorization, MAT-titre and the pooling of samples for PCR and bioassay 
for each chicken is provid; d in Appendix 5. Briefly, chickens with a low MAT-titre 
were pooled in groups of 3-5, while the 20 chickens with a titre of at least 1:20 were 
bioassayed individually, and the same was true for the direct PCR-detection and 
genotyping. This cut-off value 'Was based on Prof. Dubey's experience of isolation 
success in chickens with different MAT-titres. 
The chickens from Buloba were considerably younger then the chickens from 
t~e other areas, which may be one explanation for the lower seroprevalence seen in 
this group. As described in section 3.2.1, chickens were divided into four age 
groups, and 76% of Buloba chickens belonged to age group 1 (6-9 mol, compared 
with 10-28% in the other groups (Figure 3-5). 
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Figure 3-5. Chicken age distribution, by place of origin. The chickens from Buloba had a higher 
proportion of young animals (6-9 months old), which is probably correlated to the lower level of T. 
gondii exposure seen in this group. 
A tendency towards an increase in seroprevalence with age was observed, and 
the prevalence rate reached 69% in chickens aged ~18 months (Figure 3-6), but the 
difference between age groups was not statistically significant (as tested by the chi-
square test) and chickens of all ages carried T. gondii infections. 
80% 
70% 
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20% 
6-9 mo (N=27) 10-13 mo (N=13)14-17 mo (N=32) ~18 mo (N=13) 
Figure 3-6. Chicken seroprevalence in different age groups. Older chickens are more likely to have 
been exposed to T. gondii infections, but the difference in seroprevalence was not significant 
between age groups among the Ugandan chickens. . 
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Ten rats and nine mice were captured in the Mulago area during the sampling 
periods in 2006 and 2007. MAT serology revealed T. gondii infection in two rats 
(22%), at titres 1:40 and 1:160, but no mice were seropositive. Five mice, captured 
in 2006, were pooled for bioassay but did not generate infection in laboratory mice, 
indicating a low prevalence of T. gondii in house mice in this area. The two 
seropositive rats were bioassayed individually, while the seronegative rats were 
pooled. However, no inoculated mice did seroconvert and no parasites could be 
detected by PCR or microscopy of the mice brains. Thus, there was unfortunately no 
success in isolation of T. gondii strains from wild-caught rodents from Uganda, but 
serological evidence of infection was found in two out of nine rats (Appendix 6). 
3.3.2 Direct genotyping of T. gondii from Ugandan chickens and 
rodents 
Thirty DNA samples plus positive and negative controls were used for direct 
genotyping from chicken and rodent tissues, where a multiplex external PCR was 
followed by separate amplifications with internal primers for five different genes 
(section 3.2.9). The samples consisted of twenty individual chickens, three groups of 
pooled chickens with a MAT-titre of 1:10 (lOA, lOB, 10C), two pools of chickens 
with titre 1:5 (pools SA and 5B), two individual rats, two groups of pooled rats (RA 
and RB) and the pooled samples from five mice (M), as listed in Appendices 5 and 6. 
T. gondii-DNA was detected directly from tissue samples in all the 20 chickens 
that were bioassayed individually (MAT-titre ~ 1:20). Figure 3-7 shows the first 
screening at locus SAG2-3' (repeat amplification later yielded three more positive 
samples), and genotyping results for all samples are listed in Table 3-3. Six out of 20 
chickens (30%) were found to be infected with parasites of genotype I. Nine 
samples (45%) harboured parasites that had type II alleles for all amplified markers, 
and a single sample (5%) contained a pure type III strain. Results from the remaining 
four chickens displayed variable genotyping results at different markers, indicating 
the presence of unusual genotypes or mUltiple infections in the same host. For Ch-
62 and Ch-78 alternating type I and type II alleles were detected, while Ch-2 and Ch-
70 contained parasites with alleles from types II and III. 
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Figure 3·7. Nested SAG2·3' first screening results for Ugandan chicken and rodent samples. RH (T. 
gondii type I) and DNA from human fibroblasts were used as positive and negative controls at the 
first line of the gel, where a ladder is present in the last well, while Me49 (T. gondii type II), VEG (T. 
gondii type III) and water were used as controls on the second row. Numbers indicate the samples, 
l =Ch-l, 2=Ch2 and so on . The amplified fragments are 222 bp of length. 
In addition, the sam ple from Ch-70 contained an atypical allele "u-l/l at the 
SAGl locus (Figure 3-8). This allele is digested by both restriction enzymes (Sau9GI 
and Haell), and had previously been found in T. gondii strains from Colombia 
(Dubey et aL, 200Gb), and later also in Sri Lanka, China and Brazil (Dubey et aL, 
2007b; Dubey et aL, 2007d) . 
1 17 25 52 64 68 70 79 81 82 83 10C Rat5 RB RH Me49 VEG 
j 11111 11/111 11/111 11/111 11/111 u-1 11/111 11/111 11/111 11/111 11/111 
Figure 3·8. Double restriction enzyme digests of SAGl amplicons. Hoell cuts the 390 bp product of 
type II or type III strains into two fragments of 293 and 97 bp, while Sou961 digests type I amplicons 
into 334+56 bp. For the parasites present in Ch-70 a double digest was seen, resulting in fragments 
of 237+97+56 bp, and this allele has also been detected in South America and Asia. 
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Table 3-3. Direct genotyping results from chicken and rodent tissues. 
IgG-titre SAGla SAG2 S,b SAG23,e SAG3 
Ch-1 1:80 II / III 1/11 II II 
Ch-2 1:40 - 1/11 II -
Ch-1s 1:40 
- 1/11 - II 
Ch-17 1:160 II / III 1/11 II II 
Ch-20 1:20 - - II II 
Ch-2s 1:20 I 1/11 I / III -
Ch-s2 1:40 II / III 1/11 II II 
Ch-ss 1:20 - - I / III I 
Ch-s8 1:40 - 1/11 - I 
Ch-61 1:40 - 1/11 1/111 I 
Ch-62 1:20 - - II I 
Ch-64 1:320 II / III III 1/111 III 
Ch-68 1:40 II / III - - -
Ch-70 1:40 u-1 1/11 II III 
Ch-73 1:40 - - 1/111 I 
Ch-78 1:20 II / III 1/11 1/111 I 
Ch-79 1:40 II / III 1/11 II II 
Ch-81 1:40 II / III 1/11 II II 
Ch-82 1:40 II / III 1/11 - II 
Ch-83 1:40 I 1/11 1/111 I 
Pool SA 1:5 - - - -
PoolsB 1:5 - - - -
Pool10A 1:10 - - - -
Pool10B 1:10 - - - -
Pool10C 1:10 I - 1/111 -
Rat-2 1:160 - 1/11 - -
Rat-s 1:40 I - - -
PoolRA 0 - 1/11 - -
PoolRB 0 I 1/11 - -
PoolM 0 - - - -
RH NA I 1/11 1/111 I 
Me49 NA II / III 1/11 II II 
VEG NA II / III III 1/111 III 
water NA - - - -
• SAG1 can only differentiate between type I and non-type I. 
b SAG2-s' can only differentiate between type III and non-type III. 
e SAG2-3' can only differentiate between type" and non-type II. 
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One of the pooled chicken samples was PCR-positive (Pool 10C, consisting of 
three Mulago chickens with MAT-titre 1:10), and was found to contain a type I 
strain. The samples from chickens with titre 1:5 or 1:10 were negative by PCR, as 
was the mouse sample (Pool M). However, all four rat samples (Rat-2, Rat-5 and 
pools RA and RB) were positive at one or more genotyping loci. Two of these, Rat-5 
and Pool RB, were shown to harbour parasites of genotype I, while the other two 
(Rat-2 and Pool RA) could only be classified as being either type lor II (Table 3-3). 
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3.3.3 Bioassay results and genotyping of isolates 
Tissues from 20 chickens with MAT-titre of 1:20 or higher were homogenized, 
digested in acidic pepsin and inoculated into four mice per sample. Mice from nine 
of these twenty groups were seropositive, while none of the pooled samples caused 
the mice to seroconvert, indicating an insufficient quantity of viable parasites for 
infection. Furthermore, none of the cats fed seronegative chicken tissues shed 
oocysts, which confirms that chickens with undetectable antibodies were 
uninfected, and no mice inoculated with rat or mouse tissues did seroconvert. The 
isolation rate was thus 45% among chickens with MAT ~1:20. 
The nine T. gondii strains that were infective to mice originated from Ch-1, 2, 
17, 52, 68, 70, 79, 81 and 82. Out of 35 mice infected with these samples (nine 
groups of four, minus one mouse who died), 33 were seropositive at a MAT-titre of 
1:25. The parasite density was low for all of these strains; only a small number of 
tissue cysts were visible in the brains, and for nearly a third of the positive mice no 
parasites were detected by careful microscopic examination performed by an 
experienced parasitologist (Prof. J. P. Dubey). All the nine isolates thus appeared to 
be slow growing, and since none of the Ugandan strains caused symptoms in 
laboratory mice, they were classified as avirulent. Table 3-4 lists all mice that 
became infected, and all mice where no tissue cysts could be seen in the brain are 
shaded in grey. 
Six of the retrieved isolates originated from samples that had been found to 
be infected with type II strains through direct genotyping (Ch-1, 17, 52, 79, 81 and 
82), and genotyping of DNA extracted from the brains of infected mice using four 
markers (SAG2-5', SAG2-3', SAG3 and GRA6) confirmed this typing (Table 3-4). 
These samples had all been readily genotyped on most markers straight from tissue 
samples and all mice in these groups seroconverted (4/4 mice, but 3/3 in the Ch-1 
group, where one mouse died before the end of the experiment), which indicates a 
comparably high parasite density. Tissue cysts were visible in the brain for most of 
these mice, except one mouse from the Ch-81 and two from the Ch-82 group (Table 
3-4). 
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Table 3·4. Genotyping results from mice inoculated with tissue from infected chickens 
Mouse-lOa SAG25' SAG23' SAG3 GRA6 Totalb 
A1 1/ II II II II 
A2 1/11 II II II 
Ch-1 A3 1/11 II II II II 
1/11 I / III I + II II 
A5 III I / III III 
Ch-2 A6 III III III Mix 
AS 1/ II 
A9 1/ II 
AID 1/ 
Ch-17 All II 
A12 
A13 
A14 
Ch·52 II 
/111 
II I + II 
Ch-6S II II Mix 
I / III I 
II 1+111 I + II 
1/111 II + III II 
Ch-7D III Mix 
A26 / 
A27 / 
A28 / 
Ch-79 A29 / II 
A3D / 
A31 / 
/ 
Ch-S1 / II 
/ 
/ 
/ 
/ II 
ropositive mice without visible tissue cysts are shaded in grey. 
bSix strains, from chickens Ch-1, 17, 52, 79, 81 and 82, were type II strains as determined by direct 
genotyping from chicken tissues as well as the typing from brains of infected mice shown above. 
Strains originating from chickens Ch-2, Ch-68 and Ch-7D all had a mixture of alleles and divergent 
patterns seen in different mice. The presence of more than one allele at the same locus showed that 
these were mUltiple infections of two (Ch-68) or three (Ch-2 and Ch-7D) different strains. 
The last three isolates came from samples that had been found by direct 
genotyping to contain parasites with type II alleles (Ch-68) or a mixture of type II 
and III alleles (Ch-2 and 70). Three out of four mice (A4-A6) from the Ch-2 group had 
seroconverted, and brain cysts were visible in two of them (AS and A6). Genotyping 
of A4 showed a mixture of type I and II alleles: type II for GRA6, type I for SAG2 and 
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a sequence pattern w ith double peaks at SAG3 (Figure 3-9). AS and A6 both had the 
same allel ic pattern, but it was different from A4: type III at loci SAG2 and SAG3, 
and type II at GRA6. This suggests multiple infections in the same chicken with three 
different strains, since three different alleles were detected at the same locus (SAG-
3) . From these data, it is not possible to deduce whether the strains in question 
were true types I, II and III or had a combination of alleles. 
~ 0 so ~ 
G IT G C - GGG AA CCCC A G AAA G T GGG R G A G R G G C 
i 
I: C I: G I: A 
II: T II: A II: G 
Figure 3-9. Chromatogram with double peaks indicative of co-infection. The figure shows a stretch 
of sequence in the SAG3 gene from Ch-2, mouse A4, and arrows point to the differences between 
genotype I and II (all other bases within this region are identical in these lineages). The proportional 
height of the type I and II is conse rved in the three SNPs, and type I appeared to be the predominant 
strain in th is infect ion. 
Out of four mice in the Ch-68 group, three were seropositive (A19-A2l) and 
cysts were seen in one (A20) . Here two different genotypes were detected, type I in 
mouse A19, type II in mouse A21, and both I and II in mouse A20. From this result it 
was concluded that Ch-68 was infected with two different strains belonging to 
lineageslandll. 
The most complex pattern was seen in the group of mice infected with tissues 
from Ch-70 (Table 3-4) . All four mice (A22-A2S) were seropositive, but none had 
visible brain cysts, and the genotype pattern found in the different mice contained 
alleles from all three lineages: the strains in A22 and A2S had type I alleles at all 
amplified loci, while A23 and A24 appeared to contain strains of genotypes I, II and 
III. Although it was not possible to deduce the genetic make-up of the individual 
infecting strains when a complex pattern was seen, it was shown that three distinct 
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alleles were present at the SAG3 locus, which indicates a mUltiple infection with 
three different strains. 
When mixed genotypes were detected via RFLP, sequencing was performed to 
verify the results. Analysis of these sequences frequently revealed double peaks at 
known polymorphic sites indicating the presence of mUltiple alleles (Figure 3-9), 
which strengthens the evidence for co-infection with several T. gondii strains in the 
same host. The short gene fragments utilized for genotyping in this study appear to 
be fairly well conserved. Based on PCR-RFLP, only one sample (Ch-70) was found to 
contain parasites with an atypical allele; the unusual digestion pattern for SAGl 
discussed in section 3.3.2. Sequencing confirmed that this digestion pattern was 
due to a polymorphism in a single strain rather than double digestion caused by 
mUltiple strains being amplified. Overall, 47 sequence fragments covering >l5kb 
were retrieved (GenBank Accession numbers EF585673-EF5857l5) from different 
strains, mostly from the SAGl, SAG3 and GRA6 loci. A total of five new SNPs were 
identified: three were present in the SAG3 sequence of the type III strain from Ch-
70, one in the SAGl sequence from Ch-25, and one in the SAG2-3' sequence from 
Ch-83 (see Appendix 7). These results indicate a high level of conservation between 
the Ugandan strains and the three archetypal lineages. 
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3.4 Discussion 
3.4.1 Serotitre was related to amplification and isolation success 
In the current study, there was a clear correlation between the serological 
titre of the chicken and the success of direct PCR-genotyping and isolate recovery 
(Figure 3-10). Parasites from all chickens with a titre of 1:20 or higher could be 
genotyped directly from the chicken tissue homogenate by at least two markers, 
and all T. gondii strains from chickens with tit res of 1:80 or higher were readily 
amplified at all six loci. It is therefore likely that the amplification success and 
serological tit res were correlated to the parasite density in the organs used for 
bioassay and DNA-extraction. 
7 .-----------------------------------------------~ 
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Figure 3-10. Amplification sutcess in relation to serological titre in chicken. The higher the 
serological titre in the host, the easier was amplification of parasite DNA, suggesting a correlation 
between serological titre and parasite density in chickens. Bars show the average number of 
amplified markers plus standard deviation. 
Parasite isolation from Ugandan chickens through mouse inoculation was 
successful for nine T. gondii strains, all of which originated from birds with a MAT-
titre of at least 1:40, and the total isolation rate was 22.5% (9/40 seropositive 
chickens). MAT-titres as low as 1:5 have been shown to be meaningful in chickens 
and occasionally result in isolates (Dubey et aI., 2003a; Dubey et aI., 200Sa). 
However, isolate retrieval is accomplished more often from animals with a higher 
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titre (Dubey et aI., 2003b), and the isolation success rate of 22.5% seen in this study 
is similar to that found in most parts of the world (Table 3-1) . 
3.4.2 Genotype related bias in isolation success 
An unexpected finding in this study was the preferential selection of genotype 
II in the mouse bioassay. Mice from nine out of 20 groups showed serological 
evidence of infection 42 days post-inoculation. Six of the causing strains were pure 
type II, while three samples originated from chickens infected with type II and at 
least one other strain . Among the eleven strains that failed to grow in mice, six 
belonged to genotype " two were type II, two were mixed 1/11 infections and one 
was a type "' (Figure 3-11). The type' strains in this study were difficult to amplify 
by several PCR-markers and limited parasite numbers may be the explanation for 
isolation failure. However, the same logic cannot be applied to the type "' strain 
(Ch-64) which came from a high titre chicken (1:320) and was easily amplified at a" 
loci. Other possibilities are variability between strains in their capacity to infect mice 
or in their transmissibility through subcutaneous inoculation. 
1 2 
3 
6 DMix 
-I 
0111 
Figure 3-11 Genotype related bias in mouse bioassay_ Six of eight type II strains did successfully 
infect mice, while none of the type I strains did, and this difference was highly significant (P<O.Ol 
between type I and II, chi-square test) . In addition, three of five isolation attempts on samples from 
chickens with multiple infections were successful. 
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The ratio of tachyzoites to encysted bradyzoites can vary between strains and 
influence their survival during transport and their susceptibility to treatment with 
acidic pepsin. Tachyzoites are normally killed by pepsin, while bradyzoites are 
resistant and remain infectious upon this treatment (Dubey, 1998c), and inefficient 
tissue cyst formation has been associated with decreased oral infectivity in mice 
(Fux et aI., 2007). The pepsin treatment applied to the chicken tissues in this study 
mimics the environment in the digestive tract and aims to release bradyzoites from 
cysts. Strains with immature cysts or a low proportion of bradyzoites are therefore 
less likely to survive and remain infectious after pepsin digestion, and while the 
cystogenic ability of different strains has not been specifically investigated in 
chickens, several highly virulent type I strains are non-cystogenic in mice (Ferreira 
Ade et aI., 2006). Although type I strains have been isolated in the same laboratory 
according to the same protocol, these are almost exclusively from South America 
(see Appendix 4) and there might be inherent differences between type I strains 
from different parts of the world that render them more or less susceptible to this 
isolation bias. It has been noted previously that studies which employ direct typing 
often detect a comparatively high number of type I and mixed infection, while type 
II are preferentially selected after mouse inoculation (Villena et aI., 2004). 
Regardless of the biological mechanisms for this bias, it is important to be aware of 
this and employ direct typing for assessment of the true strain diversity, although 
isolates are necessary for in depth genetic and phenotypic characterizations. 
3.4.3 Similar genotype distribution in chickens and HIV-patients 
Direct genotyping of T. gondii from 20 asymptomatic Ugandan chickens 
showed a predominance of type II (40%) followed by type I (30%). Only one pure 
type III strain was detected, but type III alleles were also found in two samples with 
mixed infections. The genotype distribution in this study is similar to that seen in 
HIV-patients from the same part of Uganda (Figure 3-12). 
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Chickens (N=20) HIV-patients (N=30) 
Figure 3-12. T. gondii strain distribution in chickens and HIV-patients from Uganda. The stra in 
distribution was similar in HIV-patients and chickens from Uganda, with a predominance of type II 
strains. The main difference was the discovery of multiple infections in 25% of the chickens. 
The main difference was a somewhat higher proportion of type II strains in the 
human patients, but since all the multiple infections in chickens contained type II 
alleles a significant difference cannot be established, and from the current data 
there is no evidence that any particular T. gondii genotype is more likely to cause 
disease in HIV-patients. The pattern seen in Uganda, with a predominance of type II 
followed by type I and a sma ll number of type III strains, is similar to what has been 
found through direct genotyping in European patients (Fuentes et aL, 2001; 
Ajzenberg et aL, 2002; Aspinall et aL, 2003). However, the genotype distribution in 
Uganda is different from previous studies on chickens from Africa, Europe, USA, 
Middle East and Asia (results and references in Appendix 4), where types II and III 
were common and type I very rarely found. It is also very different from the 
distribution in chickens from Central and South America (Appendix 4), where there 
is a predominance of types I, III and atypical/recombinant strains, while genotype II 
is exceedingly rare. However, it is important to note that all the other chicken 
studies were performed on isolates only. Considering the isolation bias in this study, 
~here all the type I strains were lost, it is possible that some of the previous 
genotyping studies from outside South America underestimate the true prevalence 
of type I strains, which may be more widely distributed than previously thought. 
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3.4.4 High prevalence of multiple infections provides opportunities 
for recombination 
An interesting finding in this study was that five out of 20 chickens appeared 
to be infected by two or three genetically distinct strains of T. gondii. Experiments 
in mice have shown that previous infections only confer partial protection towards 
reinfection with strains of other lineages (Araujo et aL, 1997; Dao et aL, 2001), but 
multiple infections in naturally infected hosts have only been reported occasionally. 
One UK study detected simultaneous infections with type I and II in 6/19 samples 
(mostly solid tissue, but also blood and cerebrospinal fluid) from congenitally 
infected infants and immunosuppressed patients through SAG2-amplification and 
sequencing, as indicated by double peaks at polymorphic sites (Aspinall et aL, 
2003). In a study of chickens from Nicaragua, four out of 48 successful bioassays 
resulted in mixed genotype patterns in strains obtained in different mice infected 
with material from the same chicken (Dubey et aI., 2006c); similar to what was 
found in the current study. These results suggest that multiple infections are 
relatively common, but the low detection frequency may be due to the fact that 
most studies employ methods which are designed to detect and genotype a single 
strain per host, i.e. PCR-RFlP without sequencing or isolation where only one 
mouse per group is used for typing. 
Considering the high prevalence of infection in chickens and the presence of 
multiple parasite genotypes within the relatively small geographic areas of this 
study, it is not surprising that some individuals have been exposed to more than 
one parasite genotype during their lifetime. Consistent with the increased risk of 
exposure with time (Figure 3-6), it was revealed that all chickens with multiple 
infections belonged to one of the older age categories, (14-17 months or ~18 
months), and both the individuals with triple infections were ~ 18 months old. 
The presence of multiple T. gondii strains in a single chicken conveys an 
excellent opportunity for recombination if the host is consumed by a cat. Inter-
strain recombination can only occur if the definitive host is co-infected within a 
short time frame, and immunity to oocyst reshedding is developed within 6 weeks 
(Freyre et aI., 2007), therefore ingestion of multiple strains from an intermediate 
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host provides the best possibility for the successive generation of recombinant 
progeny in the feline host. Recombinant progeny can exhibit new phenotypic 
properties and in some cases be more virulent than either parent (Grigg et aI., 
200la), and the high level of multiply infected chickens discovered in this study 
could potentially prompt the creation of a multitude of novel recombinant strains. 
3.S Conclusions 
Nearly half of the Ugandan chickens had serological evidence of T. gondii 
infection and, like in HIV-patients from the same region, strains of genotype II were 
the most prevalent followed by type I. Typing of five loci on four different 
chromosomes and generation of over 15 kb of sequence revealed only five novel 
SNPs, indicating that African strains, unlike those found in South America, are highly 
similar to the archetypal lineages predominant in Europe. However, a high number 
of multiple infections were found which provides ample opportunities for 
simultaneous infections in cats and successive generation of recombinant strains 
that may be transmitted to humans. The genetic composition of the individual 
strains in these multiple infections could not be clarified from mouse tissues, which 
lead on to the work presented in Chapter 4, where the isolates are adapted to in 
vitro culture for thorough genotypic and phenotypic characterization. 
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Chapter 4 Characterization of a natural recombinant Toxoplasma 
gondii isolate from Uganda reveals an intermediate phenotype in vivo. 
4.1 Introduction 
T. gondii has an unusual population structure, where a small number of highly 
successful strains have expanded clonally through self-fertilization and asexual 
propagation to occupy large environmental niches. The most well-documented 
lineages are genotypes I, II and III, which are highly predominant in Europe and 
North America and, as shown in Chapters 2 and 3, these are also present in humans 
and chickens in Uganda. Sexual recombination between strains appears to be 
relatively infrequent in T. gondii, or at least very few progeny survive to tell the tale, 
but when the isolates from Ugandan chickens were secured in vitro, one natural 
recombinant between type II and III was found. The following chapter explores 
genotypic and phenotypic characteristics of this recombinant strain and closely 
related but non-recombinant type II and type III strains from the same source. 
4.1.1 Sexual recombination in T. gondii 
Sex, the combination of genes from more than one source in a single cell (Xu, 
2004), is together with mutations and natural selection one of the major forces that 
drive evolution (Heitman, 2006). The first sex may have occurred among the first 
cellular life forms around 3.85 billion years ago, and been driven by selfish genetic 
elements like bacteriophages and transposons (Hickey, 1982). Eukaryotic organisms, 
which have probably existed for less than 1.5 billion years (Rivera, 2007), have 
developed a different mode of sex, which involves meiosis and gamete formation, 
and sexual reproduction is obligate in most multicellular organisms (Xu, 2004). 
Sexual recombination can benefit a population through the accumulation of 
beneficial mutations and removal of deleterious ones, and the greatly enhanced 
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genetic variation can be a major advantage for rapid adaptation to a changing 
environment and evasion of infectious diseases (Xu, 2004). However, there is also a 
risk of breaking up favourable gene combinations and there is often a cost involved 
in the process of finding a mate, and for unicellular organisms the sexual process is 
often much slower than asexual replication (Agrawal, 2006). Several parasitic and 
fungal pathogens exhibit largely clonal population structures even though they 
remain capable of sexual reproduction (Heitman, 2006), and predominantly asexual 
reproduction with infrequent sexual contributions may provide the optimal 
combination for rapid spread of successful clones while retaining the ability of 
efficient adaptation to environmental changes. In the case of T. gondii, 
experimental crosses (Pfefferkorn and Pfefferkorn, 1980; Sibley et aI., 1992) have 
shown that a single mating opportunity between two strains in the definitive host 
can result in a large number of new strains with altered phenotypic properties, yet a 
very limited number of clonal types are highly overrepresented in nature (see 
Chapter 1.3), indicating a mainly clonal dispersal with limited sexual recombination 
(Grigg and Sundar, 2009). 
The details of the genotyping of progeny from three experimental crosses 
(one between a type I and III and two between types II and III) have been made 
publicly available by LD Sibley at Washington University of St Louis, through the 
Toxoplasma Genome Mapping Database (http://toxomap.wustl.edu/interface.htm). 
In total, 40 type II/III progenies have been typed at 132-134 loci, but the markers 
were unevenly distributed and chromosomes VI and XI were only typed at a single 
locus. Thirty-five progeny from the type 1/111 cross have been genotyped at 177 
markers (6-25 per chromosome), and genetic recombination was detected at a high 
level in all fourteen chromosomes with this close typing (see Table 4-1). 
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Table 4-1. Summary of recombination patterns in progeny from experimental crosses. 
Cross between JI/III (N=40) Cross between 1/111 (N=35) 
Length 
Chrom (Mb) Nooflod JIb IIIb recb Nooflod Ib IIIb recb 
la 1.89 3 40% 38% 23% 6 9% 29% 63% 
Ib 1.95 3 45% 55% 0% 6 6% 46% 49% 
II 2.30 7 50% 45% 5% 5 46% 14% 40% 
III 2.47 6-7 73% 25% 3% 6 9% 34% 57% 
IV 2.57 12 30% 30% 40% 15 37% 14% 49% 
V 3.14 13-14 50% 28% 23% 6 17% 31% 51% 
VI 3.60 1 28% 73% 0% 9 31% 20% 49% 
Vila 4.50 21-22 15% 68% 18% 21 26% 11% 63% 
Vllb 5.02 6 45% 48% 8% 9 23% 20% 57% 
VIII 6.92 11 38% 23% 40% 17 26% 20% 54% 
IX 6.38 14-15 10% 75% 15% 16 3% 34% 63% 
X 7.41 23 13% 60% 28% 12 20% 17% 63% 
XI 6.57 1 83% 18% 0% 25 43% 0% 57% 
XII 6.87 10 30% 18% 53% 24 11% 29% 60% 
iNo of genotyping markers tested at each chromosome (PCR-RFLP). 
bpercentage of progeny containing chromosomes of type 1/11/111 or recombinant chromosomes. 
The table is a compiled summary of the raw data available at http://toxomap.wustl.edu/ 
interface.htm. 
Recombination can occur through assortment of chromosomes, cross-over 
within a chromosome or a combination of both these processes. Chromosome 
sorting is present in all the progeny listed in the Toxoplasma Genome Mapping 
Database, where the number of chromosomes inherited in their entirety from 
either parent ranged from one to ten. Furthermore, all but five strains had at least 
one case of chromosomal cross-over. In all the 75 recombinant progeny, the 
average number (± standard deviation) of recombinant chromosomes was 3.S 
(±2.2), with a higher degree found in the more closely typed 1/111 cross (Figure 4-1). 
A maximum of 10 recombinant chromosomes was found in one strain, and there 
were also a small number of cases with up to four cross-over events within the 
same chromosome, suggesting gene conversions (Khan et aI., 200Sb). This analysis 
of the data from experimental crosses shows that T. gondii strains undergo sexual 
recombination with a high degree of inter- and intra-chromosomal recombination 
and emphasizes the need for high density genotyping for accurate genetic 
characterization of recombinant strains. 
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Figure 4-1. Prevalence of recombinant chromosomes in experimental T. gondii crosses. In t he 
crosses between genotypes II and III most progeny had two or three chromosomes containing alleles 
from both parental strains (grey) . The maximum number of recombinant chromosomes among these 
strains was six (one strain), while three strains had no evidence of chromosomal recombination . In 
the cross between I and III (black) the number of recombinant chromosomes was higher, which may 
be due to the higher density of genotyped loci. Most 1/111 recombinant strains had between four and 
six recombinant chromosomes, but one had as many as ten and two had none. The raw data were 
retrieved from the Toxoplasma Genome Mapping Database (http ://toxomap.wustl.edu/ 
interface.htm) and analyzed in Excel. 
4.1.2 Origin of t hree clonal lineages I, II and III 
The global population structure of T. gondii is more complex than three clonal 
lineages, and the classification into type I, II and III is of little use in South America 
(Sibley and Ajioka, 2008). The designation is, however, of use for classification of 
the majority of strains from Europe, North America and probably also for parts of 
Africa, and these lineages have been found in many hosts and locations across the 
globe. Where appropriate, this categorization is very useful since these three 
lineages have been extensively studied at both the genotypic and phenotypic level. 
Representative strains from all three lineages (GTl (I), Me49 (II) and VEG (III)) have 
had their full genome sequenced and annotated (see Chapter 5.1), and additional 
transcriptome and prot eome data is also available in ToxoDB and detailed sequence 
analysis have provided a good understanding of the origin of the three archetypal 
lineages, I, II and III. 
One interesting feature of the three lineages is the bi-allelic SNP pattern : for 
practically all SNPs, two of the three strains share one allele while the third strain 
- 93 -
has a different one. The divergent type classifies these SNPs, for example a SNP 
where type I has a "e" while type II and III both have a "Gil is categorized as a type I 
SNP. The consistent presence of only two alleles on each locus led to the hypothesis 
that these three genotypes had arisen through recombination of two ancestral 
strains "Adam" and "Eve" (Boothroyd and Grigg, 2002). 
A few years later, Boyle et al (2006) performed a detailed SNP analysis using 
the whole genome sequence data from the type I, II and III reference strains. This 
showed a non-random distribution of the SNP types in large haploblocks, where 
each had a clear predominance of either type I, II or III SNPs. Interestingly, the type 
II dominated regions had a much higher level of divergence (Le. presence of type I 
and III SNPs) than the regions where type I or type III SNPs were predominant. This 
pattern was used to make predictions for the origin of these lineages, and a model 
with recombination and back-crosses between five ancestral strains; Ill, Ib, 113, a 
and ~, was proposed (Figure 4-2). According to this model, the three type II strains 
were very closely related, while a and ~ were distinct, but closer to each other than 
to the type II strains). Briefly, the model proposes that modern day type I derive 
from a cross between 111 and a plus a backcross of 111 with the F1 progeny, while 
type II descends directly from 112 and type III is a recombinant of 113 and ~ (Boyle et 
aI., 2006). This model was found to be highly relevant for the SNP distribution found 
in the recombinant strain from Uganda, and is discussed in more detail in Chapter S. 
Figure 4-2. Schematic of the cross that gave rise to the canonical three lineages " II and III. Adapted 
from Boyle et aI., 2006. The three type II strains were close relatives, while a and ~ were closer to 
each other than to the type II strains. 
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Phylogenetic analysis of >270 kb of published sequence from atypical strains 
as well as strains within the I, II, III lineages led to the proposition that the most 
recent common ancestor (MRCA) of all modern T. gondii strains (including the 
parental strains that gave rise to types I, II and III) existed around 150,000 years ago 
(Morrison, 2005). The actual crosses that yielded the clonal lineages occurred later, 
but the timing of this is under debate. Grigg and Suzuki suggested two hypotheses 
"intermixing early" and "intermixing late", where the first theory suggests that the 
crosses occurred relatively soon after the time of the MRCA of modern strains but 
the rapid clonal expansion was delayed, the second hypothesis states a recent 
recombination event around 10,000 years ago with immediate expansion (Grigg and 
Suzuki, 2003). "Intermixing late" was supported by intron sequence comparisons 
between clonal and "atypical" strains (Su et aI., 2003), while Morrison's reanalysis 
of this and additional data supports the early recombination theory, with the cross 
taking place around 100,000 years ago (Figure 4-3). 
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Figure 4-3. Overview of T. gondii divergence over time. Toxoplasma has existed as a genus for 
around 11 million years, and probably originates from Eurasia, where modern felines evolved 
(O'Brien et aI., 2008). Most modern strains exhibit relatively little divergence and have gone through 
a genetic bottle neck some 1S0,000 years ago (Morrison, 200S), but ancient strains may remain in 
areas where they have not been outcompeted. A few crosses within the past 100,000 years created 
the highly successful lineages I, II and III, and these populations are believed to have undergone 
rapid expansion which is correlated to the domestication of animals around 10,000 years ago. 
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The three lineages appear to have undergone a rapid expansion correlated in 
time with the domestications of animals around 10,000 years ago, and it is plausible 
that the new situation with many species including cats living close together 
provided optimal conditions for a subset of the circulating strains, leading to the 
predominance of the clonal types seen today (Su et aI., 2003). 
4.1.3 Global population structure 
In a worldwide population survey initiated by Prof. J. P. Dubey and Dr. Chunlei 
Su, the aim is to collect strains from a range of hosts and geographic location, and 
genotype all parasites with a set of 11 PCR-RFLP markers. More than 950 strains 
have been investigated so far, representing 131 different allelic combinations. 
Interestingly, most strains do belong to one of the archetypal lineages, I, II or III, and 
a smaller but significant number belong to a handful of other clonal types (for 
example the Brazilian lineages Br I-IV (Pena et aI., 2008), or differ from these 
lineages on the apicoplast locus only, while only one single representative strain has 
been identified for most of the new multi-locus genotypes (Su, Dubey et al" 
unpublished). A comparative study using a subset of these isolates was performed 
by Lehmann et al in 2006, when microsatellite analysis of seven loci were used for 
genotyping of 275 isolates originating from chickens from five continents. Four 
major haplogroups were found: one with a world-wide distribution (type I), one 
genotype corresponding to types II and III that was found everywhere except South 
America, and two genotypes that were confined to South America. The authors 
then hypothesized that T. gondii had existed for a long time as a rare parasite in the 
wild felines in South America, which increased in prevalence after the introduction 
of the domestic cat and spread to other continents through human activities 
(Lehmann et aI., 2006). 
However, another study published the following year reported no less than 11 
haplotype groups among 46 strains from Europe, North America and South America 
through sequence analysis of eight intronic regions from five genes spanning >3.7 
kb (Khan et aI., 2007), and all these haplogroups appeared to derive from four 
ancestral strains. While two of these haplogroups were found on all three 
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continents, the archetypal I, II and III were confined to Europe and North America, 
while the remaining six types were exclusively found in South America. Their 
analyses reached the conclusion that the parasite was introduced in South America 
when the big cats first crossed the Panamian land bridge about 1-2 million years ago 
and that the separation between North and South American strains began by that 
time. Furthermore, they linked the ability of clonal expansion with direct oral 
transmission, which was correlated with the presence of a monomorphic version of 
chromosome la (Khan et aI., 2007). It thus appears that T. gondii has a much more 
diverse population structure than previously thought, but it also appears that 
strains which possess advantageous genetic combinations for the niche(s) they live 
in can undergo rapid clonal expansion and outcompete less successful siblings. 
4.1.4 Ainns 
The extent of T. gondii sexual recombination in nature is unknown, but it is 
clear that a single recombination event can exert a dramatic effect on the 
population structure and transmission patterns of this parasite. Among the strains 
isolated from Ugandan chickens (Chapter 3), there were representatives from both 
the type II and type III lineages, but also one unusual strain that was found to 
contain alleles typical of both type II and III. The objectives of the work described in 
this chapter was to assess the level of divergence on the genetic level among the 
Ugandan isolates with particular reference to the recombinant strain, in order to 
see if this isolate was likely to be a recent recombinant or belong to an ancient 
lineage, and also to investigate whether the recombinant strain had any unusual 
phenotypic properties in relation to the clonal representatives. 
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4.2 Materials and methods 
4.2.1 Toxoplasma gondii strains 
Nine T. gondii isolates obtained in mice at USDA and cryopreserved (described 
in Chapter 3) were thawed and injected into outbred, female Swiss-Webster mice at 
USDA by Dr. Natrajan Sundar. The animals were then euthanized six weeks post-
inoculation and half the brain was cryopreserved (Dr. Sundar), while the other half 
was sent to SMI, where the rest of the mouse work and initial transfer to cell 
culture was performed. Isolate names were applied according to the Dubey lab 
system, which denotes the parasite (Toxoplasma gondii = Tg), the host species 
(Chicken = Ck), country of origin (Uganda = Ug) and isolate number. Thus, the nine 
isolates from chickens Ch1, 2, 17, 52,68, 70, 79, 81 and 82 were named TgCkUgl-9. 
Originally, each chicken sample was inoculated into four mice (section 3.2.5), but 
due to the large number of samples handled at the Dubey lab, only one brain from 
each group was cryopreserved. If possible the tissue selected was from a source in 
which tissue cysts had been detected by microscopy and the cryopreserved brains 
that were used for the retrieval of isolates in this study originated from mice A1, AS, 
A8, A12, A20, A23, A26, A30 and A35 (Table 3.4) 
Two laboratory strains of T. gondii were kept in culture at Leeds University and 
used as reference strains in the growth experiments; RH (type I) and Me49 (type II). 
DNA from the type III strains VEG (from USDA) and NED (from SMI) were used as 
reference strains for molecular work. The genomic data from GT1 (type I), Me49 
(type II) and VEG (type III) that is available at ToxoDB, was utilized for sequence 
references. 
4.2.2 Cell culture methods 
Human foreskin fibroblasts (HFFs) were cultured in DMEM (Dulbecco's 
Modified Eagle's Medium with L-Glutamine, Invitrogen), supplemented with 10% 
FBS (heat-inactivated foetal bovine serum, GIBCO) and 1% PEST (10,000 U penicillin 
and 10 mg streptomycin/ml in 0.9% NaCI, SIGMA). During the first passages after 
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inoculation of parasites from mouse brains 1% Fungizone (250 Ilg/ml Amphotericin 
B, GIBCO) was added to prevent fungal contamination. The cells were grown at 37·C 
in a humidified incubator with 5% C02 in flasks with a vented lid or with loosened 
cap to allow gas exchange. 
HFFs were maintained through subpassage every 4-7 days in T25 culture flasks 
and all the work was performed in a sterile flow hood. When the cells had formed a 
nearly confluent monolayer, the old medium was discarded and the monolayer was 
rinsed with sterile PBS. The cells were incubated with 2 ml Trypsin-EDTA (0.5%, 
Invitrogen) for 2-3 min at 37"C, until they detached after tapping the flask on the 
hood floor to dislodge cells, full detachment of cells was checked in an inverted 
microscope. Cells were then pelleted by centrifugation for 5 min and resuspended 
in 24 ml fresh medium, which was distributed into four new T25 flasks (6 ml/flask), 
or a 24 well plate (1 ml/well). 
Freeze-down of HFFs and parasites was completed when the cells were in the 
exponential phase of growth. HFFs were trypsinized and centrifuged, as for sub-
passage (described above), while the parasites were released from their host cells 
by rapping the flask on the hood floor and passing them through a 26-gauge needle. 
Cells were pelleted through centrifugation (4000 g, 10 min) and the pellet from 
each flask was resuspended in 1 ml cryomedium (80% DMEM, 10% FBS and 10% 
DMSO) and transferred to cryovials and stepwise frozen at -20QC for 3-4 hours, -
80QC over night, liquid nitrogen for long-term storage. 
4.2.3 Sub-passage in mice 
Infected mouse brains were received from USDA on cold packs, and each of 
them was homogenised in 1 ml sterile PBS by repeated passage through a blunt 19 
gauge needle1• 250 III of the homogenate was inoculated directly in one NMRI 
mouse through the subcutaneous route, while the remaining 750 III was digested in 
trypsin according to a procedure adapted from a published protocol (Dubey, 1998c). 
1 This was a larger needle than the one used for separation of tachyzoites from cell culture since the 
brain is a tougher material and this procedure aimed for homogenization, not release of parasites, 
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Briefly, brain homogenate was transferred mixed with an equal volume of 0.5% 
Trypsin-EDTA, incubated at 37QC for 20 min, washed in 5 ml PBS, thoroughly mixed 
before pelleted through centrifugation at 2,000 g for 10 min. The supernatant was 
removed and the pellet resuspended in 250 ~I PBS with 1% PEST giving a total 
volume of approximately 400 ~I, which was inoculated into two NMRI mice. All mice 
were bled (by technical personnel at the animal house at SMI) for serology six 
weeks post-inoculation. The serology was performed using the Toxo-Screen DA as 
described in 2.2.3, at dilutions 1:25 and 1:250. 
4.2.4 Isolation of T. gondii in cell culture from infected mouse brains 
Infected mice were euthanized (by personnel at the animal house) through 
exposure to the anaesthetic isofluoran until dead\ and thereafter dissected in a 
sterile flow hood. A small piece of brain was removed for DNA-extraction and the 
rest was homogenized in 1 ml of PBS through needle passage. 500 ~I of brain 
homogenate was mixed with 10 ml cell culture medium and added directly to a 
confluent monolayer of HFFs in T25 flasks. The remaining 500 ~I was subject to the 
trypsin digestion procedure described in 4.2.3 before the pellet was resuspended in 
10 ml medium and added to a confluent HFF-monolayer2. The parasites were 
allowed 24 hours to invade before the monolayer was washed with sterile PBS to 
remove brain cells and 6 ml fresh medium was added. Once transferred to cell 
culture the isolates were propagated according to standard protocols, but as the 
time to consume a monolayer was several weeks compared with a few days for 
laboratory strains, interim medium changes were necessary approximately twice a 
week, and the removed media was used for quantification of free parasites. 
1 Procedures were different at the animal facilities at USDA and SMI. 
2 Trypsin digestion releases the bradyzoites from tissue cysts and cultures with trypsinized 
samples were found to be cleaner and the brain cells were easier to remove at the first media 
change. 
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4.2.5 In vivo growth assay 
Small samples of brain, heart, lung and quadriceps muscle were dissected 
from each mouse in order to determine the parasite burden in these organs. Each 
tissue sample was weighed and the DNA was extracted using the QIAamp DNA kit 
(as in 2.2.4) and eluted in exactly 100~1. Five III (1/20 of the total extraction) were 
used as template in each Q-PCR reaction (performed in duplicate according to the 
protocol described in 2.2.6). The parasite burden per gram of tissue was calculated 
using the following formula: ((Average number of parasites detected per Q-PCR-
reaction}*20}/(Weight used for DNA-extraction (grams)). 
4.2.6 Separation of mUltiple strains 
Chickens 2, 68 and 70 had been found to be infected with several strains of T. 
gondii by sequencing and mouse bioassay (see Chapter 3.3.4). In order to secure the 
propagation of single clones in culture, dilutions were made on 24-well plates. 
Parasites were counted in a haematocytometer and a volume containing 10 
parasites were added to the HFF monolayer in each well. The plate was then 
incubated for four days without being moved and thereafter the wells were 
inspected under an inverted microscope, and all wells with a single plaque were 
marked. The medium was then changed and the parasites were allowed growing for 
another week before the DNA-extraction was done for ten single-plaque wells from 
each sample. The DNA was then genotyped at the SAG3 and SAG2-S' loci as 
described previously (3.2.9). 
However, no differences were seen between any samples originating from the 
same chicken. All samples from Ch-2 (TgCkUg2) and Ch-70 (TgCkUg6) were type III 
for SAG2-S' as well as SAG3, while Ch-68 (TgCkUgS) showed type II alleles for these 
loci. It thus appears that the multiple infections were lost in earlier passages and a 
single isolate was retrieved from each chicken. 
4.2.7 In vitro growth assay 
The growth during the very first cell culture passage was monitored for each 
strain in order to compare the efficiency of direct inoculation versus trypsin 
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digestion. In order not to impair the growth of the parasites, the measurements 
were performed on the medium as it was changed. DNA was extracted from the 
pellet from 5 ml of medium (out of a total volume of 6 ml), which was eluted in 100 
III and quantified by Q-PCR in the same manner as the in vivo growth assay (section 
4.2.5). 
The growth in vitro was also quantified at passage eight, when the strains had 
had some time to adjust to growth in cell culture, and the same method with 
quantification of parasites in 5 ml medium was used. This time, 100,000 parasites 
were added to each T25 flask, and medium was changed and used for extraction on 
days 2, 4, 7, 10 and 13 post-inoculation. Reference strains RH and Me49 were also 
included in this experiment. 
4.2.8 Transmission Electron Microscopy 
Parasites from nearly lysed mono layers were collected and pelleted in 1.5 ml 
tubes. Samples were fixed over night in 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (Na2(CH3hAS02.3H20, pH 7.0). Following two subsequent washes 
in the same buffer they were stained for two hours in 1% osmium tetroxide. The 
samples were dehydrated in ethanol-water dilutions of increasing alcohol 
concentration (20%, 40%, 60%, 80% and 100%), washed with propylene oxide and 
embedded in Spurr's resin by overnight incubations in ascending concentration and 
finally allowed to solidify in 100% resin at 70·C. 
The blocks were trimmed in a microtome by glass knife and thereafter cut to 
ultra-thin sections (80 nm) using a diamond knife. Sections were collected on plastic 
coated copper grids, stained with electron-dense metals (uranyl acetate for 2 hours 
and lead citrate for 20 minutes), washed and thereafter examined on a JEOl 1200EX 
transmission electron microscope. This work was done with the assistance of Mr. 
Adrian Hick at leeds University. 
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4.2.9 Sequencing and sequence analysis 
Five genomic loci with a high SNP density were identified using the 'Identify 
genes based on SNP-characteristics'-tool on ToxoDB (Figure 4-4). 
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Figure 4-4. Polymorphic loci selected for sequencing. The sequenced loci are marked with boxes and 
the coloured diamond shapes indicate SNPs (red = type I, green = type II, blue = type III). The chosen 
regions are located on five chromosomes (IV, Vila, IX, X, XII) and the apicoplast. No SNP data is 
available for the apicoplast and the locus was randomly chosen by the primer design tool. 
Alignments for the selected loci of the three sequenced strains were compiled 
in BioEdit and used to find conserved regions, where the primers could be placed. 
The primer design tool at the website of University of Massachusetts Medical 
School (http://biotools.umassmed .edu/ bioapps/primer3_www.cgi). were used for 
selection of forward and reverse primers. The best option was chosen by manual 
controls of each pick: absence of hairpin loops or palindrome sequences was 
checked at http://www.cybergene.se/primer.html. melting temperature for all 
primers was adjusted to be approximately 55·C, and a general comparison with all 
available T. gondii sequence was performed to avoid unspecific products 
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(http://www.toxodb.org/toxo/showQuestion.do?questionFullName=GenomicSeque 
nceQuestions.SequencesBySimilarity). 
Primers for the apicoplast were designed in the same manner, but from an 
arbitrary region as only one apicoplast sequence (from the RH strain) is available it 
is not possible to perform SNP comparisons. In addition, sequencing was applied to 
the UPRT-1 intron and two microsatellite loci (B17 and W35), since they have been 
utilized in other T. gondii population studies (Ajzenberg et aI., 2005; Khan et aI., 
2005a). For the microsatellites new primers were designed, external to the ones 
used by Ajzenberg et al (2005), in order to achieve longer sequence reads; for the 
UPRT-1 intron the original primers by Khan, Su et al (2005) were used. The GenelD 
(from ToxoDB version 4.3), chromosomal location, primers and amplicon lengths for 
all sequenced loci are listed in Table 4-2. 
Table 4-2. Genomic locations and primers used for sequencing. 
GenelO" Chrom Start Forward primer Reverse primer Lengthb 
641.m01562 IV 404650 GCCTTGACAGTCACCAACAC GTGAATGACAGTTTCCGTTGA 1037 
20.m03896 Vila 1480563 CCTGCTGTTCGAAGTTTTGC GATACAGCCGTTGACAAAGC 1601-7 
80.m05038 IX 4736806 GTGAGTAATTGCGGCAACG TGTCACTCTCACTTTGCATG 949 
33.m02185 X 5953214 CGCAATACAAGTCACGCCCT TGAGGGAATGCGTCTGTGCC 874-7 
65.m01164 XII 6119813 TGGAACAGGGCTGTGCTG GACTCATTCGTGTCCCTTCC 631-4 
Apico Apico 33056 CAGCCGAAAGCTCTAACCAC GCCATGCACCTCCTGTAAAT 904 
W35 II 633228 GCTCGCAGAGGAGGTTCACT AGTCATCCGTGCGTTAGCGT 196 
UPRT-1 XI 2709204 TCCACAGGGCTTCTAAAAT GAGTTGAGAACAGGCTTCAG 688 
817 XII 6452115 CCAGTTTCGCGAACAAGTGA CATAGTTCAGTCTCGGGTGA 342 
OGene products are shown in Figure 4-4. 
bLength indicates the actual good quality sequence length obtained for all isolates, which was used 
for comparative analysis. This does not always extend to the full length encompassed by the primer 
pairs. 
Sequencing reactions were performed as described in 3.2.10, and all 
sequences were manually controlled and edited in BioEdit. All sequences from the 
same locus were truncated to the same length as the strain with the shortest good 
quality sequence, and the corresponding sequences for GT1, Me49 and VEG were 
retrieved from ToxoDB. Alignments and creation of Nexus-files were performed 
using CiustalX2 (http://clustalx2.software.informer.com/2.0/), the phylogenetic 
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trees were generated in MrBayes (Huelsenbeck and Ronquist, 2001) until P<O.Ol 
and thereafter visualized in TreeView (http://taxonomy.zoology.gla.ac.uk/rod/ 
treeview.html). For the microsatellite sequences B17 and W35 all reference strains 
available in GenBank were retrieved and analyzed in the same manner together 
with the sequences from four Ugandan strains: TgCkUg2, 5, 6 and 8. The sequence 
data generated for these isolates has been submitted to GenBank (Accession 
numbers: FI274744-FI274973). 
4.2.10 Random Amplification of Polymorphic DNA 
In addition to the targeted genotyping efforts, random amplification of 
polymorphic DNA (RAPD) was used as a more general approach to detect genetic 
variation. In addition to the Ugandan strains, DNA from five reference strains were 
included, Me49 (type II), NED (type III), and three atypical strains: VAND, TONT and 
RUB (DNA from these strains were kindly provided by the BRC ToxoBS group 
through Dr. Benjamin Edvinsson at SMI). Two 10 nucleotide oligos (B12 and C20) 
were selected because they have been found to readily differentiate between 
virulent and avirulent strains (Guo et aI1997). 
Eight additional random primers, four 10 nt and four 12 nt oligos, were 
randomly chosen with the help of a dice where l=A, 2=C, 3=G and 4=T. Five of these 
were found to be suitable for differentiation between strains either alone or in 
pairs: 10.1: CTGGGGTCAC, 10.2: AAGCCnCGA, 12.2: ACCCCCAATGGA, 12.3: 
ACTACCCCAGGA, 12.4: GTGAAGGTCGCT. The DNA template concentration was 
standardized and 10 ng was used in each reaction which was performed under the 
same conditions as for the PCR-RFLP reactions (3.2.9) with the exception of 
decreased annealing temperatures (34-40"C) and prolonged extension time (1 min 
45s). The fragments were separated on 2% agarose gels and the absence or 
presence of bands was recorded and analysed using the Treecon software (Van de 
Peer and De Wachter, 1994) with the Nei & li method, Neighbour joining tree 
topology and Bootstrap analysis of 2000 samples. 
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4.3 Results 
4.3.1 Isolation in mice 
Previously cryopreserved mouse brains infected with T. gondii from Ugandan 
chickens (Chapter 3) were thawed and passaged in mice at USDA, sent to SMI where 
they were inoculated in mice and transferred to cell cultures, which were later 
brought to Leeds where the molecular genotyping took place. An overview of the 
whole isolation procedure is shown in Figure 4-5. 
Makerere 
2 
USDA 
Leeds 
8 
Figure 4·5. Overview of the isolate retrieval procedure. Coloured circles indicate where each step 
took place and the stars specify samples that were genotyped. 1. Brain and heart tissues from 8S 
chickens were brought from Makerere to USDA and inoculated into four mice per chicken, as 
described in Chapter 3. 2. Brain material from one infected mouse from each group was 
cryoprese rved (preferentia lly those with visible tissue cysts) . 3. Later, these isolates were thawed 
and inoculated into one mouse per sample at USDA, and the infection was allowed to progress to 
brain cyst fo rmat ion (6 weeks). 4. Half the brain was cryopreserved at USDA and the other half 
shipped to SMI. 5. At SMI, each sample was used to infect three mice, and the tissues from these 
mice were used for quantification of parasites in different tissues (the in vivo growth assay) 6. 
Infect ions were allowed to progress to tissue cyst formation and thereafter brains were used for 
inoculation into cell culture, with and without trypsin digestion. Here the in vitro growth assay for 
passage 1 was perfo rmed. 7. Isolates were brought to Leeds where subsequent cell culture work, 
includ ing the in vitro growth assay for passage 8, and molecular typing was performed. 8. All isolates 
are preserved in liquid nitrogen at the University of Leeds . 
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Eight of the nine isolates sent from USDA were successfully passaged in mice 
at SMI, but T. gondii DNA was not detected by nested PCR or by Q-PCR of the brain 
homogenate from the last strain (TgCkUg4 from Ch-52) . Basic PCR-RFLP genotyping 
(SAG2, SAG3 and GRA6 as described in 3.2.9) was performed on DNA extracted 
from the mouse brains from USDA and the mice at SMI, to check which isolates had 
survived . All strains originally typed as II continued to type as plain type II strains, 
while the multiple infections appeared to have been decimated to one type II strain 
from Ch-68 (mouse A20L one type III strain from Ch-70 (mouse A23) and a 
recombinant type II/III strain from Ch-2 (mouse AS) . See Table 4-3 for an overview 
of the chicken designation, strain types in the original USDA mouse used for 
cryopreservation, the new strain designation and the genotype of the isolates that 
were finally retrieved. 
Table 4-3. Origin and designation of retrieved isolates. 
Chicken Mouse Genotype Isolate Genotype 
ChI Al II TgCkUgI II 
Ch2 AS II + III TgCkUg2 II + III 
Chl7 A8 II TgCkUg3 II 
Ch52 A12 II TgCkUg4 N/A 
Ch68 A20 I + II TgCkUgS II 
Ch70 A23 I + II + III TgCkUg6 III 
Ch79 A26 II TgCkUg7 II 
Ch81 A30 II TgCkUg8 II 
Ch82 A3S II TgCkUg9 II 
Overview of the isolates retrieved in culture and their origin . For example, strain TgCkUg6 is a type III 
strain, w hich originates from chicken 70, via mouse A23 . The original chicken and mouse A23 had 
mu lt iple infections (see Table 3-4), but only one strain was finally retrieved in culture. In the case of 
TgCkUg2 from chicken 2, mouse AS possessed alleles from type II and III, and so did the mice and cell 
cultures at SMI, and this turned out to be a recombinant strain. 
All infections with Ugandan T. gondii isolates were asymptomatic in mice; this 
was true for the first two passages in Swiss-Webster mice (USDA) as well as for the 
following passage in NMRI mice (SMI). Two conventional nested PCRs (SAG2-5' and 
SAG2-3' ) and two Q-PCRs (B1 and AF) were used to test for the presence of 
parasites in mouse brains from USDA. Six samples (TgCkUg1, 2, 5, 6, 7, 8) were 
positive by all methods, but the two samples with the lowest parasite numbers 
(TgCkUg3 and 9) were only detected by Q-PCR of multiple copy genes. The most 
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sensitive method was the Q-PCR of the highly repetitive AF-sequence (described in 
section 2.2.6), therefore this was the method of choice for detection and 
quantification in the in vivo and in vitro growth assays. TgCkUg4 was negative for all 
PCRs. An overview of these results is shown in Table 4-4. 
Table 4·4. Detection and quantification of parasites and isolation success in mice. 
Brain No of T. Seropos Seropos Sub· 
SAG2· SAG2- Q-PCR Q-PCR homog T. gondii gondii / mice mice passage 
Isolate 5' 3' B1 AF (~lg) /reaction g brain (direct) (tryps) (direct) 
TgCkUg1 + + + + 203 3 2,956 1/1 2/2 ND 
TgCkUg2 + + + + 298 105 70,470 1/1 0/2 2/2 
TgCkUg3 + 5 1 40,000 1/1 2/2 ND 
TgCkUg4 258 0/1 0/2 ND 
TgCkUg5 + + + + 263 4 3,042 1/1 2/2 ND 
TgCkUg6 + + + + 95 140 294,737 1/1 2/2 ND 
TgCkUg7 + + + + 213 27 25,352 1/1 2/2 ND 
TgCkUg8 + + + + 303 37 24,422 1/1 2/2 ND 
TgCkUg9 + + 319 2 1,254 1/1 2/2 ND 
DNA was extracted from the amount of brain homogenate (brain in PBS, 1:10) remaining after 
inoculation of the brain material from USDA into mice at SMI. This was carefully we ighed and from 
this amount, the DNA elu t ion volume (100~1) and volume used as template in the PCR-reaction (5~1), 
the number of parasites per gram of each brain could be calculated based on the Q· PCR result per 
reaction. DNA from at least three parasites per reaction was necessary for detection with all 
markers. 
At SMI, most of the mouse infections were successful, whether trypsin 
digestion was used or not. Seven strains caused infection in all three mice, but only 
one mouse got infected with the TgCkUg2 strain, and this was with the sample that 
had not been subject to trypsin digestion (Table 4-4). The brain from this infected 
mouse was homogenized and sub passaged into two new mice, which both got 
infected . As seen in Table 4.4 the parasite density in the brain of TgCkUg2 was high, 
so the lack of infectivity is more likely to be due to trypsin treatment sensitivity than 
low parasite numbers. TgCkUg4 did not infect any mice, but since the original brain 
sample from USDA was negative for all PCR-reactions it appears to have been 
uninfected or had a very low number of viable parasites to begin with. 
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4.3.2 Quantification of parasites in mouse organs 
The density of T. gondii parasites in brain, heart, lungs and leg muscle from 
infected mice was determined through Q-PCR of the highly repetitive AF-fragment. 
This method revealed significant genotype-related differences in the parasite 
density and also detected a considerable tissue tropism (Table 4-5). The type III 
strain (TgCkUg6) produced the highest tissue burden in all organs; lungs, brain, 
muscle and heart contained 4, 30, 40 and 200 times higher parasite densities 
respectively compared with the type II average (significant for brain (P<O.OOl), 
heart (P<0.002) and muscle (P<0.02) using the t-test), while the recombinant type 
II/III strain (TgCkUg2) showed an intermediate phenotype for all organs investigated 
(Figure 4-6). In brain tissue, the average density as determined by Q-PCR was 
4.5*106 parasites per gram for type III, 1.2*106 for the recombinant, and 1.5*105 for 
the six type II strains. In heart tissue, the mean values for parasite density were 
1.2* 105 (III), 8.9 * 103 (II/III) and 6.2*102 (II) parasites per gram. The parasite burden 
caused by the recombinant strain was significantly higher compared with type II 
strains (P<0.03 for brain, heart and muscle), while the difference between TgCkUg2 
and TgCkUg6 did not reach significance. 
1E~8 r-------------------------------------------------------, 
*** 
1E+07 
-Type III 
o Type II/II I 
lE+06 ** o Type II 
1E+05 
lE+04 
1E+03 
lE+02 
lE+01 
1E+OO 
Brain Muscle Heart Lung 
Figure 4-6. Parasite density per gram of infected mouse organs. The type III strain produced a high 
tissue density for all organs compared with all of the six type II strains, and the recombinant type 
II/III had intermediate values. All mice had the highest number of parasites in the brain. Significance 
levels are indicated in the figure, where one star means P<O.OS, two stars P<O.Ol and three stars 
P<O.OOl. 
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Table 4-5. Parasite density per gram of infected mouse organs 
Mouse " Brain Heart Muscle Lung 
TgCkUg1 m34 27,383 78 1,911 5 
(II) m35 (tr) 354,404 160 0 38 
m36 (tr) 17,855 52 597 14 
average 133,214 97 836 19 
TgCkUg2 m6 168,779 14,594 43,914 108 
(II/III) m8 2,285,529 3,327 217,195 103 
average 1,227,154 8,960 130,554 106 
TgCkUg3 m38 12,690 16 2 
° (II) m47 (tr) 234,607 140 67 65 
m48 (tr) 136,235 566 1 10 
average 127,844 240 23 25 
TgCkUg5 m41 92,615 39 0 0 
(II) m53 (tr) 16,242 1,150 0 27 
m54 (tr) 541,394 276 1 0 
average 216,750 488 0 9 
TgCkUg6 m40 7,697,924 306,000 0 244 
(III) m51 (tr) 4,614,821 56,553 1,006,725 487 
m52 (tr) 1,252,527 7,181 6,224 2 
average 4,521,757 123,245 337,650 244 
TgCkUg7 m42 8,007 0 146 
° (II) m55 (tr) 444,171 853 2,122 0 
m56 (tr) 82,689 3,280 206 597 
average 178,289 1,378 825 199 
TgCkUg8 m43 15,503 
° 
5,703 0 
(II) m57 (tr) 51,014 86 5S9 2 
average 33,258 43 3,131 1 
TgCkUg9 m44 61,775 1,597 0 41 
(II) m59 (tr) 433,236 1,761 129,121 0 
m60 (tr) 60,024 483 3,548 262 
average 185,012 1,280 44,223 101 
"Three mice per sample, except TgCkUg2, where only the two mice In the second inoculation were 
used (see Table 4-4), and TgCkUg8, where the third mouse had been used for cell culture inoculation 
before this test was initiated. Trypsinized samples are indicated by (tr). 
The brain was the only organ where parasites were detected in 100% of the 
seropositive mice. Regardless of genotype, all isolates showed a similar tissue 
tropism, with the highest affinity for the brain, although the actual numbers varied 
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from nearly eight million parasites per gram in mouse m40 (TgCkUg6) to just eight 
thousand in mouse m42 (TgCkUg7). The second highest abundance was found in 
the heart of some mice and the muscle of others, but the variation was large and 
more than one in three mice (8/22, five different isolates) had undetectable or very 
low parasite levels (0-2 parasites/gram). This can probably be explained by an 
uneven distribution of tissue cysts within muscle. Hearts of all but two mice were 
found to harbour T. gondii parasites, but the relative level compared with the brain 
was only about 1:50. The lowest density was detected in lung tissue, where the 
maximum density was around 600 parasites per gram, less than one per cent of the 
level found in the brain of the same mouse (m51). 
Since the variation between mice in the same group was substantial and the 
number of mice was small it is difficult to make a ranking of the type II isolates. The 
highest densities were found in the brains of three mice infected with TgCkUgS, 7 
and 9, all of which had over 400,000 parasites per gram. A larger experiment with 
known inoculation loads is required to draw definitive conclusions about differences 
in growth rate between the type II strains in vivo, but due to the nature of the 
animal license further mouse inoculations could not be performed for this study. 
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4.3 .3 Isolation and growth in cell culture 
When the isolates were transferred to cell culture, homogenized brain tissue 
was either transferred directly to HFF monolayers or treated with trypsin for 30 
minutes and washed in PBS before inoculation. Growth data was collected by Q-PCR 
quantification of free parasites in the medium (except TgCkUg8, which was 
processed earlier) during their very first passage in cell culture . Parallel comparisons 
with and without trypsin digestion for each sample showed that both methods were 
successful for all isolates, but that trypsinization greatly enhanced the growth rate. 
A growth characteristic observed in the samples which were not treated with 
trypsin (and for all Ugandan samples in subsequent cell culture passages) was an 
extended lag-phase. The number of free parasites decreased to very low levels 
around day four and never recovered to reach the same levels as the samples that 
had been subject to trypsin digestion (Figure 4-7). 
1E+07 ~---------------------------------------------------------. 
1E+06 
1E+05 
1E+04 
1E+03 
1E+02 ---_#~ 
1E+01 
2d 4d 
,. 
.". ,. 
,. , 
,. " 
,. " 
,. " ,. , 
,. " , 
, 
, 
10d 
--- -
---
---
-TgCkUg1 Tr 
--- TgCkUg1 
-TgCkUg3Tr 
- -TgCkUg3 
14d 
Figure 4-7. Growth rate comparison in vitro, between directly inoculated versus trypsinized 
parasites. The graph shows the average number of free parasites per ml of medium (average from 
two Q-PCR repl ica tes) for stra ins TgCkUgl and 3 with direct inoculation and after trypsin digestion 
('Tr') . Trypsin digestion resulted in enhanced growth rate for all parasite strains. 
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The difference in strain growth rate was remarkable in the first passage, 
where the type III strain (TgCkUg6) had reached 2.1 million parasites per ml after 
four days, while the type II strain range by that time was between 3,500-16,500 
parasites per ml for the trypsinized samples. TgCkUg2 had an intermediate value of 
580,000 T. gondii/ml. In this initial culture the quantity of parasites in the inocula 
was directly dependent on the parasite density in mouse brain, thus the growth 
advantage seen with TgCkUg2 and 6 (Figure 4-8) may be correlated to this. Among 
the type II strains, the distinction between the faster growing TgCkUg1, 3 and 7 and 
the slower TgCkUg5 and 9 was observable from the start and remained throughout 
the months of culturing. Interestingly, this was not correlated with the growth in 
vivo, where mice infected with TgCkUg5 and 9 had high parasite densities in the 
brain . 
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Figure 4-8. Growth during the first passage in culture (trypsinized samples). The strains that had the 
highest parasite density on day 2 (the type III TgCkUg6 and the recombinant TgCkUg2) also had the 
highest densities on days 4 and 7. Among the type II strains, which all started with a lower density, 
strains TgCkUgl, 3 and 7 had a good growth rate, while TgCkUgS (data for days 2, 4 and 7 only) and 
TgCkUg9 were more difficult to culture . 
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During the eighth passage in cell culture, a controlled growth experiment was 
initiated where 100,000 parasites were added to each flask (approximately 16,600 
per ml medium). The genotype related growth bias seen in mice was not consistent 
in passage eight, suggesting different selective pressures. There was considerable 
variability among the Ugandan strains, but the fastest and slowest growing strains 
in vitro all belonged to genotype II, while the recombinant and type III strains were 
found in the middle of the spectrum. As shown in Figure 4-9, even the fastest 
growing Ugandan strains experienced a lag phase around day 4 and they were all far 
behind the established lab strains RH and Me49. Based on their growth rate in 
culture, the Ugandan strains could be divided into three groups: the fast growing 
strains TgCkUg3 and 8, the intermediate ones: TgCkUgl, 2, 6 and 7, and the slow 
growing TgCkUgS and 9. 
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Figure 4-9. Growth during the eighth round of cell culture. RH and Me49 quickly destroyed the 
monolayer and few HFF cells remained around day 4, while all Ugandan strains experienced a lag 
phase and slow growth at this time. The type III (TgCkUg6, '6') and the recombinant strain (TgCkUg2, 
'2') had intermediate growth rates compared with the other strains from Ugandan chickens . 
TgCkUg5 ('5' ) and TgCkUg9 ('9' ) were consistently more slow-growing in vitro compared with the 
other type II stra ins. 
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4.3.4 Morphology 
Transmission electron microscopy (TEM) was performed to examine the 
morphology of Ugandan T. gondii isolates from tissue culture (Figure 4-10). Samples 
were taken from TgCkUg6 (III), TgCkUg8 (II), TgCkUg2 (II/III) and Me49 (II, ref) after 
seven days in culture (four days in the case of Me49), and processed as described in 
4.2.8. For the Ugandan parasites, a high number of polysaccharide storage granules 
and micronemes were observed in many parasites and, in addition, the wall of the 
parasitophorous vacuole was thickened and the rhoptries were dense. These 
features are typical of bradyzoite development within tissue cysts. It thus appears 
that the Ugandan parasites spontaneously convert to bradyzoites to some extent 
under standard cell culture conditions. 
Figure 4-10. TEM pictures of Ugandan isolates and the Me49 reference strain. A & B show parasites 
- (TgCkUg6 (A) and TgCkUg8 (B)) inside vacuoles/cysts. The thickness and relatively loose fit of the 
membranes indicate that these are bradyzoite tissue cysts. The large vacuole in B contains parasites 
with odd shapes, which may be dying. C shows one and a half parasite of the TgCkUg2 strain. Note 
the posterior position of the nucleus, another sign of bradyzoites. D shows free parasites of the 
Me49 strain. Scale bars represent 111m. 
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In some instances parasites inside vacuoles appeared to be dead or dying 
(note the odd shapes among parasites in Figure 4-10 B), which may be another 
reason why their growth was delayed. In contrast, the Me49 strain, which is well 
adapted to cell culture, consistently consumed the HFFs within a few days and no 
cysts or vacuoles were found at day 4, but instead there were many free parasites 
(Figure 4-10 0). 
4.3.5 Microsatellites and sequence analysis 
Microsatellite analysis is based on the presence of length polymorph isms due 
to a variable number of repeats. The microsatellite markers B17 and W35 have 
been applied to a large number of strains and been shown to be highly variable 
between different strains of T. gondii (Ajzenberg et aI., 2004). Fragment length 
analysis at these loci showed that amplicons from all eight Ugandan strains were of 
the same length for these markers, and sequencing of four amplicons (TgCkUg2, 5, 6 
and 8) did not reveal any substitution polymorph isms. This analysis showed that the 
Ugandan type " strains (including TgCkUg2) were identical to Me49 and the 
Ugandan type III to VEG, which confirmed that the Ugandan strains are indeed 
highly similar to each other and the reference strains. In addition to the four 
Ugandan isolates, sequences for B17 and W35 from 46 strains were downloaded 
from GenBank, and a Bayesian phylogeny was generated from the concatenated 
B17+W35 sequences. As shown in Figure 4-11, a high level of divergence exists over 
these loci, but the Ugandan strains were conserved and clustered with the 
archetypal" and "I strains. 
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Figure 4-11. Phylogram for microsatellite markers B17 and W3S. Sequence from 46 strains (mostly 
of South American origin) have been generated by Ajzenberg et al (2004) and these data were 
retrieved from GenBank and analyzed together with the sequence from four Ugandan strains. This 
tree shows th e high degree of conservation between TgCkUg6 and VEG (blue circle) and also 
between TgCkUg2, 5 and 8 and Me49 (green circle), while there is a high level of divergence among 
the other strains for these two polymorphic loci . 
Targeted sequencing of selected polymorphic loci (see 4.2.9) was performed in 
order to further characterize these strains and potentially find new SNPs. The UPRT-
1 intron is located on chromosome XI, which is dominated by type I SNPs, meaning 
that type I has polymorphisms compared with types II and III, which are mostly 
identical. Several new polymorphisms have been detected at this locus for various 
strains (Table 4-6), but it was not useful for differentiating between the Ugandan 
strains, wh ich were all identical to Me49 and VEG. 
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Table 4-6. Polymorphic sites in the UPRT-l intron. The UPRT-l intron has been shown to contain 
numerous polymorphic sites between strains of diverse origin, but the eight Ugandan isolates were 
allidentical to the archetypal lineages II and III. 
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Sequencing of the loci chosen specifically for this study resulted in the same 
conclusion; the T. gondii isolates from Uganda are highly conserved and fit well into 
the clonal lineages observed in Europe and USA (Table 4-7). Based on analysis of 5.1 
kb high-quality sequence from five polymorphic chromosomal regions it was 
possible to detect a low level of variation between the type II strains, and discover 
SNPs that were conserved in several of the Ugandan type II strains, but not present 
in Me49. The Ugandan type III strain(s) (TgCkUg6, plus TgCkUg2 for one locus), was 
however identical with VEG at all positions. The very limited divergence between 
Me49 and Ugandan type II and between VEG and Ugandan type III is in sharp 
contrast to the comparably high level of difference between VEG and Me49. 
The amplified sequence of the apicoplast genome encompassed 904 bp and 
contained two SNPs compared with the type I strain RH (the only sequence 
presently available in ToxoDB). Both SNPs (one deletion and one C-A substitution) 
were present in the coding sequence of the rRNA coding gene TogoCr30, and were 
conserved in all eight Ugandan isolates. 
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Table 4-7. Summary of divergences between strains over >5 kb of sequence 
SNPs SNPs 
SNPs between Divergence between between 
Locus Chromo Length (bp) Me49/VEG Me49/VEG Me49/Uglla VEG/Uglilb 
641.m01562 IV 1037 98 9.5% 2 0 
20.m03896 (ROP18) Vila 1601-7 97 6.0% 0 0 
80.m05038 (SR536A) IX 949 43 4.5% 0 0 
33.m02185 (Toxofilin) X 874-7 138 15.7% 1-3 0 
65.m01l64 XII 631-4 14 2.2% 0 0 
Total 5107 390 7.6% 3-5 0 
aUglI=TgCkUg1, 3, 5, 7, 8, 9 plus TgCkUg2 for loci 641.m01562, 20.m03896, 80.m05038, 33.m02185. 
bUglII=TgCkUg6 for all loci, plus TgCkUg2 for locus 65.m01l64. 
Toxofilin (33.m0218s), is a highly expressed rhoptry protein that binds to host 
actin, and may affect the virulence of the parasite (Bradley et aI., 2005). This protein 
is highly polymorphic with a predominance of type III SNPs (Figure 4-4 D). Sequence 
analysis revealed between one and three SNPs in the Ugandan type II strains 
compared with Me49 for this gene. Two of these SNPs were also found in the type I 
strain GT1, but one was exclusively found in TgCkUg7 and TgCkUg9. Interestingly, all 
of these SNPs were non-synonymous and resulted in amino acid substitutions, as 
shown in Figure 4-12. 
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Figure 4-12. Amino acid substitutions in Toxofilin. The Toxofilin amino acid sequences for GTl (I), 
Me49 (II) and VEG (III), plus the eight strains from Uganda (abbreviated to 1, 2, 3 .,,). This protein has 
a relatively high level of SNPs between the reference strains, especially type III SNPs. TgCkUg6 was 
identical to VEG, but all type II were different from Me49 for at least one position. TgCkUg1, 2, 3 and 
8 had one amino acid substitution, TgCkUg5 and 9 had two and TgCkUg7 had three (grey shading). 
The bold italic text mark the predicted actin-binding motifs (Jan et aI., 2007). 
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The bradyzoite specific surface protein (641.m01562) contained two SNPs, 
which were conserved in five of the Ugandan type II strains (TgCkUg1, 2, 3, 7 and 8). 
One of these SNPs was non-synonymous, leading to a change from alanine to 
glutamic acid at position 75. The two remaining type II strains, TgCkUg5 and 9, were 
identical to Me49, and TgCkUg6 was identical to VEG. No new SNPs were found in 
the other polymorphic genes ROP18 (20.m03896), SRS36A (80.m05038) and the 
hypothetical protein 65.m01164; at all positions the Ugandan type II strains were 
identical to Me49 and the Ugandan type III strain was identical to VEG. TgCkUg2 
was shown to possess type II sequence for all these loci except 65.m01164, where it 
was identical to the type III strains (see Figure 4.14). Additional sequencing was 
performed later and is reported in Chapter 5, and the final phylogenetic trees are 
shown in Figure 5-12. 
4.3.6 RAPD analysis 
PCR amplification with random primers was used to compare the "genetic 
fingerprints" of the strains without the bias of targeted amplification. Results from 
seven RAPD reactions (using primers C20, B12, 10.1, 10.2, 12.2+12.3, 12.2+12.4 and 
12.3+12.4) immediately showed that the Ugandan strains were similar to each 
other and the clonal types Me49 (II) and NED (III), while the atypical strains VAND, 
TONT and RUB were different from the clonal types and more similar to one 
another (Figure 4-13). 
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Figure 4-13. Amplification with random primers 12.2+12.4. Ugandan isolates (1-9) were highly 
similar to each other and to the clonal strains Me49 (II) and NED (III). DNA from atypical strains 
VAND, TONT and RUB were easily differentiated from the Ugandan and clonal strains by all primers. 
The size marker is a 100 bp marker with the 1000 bp and 500 bp bands indicated by arrows. 
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The final analysis included 60 bands, which were noted as present or absent 
for each strain, and the overall difference between strains ranged from 1-46 bands, 
but excluding the atypical strains, this was narrowed down to 1-14 fragment 
differences (Table 4-8). The highest level of similarity was found between TgCkUg1 
and 3 (98%), TgCkUg5 and 9 (98%) and between TgCkUg7 and 9 (97%). 
Table 4-8. Summary of RAPD results. 
Strain Ugl Ug2 Ug3 Ug5 Ug6 Ug7 Ug8 Ug9 Me49 NED VAND TONT RUB 
TgCkUg1 - 5 1 5 8 6 9 4 13 6 45 31 32 
TgCkUg2 92% - 6 4 3 3 12 3 8 3 42 26 27 
TgCkUg3 98% 90% - 6 9 5 10 5 14 7 44 32 31 
TgCkUg5 92% 93% 90% - 7 3 12 1 10 7 44 3D 29 
TgCkUg6 87% 95% 85% 88% - 6 9 6 7 4 43 27 28 
TgCkUg7 90% 95% 92% 95% 90% - 13 2 9 6 43 29 29 
TgCkUg8 85% 80% 83% 80% 85% 78% - 11 12 11 46 3D 29 
TgCkUg9 93% 95% 92% 98% 90% 97% 82% - 9 6 45 29 28 
Me49 78% 87% 77% 83% 88% 85% 80% 85% - 9 40 26 25 
NED 90% 95% 88% 88% 93% 90% 82% 90% 85% - 43 29 3D 
VAND 25% 30% 27% 27% 28% 28% 23% 25% 33% 28% - 22 21 
TONT 48% 57% 47% 50% 55% 52% 50% 52% 57% 52% 63% - 7 
RUB 47% 55% 48% 52% 53% 52% 52% 53% 58% 50% 65% 88% -
For the hOrIZontal row the strain names of the Ugandan strains are abbreViated for clarity. 
Ugl=TgCkUgl etc. 
The upper right part of the table shows the number of bands which were present in one but not the 
other of two strains (>20 in italics), while the lower part shows the degree of identity between each 
strain pair (>95% in bold). 
4.3.7 Composite genotype of the recombinant strain 
The TgCkUg2 strain was isolated from a chicken with mUltiple infections and 
the genotype was difficult to determine prior to clonal propagation in cell culture 
(section 4.2.6). PCR-RFLP of four genes from the first isolation in culture revealed 
type III alleles for the SAG2 and SAG3 loci, but type II for GRA6. Subsequent 
sequencing disclosed type II alleles for five additional loci and type III for one locus, 
and the high level of sequence similarity with the other Ugandan strains and the 
reference strains suggested a recombinant of two modern strains. The locations of 
the genotyped markers are shown in Figure 4-14. 
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Figure 4-14. Mapping of genotyped loci in TgCkUg2. The approximate location of informative 
genotyped loci in the recombinant strain TgCkUg2 is mapped to the fourteen chromosomes (la -XII). 
The results of nine loci, which distinguish between genotype II and III, showed that TgCkUg2 held 
type II alleles at six loci (green) and type III alleles at three (blue), provid ing evidence of its 
recombinant nature. 641 = 641 .m01562, 80=80.m05038, 65=65.01164. 
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4.4 Discussion 
4.4.1 Phenotypic differences and similarities between isolates 
The eight T. gondii strains isolated from Ugandan chickens were avirulent in 
mice in the sense that none of the infected mice showed disease symptoms or died 
from infection. However, quantification of parasite burden in brain, lung, heart and 
quadriceps muscle revealed significant differences between isolates. The brain was 
the most heavily parasitized organ in all infected mice, with parasite densities 
ranging from 8000 to nearly 8 million parasites per gram (Table 4-5). On average, 
the parasite burden in the brain of each mouse was around 15 times the density 
found in skeletal muscle, 100 times the amount in heart muscle and 1000 times 
more than in lung tissue. The preferential location of T. gondii in the central nervous 
system of chronically infected mice is in agreement with previous studies, which 
have shown an early, transient infection in lungs and lymphoid organs, followed by 
long-term persistence in the brain (Sumyuen et aI., 1995; Dubey, 1997b). The 
current study utilized Q-PCR for quantification of T. gondii in mouse tissues, and the 
accuracy of this method revealed substantial variation between individual mice 
infected with the same T. gondii strain (occasionally more than 100-fold within the 
same organ), and this variation indicates that host genotype and immune response 
plays an important role in the outcome of T. gondii infection. Nevertheless, parasite 
genotype appeared to be the major determinant for tissue burden in mice in this 
study, where the type III strain caused significantly higher parasite densities 
compared with the type II strains, and the recombinant strain had an intermediate 
phenotype (Figure 4-6). 
Virulence of T. gondii strains is traditionally determined by mouse mortality, 
where type I strains generally kill all mice, type II less than ten per cent and type III 
strains display more variability and intermediate levels of virulence (Araujo and 
Slifer, 2003). However, quantification of tissue burden through Q-PCR provides 
insight into the more subtle differences between strains and also differences 
between individual mice. A high number of parasites in the mouse brain may 
-123 -
augment the behavioural influence, which enhances the possibility of T. gondii 
transmission to the definitive host (Vyas et aI., 2007). Furthermore, an overall high 
parasite burden contributes to a higher infectious dose in the cat (or other 
carnivore), increasing the likelihood of successful transmission. A parasite that 
causes a high tissue burden without critical impairment of the host fitness is most 
likely to be successfully transmitted (de Roode et aI., 2008). In the current study, 
the Ugandan type III strain caused a higher parasite density in mice without causing 
disease symptoms and thus appears to be better adapted than the type II strains to 
murine hosts. The genotype related differences detected in mice was not correlated 
to the growth rate in culture, where three of the type II strains grew more rapidly 
than the recombinant and type III strain (Figure 4-9). Thus, the variation in mouse 
tissue burden could not be explained by intrinsic differences in replication rate 
between the lineages, instead it might be caused by strain-specific differences in 
the activation of the mouse immune response. Consistent with this, type II strains 
have been shown to be more potent inducers of the immune activators IFN-y and 
IL-12 compared with type III strains, due to differential immunogenic pathway 
interactions of polymorphic rhoptry proteins (Saeij et aI., 2005; Saeij et aI., 2007), 
and the contribution of several genes can explain the intermediate virulence of the 
recombinant strain. The nature of the recombinant strain TgckUg2 is further 
investigated and discussed in Chapter 5. 
An unexpected trait common to all the new isolates, regardless of their 
genotype or subsequent growth pace, was the slow initial growth at every new 
passage in cell culture, with the exception of trypsin treated parasites in passage 1 
(Figures 4.7, 4.8 and 4.9). Trypsin is used to release bradyzoites from tissue cysts 
and promotes transition to the rapidly dividing tachyzoite form (Dubey, 1998a), 
therefore application of trypsin digestion to half of the samples explains the 
variable growth rates in the first passage, where parasites were retrieved from 
chronically infected mice with bradyzoites in the brain. However, the lag-phase seen 
in subsequent passages, where parasites were transferred from one culture flask to 
another, was unexpected. This growth retardation may be caused by spontaneous 
conversion to the bradyzoite stage, as indicated by transmission electron 
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microscopy (Figure 4-10), and may be due to their very recent isolation. Few papers 
describe the in vitro growth characteristics of primary T. gondii isolates, but a study 
from Zimbabwe also reported that new isolates required several weeks to consume 
a monolayer and that the numbers of free and viable parasites were low compared 
with well-adapted strains (Hove et aI., 2005). It is possible that some strains are 
inherently less agile in tissue culture, but more data on primary cell culture isolation 
of T. gondii strains from different parts of the world would be needed to find out 
whether this is a specific attribute of some African strains or if a higher level of 
'bradyzoiteness' is commonly seen during the first months in culture. 
4.4.2 Limited genetic divergence among T. gondii from Uganda 
Five unlinked genetic loci, situated on chromosomes IV, Vila, IX, X and XII, 
were sequenced in the Ugandan isolates and compared with the reference strains. 
More than 5 kb high quality sequence was retrieved from each of the isolates, but a 
very limited level of diversity was detected. These loci were selected due to their 
polymorphic nature; a total of 390 SNPs are present between types II and III, 
corresponding to a nucleotide difference of 7.6% (the genome wide difference 
between these lineages is just over 0.5%, see Table 5-1 in section 5.1.2). Over the 
total length of 5107 bp, TgCkUg6 was identical to VEG, TgCkUg2 was identical to 
VEG and TgCkUg6 for one of the sequenced loci (6s.m01164), but otherwise 
identical to three of the Ugandan type II strains (TgCkUg1, 3 and 8). The total 
number of SNPs between the Ugandan type II strains compared with the reference 
strain Me49 was 3-5 «0.1%), and there were no genetic differences at all between 
the Ugandan type III strain and the VEG strain isolated from USA two decades ago. 
This minimal genetic drift implies that the strains from the same lineage share a 
very recent common ancestor and it is possible that there has been a recent 
human-mediated movement of these strains between continents (Lehmann et aI., 
2006). In that case, the strains isolated from Uganda may represent strains present 
in the human and domestic animal cycle, which is connected through inter-
continental travel and trade, and may have less resemblance to ancient African 
strains which could have been introduced when the big cats arrived from Asia 
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millions of years ago. The presence of these supposed ancient African strains has 
not been shown, but the relative tolerance to overt toxoplasmosis in 'Old World' 
animals suggests that T. gondii has evolved together with these species for a long 
time (Innes, 1997), and it is possible that non-clonal strains exist in other habitats or 
regions in Africa, perhaps relying on other definitive hosts than the domestic cat. 
The sequence divergence that was found among the type II strains indicated a 
division into two groups with TgCkUg1, 3, 8 and the type II part of TgCkUg2 on one 
side and TgCkUgS, 9 on the other, while TgCkUg7 had SNPs representative of both 
groups (Figure 4-1S A). Interestingly, this correlated well with the growth in the 
eighth cell culture passage, where TgCkUg1, 3 and 8 had a more rapid growth 
compared with TgCkUgS and 9, while TgCkUg2 and 7 were in between (Figure 4-9). 
Furthermore, the close relationship between strains TgCkUg1 and 3, as well as that 
between TgCkUgS and 9 was confirmed by RAPD analysis (Figure 4-1S B), and 
together these results point to at least two populations among the Ugandan type II 
strains which have a genotype related growth rate in vitro. 
A. B. 
Me49 T A A C G 
TgCkUgl A • • T T 
TgCkUg2 A • • T T 
TgCkUg3 A • • T T 
TgCkUg5 • G • • Me49 
TgCkUg7 A T G T T 94 TgCkUg8 
TgCkUg8 A T T RUB 
TgCkUg9 T G TONT • • VAND 
Figure 4-15. Genetic subgroups among the Ugandan type II strains. A. Sequencing revealed a 
maximum of five SNPs over 5109 bp between the Ugandan type II strains and Me49, which showed 
that TgCkUg1, 3, 2 and 8 were identical to each other, while TgCkUgS, 7 and 9 showed different SNP 
patterns. B. RAPD analysis confirmed the close relationship between the isolates from Uganda and 
the clonal lineages and the relationships suggested by the SNPs were partly confirmed by RAPD 
analysis (encircled). The tree is a neighbour-joining tree generated in Treecon (see 4.2.10). 
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4.4.3 Isolation of a natural recombinant strain 
The discovery of multiple infections in chickens and the isolation of a 
recombinant strain suggest that, under the right circumstances, the sexual cycle 
may be more common than previously thought. The recombinant TgCkUg2 did not 
exhibit more divergence from the archetypal lineages at any single locus, but was 
identical to type III on loci tested from chromosomes VIII and XII, and to type II on 
chromosomes II, IV, Vila, IX and X, and is thus highly likely to be a recent 
recombinant rather than an ancient, atypical strain. Recombination between 
different strains has been assumed to be a rare event in nature (Boothroyd, 1993). 
First, more than one genotype must be present in the environment and then they 
must be ingested by the definitive host within a short time frame. The most likely 
way for this to happen is for a cat to eat a host animal which is infected by two 
different strains, but the strong immune response elicited by the primary infection 
may prohibit the establishment of a second infection in some host species. 
However, the possibility of multiple infections has been proven in laboratory mice. 
Araujo and co-workers demonstrated that 100% of mice chronically infected with a 
type II strain were successfully infected with a type III strain via the oral route, and 
the mice brains were later found to harbour tissue cysts from both strains (Araujo 
et aI., 1997) . These results have later been confirmed for types II and III (Dao et aI., 
2001) as well as for type II infections followed by type I (Dzitko et aI., 2006). 
However, the relative abundance of the different strains in the host tissues may 
vary considerably and if one strain is largely predominant, self-fertilization is likely 
to be more frequent than recombination between strains. For the Ugandan strains 
we found that the difference in parasite burden in mice was up to 1000-fold and if 
this relationship would be true in a multiple infection it is likely that only the most 
abundant strain would prevail. Indeed, starting with three mUltiply infected 
chickens, three passages in mice and possibly unequal tissue burdens in the original 
host resulted in the propagation of only one strain from each chicken. Concern 
about the loss of strains from multiple infections in the process of isolation has also 
been raised previously (Villena et aI., 2004). 
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Although there appear to be many hurdles on the way to a successful 
recombination event, this may be more frequent in some environments. The study 
presented in Chapter 3 detected a high rate of mUltiple infections in chickens from 
Kampala, where two and even three strains were present at detectable levels. As 
the chickens used in this study were free-range and there are plenty of cats around, 
which may prey on the chickens, scavenge from rubbish piles or be fed chicken 
viscera, it is possible that recombination events are more common in that setting 
than in sparsely populated areas or industrialized cities. 
The benefit of recombination and genetic variation may be limited in the 
domestic cycle, since the three clonal lineages appear to be very well-adapted to 
these hosts. During the cross that gave rise to TgCkUg2, thousands and maybe 
millions of genetically distinct progeny must have arisen, but many of these might 
have been inferior and quickly outcompeted. While recombinant strains are 
sometimes discovered by direct genotyping in tissues or isolated in mice, this is the 
first time a natural recombinant strain and its putative parental strains have been 
propagated in culture and compared in vivo and in vitro. Although it is not possible 
to tell how long TgCkUg2 has existed, it has been successfully transmitted in nature. 
Therefore this strain is interesting for further investigation, in order to find clues to 
its success in the environment where other recombinant strains have failed. 
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4.5 Conclusions 
Toxoplasma gondii strains from domestic chickens in Uganda are closely 
related to the globally distributed clonal lineages, with a very low level of 
polymorph isms at the nucleotide level, but with dramatic phenotypic differences 
both in vivo and in vitro. It is possible that the clonal lineages of T. gondii have been 
introduced recently in Uganda, perhaps through trade in food or animals, and it 
remains to be elucidated if these strains, which are readily propagated between 
intermediate hosts, have outcompeted ancient African strains or if such strains can 
be found in habitats less affected by human activities. The very low level of genetic 
variation in T. gondii emphasizes the need for in depth genotyping to detect genetic 
differences between strains, which may have dramatically different phenotypic 
characteristics. Identification of a recombinant strain with intermediate growth rate 
in vivo shows that new genotypes with altered phenotypic properties may suddenly 
appear in places where different strains are circulating and cats, humans and other 
animals live close together. The unique isolation of a natural recombinant T. gondii 
isolate from Africa led on to the next phase of study where the whole genome of 
this strain was sequenced in order to fully probe the nature of the recombination 
event and divergence of this African isolate relative to the archetypal strains. 
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Chapter 5 Whole genome sequencing of a recombinant Toxoplasma 
gondii strain from Uganda reveals chromosome sorting and local 
allelic variants 
5.1 Introduction 
Sequence comparisons of entire genomes provide unparalleled opportunities 
for detection of genetic relatedness, new polymorph isms and genes under selection 
in an efficient large-scale and unbiased manner. The aim of the research described 
in this chapter was to generate the first whole genome sequencing of a 
recombinant T. gondii strain and make a thorough comparison with the reference 
type II and III strains to pinpoint new mutations that might be of biological 
significance. 
5.1.1 The T. gondii genome and ToxoDB 
Early mapping studies of the T. gondii genome using pulse-field 
electrophoresis and hybridization led to the identification of eleven chromosomes 
and a genome size estimate of 80 Mb (Sibley and Boothroyd, 1992b; Sibley et aL, 
1992). In 2005 a new composite map was assembled where the number of genetic 
markers was expanded from 57 to 250, which led to the identification of additional 
linkage groups reSUlting in the naming of 14 chromosomes (Khan et aL, 2005b), and 
this was used as a scaffold for the assembly of the first, lOx shotgun whole genome 
sequence of T. gondii. 
ToxoDB (www.toxodb.org) is a functional genomics database for T. gondii, 
which was first released in 2001 (Gajria et aL, 2008) and the original sequencing of 
B7 (a clone of Me49) was performed by The Institute for Genomic Research (now 
part of the J. Craig Venter Institute) in collaboration with David Roos at the 
University of Pennsylvania, and funded by the NIH/NIAID. This work has not been 
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published, but the methodology is described on 
http://www.tigr.org/tdb/e2k1/tgal/.Briefly. random genomic shotgun libraries 
were inserted in plasmids, which were sequenced from both ends using 
conventional sequencing (Sanger, 1977). In addition, random selections of larger 
sequences inserted in BACs were sequenced to provide a scaffold for linking the 
contigs. The first 0.7x assembly was released in March 2002; thereafter the 
coverage increased through more sequencing and enhanced contig assembly 
(http://v3-0.toxodb.org/about_data.shtml). In September 2003, ToxoDB 3.0 was 
released with lOx coverage of the Me49 strain. Version 4.3 was released in 
December of 2007 and is the version that was used for the sequence comparisons in 
this thesis. The main difference between v.4.3 and the new release (v.S.O, Nov 
2008) is the annotation of GT1 and VEG and the new nomenclature for 
chromosomal regions and genes (Figure 5-1). However, the old version can still be 
accessed and the previous gene names remain searchable in ToxoDB 5.0. 
ToxoDB can be accessed from the umbrella database EuPathDB 
(www.eupathdb.org), which facilitates comparisons between several eukaryotic 
pathogens including Plasmodium, Cryptosporidium and Giardia, with Leishmania 
and Trypanosoma soon to be incorporated. The latest version contains the full 
annotated genomes of GT1 (I), Me49 (II) and VEG (III), which were all isolated in the 
USA: GT1 from a goat (Dubey, 1980), Me49 from a sheep (Kaufman et aI., 1958) and 
VEG from a human AIDS-patient (Parmley et aI., 1992). In addition, chromosome la 
and Ib from another American type I strain, RH (sequenced by the Sanger Institute, 
Hinxton, UK) is available, this strain was isolated from a 6-year old child in 1939 
(Sabin, 1941). The apicoplast genome is available for RH only, while the 
mitochondrion sequence has not yet been made available. In addition, the draft 
Neospora genome (Sanger) is now available through ToxoDB. Through the "Queries 
and Tools"-option it is possible to browse the genome, retrieve sequences, perform 
BLAST queries and identify genes based on their SNP characteristics, expression, 
cellular location, function, motifs and many other options, and it is also possible to 
combine queries to perform more complex tasks. 
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Figure 5-1. Comparison of the genome browser in ToxoDB versions 4.3 (A) and 5.0 (B). The two 
pictures show the same region on chromosome II in the previous and new version of ToxoDB. The 
main difference is the poss ibility of direct comparison between the three strains, which have all been 
annotated in the new release. Also note the re-naming of the chromosomal regions and the genes. 
The SNP cod ing system is the same, where red indicate type I SNPs (type I different from type II and 
III, which have the sa me all ele), green for type II SNPs and blue for type III SNPs . Black diamonds 
indicate the rare instances where all three strains have different nucleotides in a certa in position . 
The full T. gondii genome sequence extends to 61 .6 Mb, distributed over 14 
chromosomes ranging in size from <2 Mb (Ia and Ib) to >7 Mb (X). The number of 
chromosomes is the same as for P. jalciparum (Gardner et ai, 2005), but the 
genome size is nearly three times larger. The AT·richness characterizing the genome 
of P. jalciporum is not present in T. gondii, which typically has a GC-content of 
around 50% and higher in coding regions (Khan et ai, 2006a). Approximately 9,000 
genes have been predicted in the three sequenced strains of T. gondii, but around 
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half of these still do not have any function assigned. Many T. gondii genes are 
heavily spliced, around 75% have at least one intron, and over 1000 genes have got 
ten or more exons, with dynein heavy chain proteins being the most extreme with 
>60 intronic regions (ToxoDS). Over 2,000 T. gondii proteins have recently been 
analyzed through proteomic analysis using 2D-gel separation followed by mass 
spectrometry, and intron spanning peptide fragments mostly confirmed the 
predicted splice sites (Xia et al,. 2008). Centromeric regions have not been defined 
in the T. gondii chromosomes (Gubbels et aI., 2008) and in spite of its large genome 
size T. gondii does not have the huge amount of repetitive DNA elements found in 
some other protozoan parasites like Trypanosoma and Plasmodium (Wickstead et 
aL, 2003). However, clusters of tandem repeats (Matrajt et aI., 1999) and mobile 
genetic elements (Terry et aL, 2001) have been identified, and in addition gene 
duplications are common. A recent bioinformaticanalysis reported the detection of 
787 duplicate genes (Dybas et aL, 2008), and this is thought to be particularly 
important for the variation of surface antigens (He et aI., 2002). 
5.1.2 Genetic differences between strains 
The clonal lineages I, II and III are highly similar on the nucleotide level, with 
an overall divergence of less than one per cent. The largest difference (as 
determined through ToxoDS searches) is >0.9%, for chromosomes Ib and XII 
between genotypes I and II, while the highest level of similarity is seen for 
chromosome XI between lineage II and III, where the dissimilarity is limited to 128 
SNPs over more than 6.5 Mb, while there are more than 50,000 SNPs to type I 
(Table 5-1). This uneven distribution shows that chromosome XI has an 
overwhelming dominance of type I SNPs (where type I has a different allele 
compared with type II and III). Chromosome la is highly conserved in all three 
lineages and was probably jointly inherited in all three lineages through the original 
crosses (see section 4.1.2). One chromosome (IV) has a predominance of type III 
SNPs, while most of the others have different regions dominated by two or three 
different SNP types (Soyle et aI., 2006). 
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Table 5-1. Nucleotide differences between types I, II and III. 
No ofSNPs Nucleotide difference (%) 
Chromo length (bp) 1-11 I-III II-III I-II I-III II-III 
la 1,896,408 324 329 56 L!l.O~~._31.~O~"'~O"*ti, 
Ib 1,956,324 17,845 16,264 6,795 0.912% 0.831% 0.347% 
II 2,302,931 20,059 15,604 20,394 0.871% 0.678% 0.886% 
III 2,470,845 21,713 15,177 18,312 0.879% 0.614% 0.741% 
IV 2,576,468 485 21,601 21,626 r:Qi~1 0.838% 0.839% 
V 3,147,601 25,579 22,199 26,177 0.813% 0.705% 0.832% 
VI 3,600,655 31,400 29,308 8,852 0.872% 0.814% 0.246% 
Vila 4,502,211 32,096 28,967 39,409 0.713% 0.643% 0.875% 
Vllb 5,023,822 43,363 36,392 24,102 0.863% 0.724% 0.480% 
VIII 6,923,375 61,101 51,333 28,961 0.883% 0.741% 0.418% 
IX 6,384,456 41,661 32,625 37,391 0.653% 0.511% 0.586% 
X 7,418,475 59,497 41,950 59,496 0.802% 0.565% 0.802% 
XI 6,570,290 54,354 54,366 128 0.827% [;j'''''''''''~''''' 0.827%>f~ 
XII 6,871,637 62,373 54,638 21,075 0.908% 0.795% 0.307% 
Total 61,645,498 471,850 420,753 312,774 0.765% 0.683% 0.507% 
The data was retrieved from ToxoDB by submitting queries for each chromosome between the 
different strains. (Tool: "Find SNPs by chromosomal location"). Grey shading indicate extreme levels 
of similarity, where entire chromosomes are dominated by one SNP type, or in the case of la, are 
virtually void of SNPs. 
The differences between strains are more pronounced on the gene level: out 
of the over 9,000 predicted or verified genes in the T. gondii genome, only around 
7,000 are found in all three strains, and 6905 are present at exactly one instance in 
each strain. The number of unique and shared genes between the three strains is 
shown in Figure 5-2. 
Figure 5-2. Shared and unique predicted genes among the three annotated strains. GTl (I) has the 
highest number of unique genes, while Me49 (II) and VEG (III) have the greatest number of shared 
genes. (Data compiled from numerous queries in ToxoDB). 
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Among the 7038 genes present in all three strains, 5282 (75%) have at least 
one coding, non-synonymous SNP between at least two strains. Of these, 644 are 
under positive selection with a dN/dS ratio of >2, which mean that the number of 
non-synonymous SNPs is twice as high as the number of synonymous SNPs. Most of 
these genes are currently annotated as hypothetical proteins, but among the 184 
with some kind of function assigned, proteins from a few families are 
overrepresented, including five dense granule proteins, eight rhoptry proteins and 
more than twenty surface antigens or SAG1 related sequences (SRS). The highest 
selective pressure is seen on the dense granule proteins GRA6 (dN/dS=16) and 
GRA3 (dN/dS=14.5), which are both located on chromosome X, while the highest 
absolute number of non-synonymous SNPs (245) is found in a hypothetical protein 
on chromosome XII (all information retrieved through queries in ToxoDB). In 
summary, the level of divergence on the nucleotide level is below 1% on all 
chromosomes between the three archetypal lineages, but the variation among 
predicted genes is in the order of 10%. Moreover, three quarters of all shared genes 
contain amino acid changing differences and many genes involved in invasion and 
host interactions appear to be under diversifying selective pressure. 
5.1.3 Massively parallel genome sequencing technologies 
In recent years, several new sequencing technologies have been developed 
that have in common that rather than the long, high-confidence reads obtained by 
conventional Sanger sequencing, they produce many millions of short reads (::30-
250 bp, and increasing). These new developments provide new opportunities since 
no cloning of source DNA is needed, thus the bias introduced in this step is 
eliminated. Furthermore the read density is directly proportional to the number of 
repeats, providing a direct quantification of minor allelic variants, tandem repeats 
etc (Swaminathan et aI., 2007). The biggest advantage is the drastically reduced cost 
and increased throughput, which for the first time have made whole genome 
sequencing of eukaryotes possible outside the big genome research institutes. The 
Roche 454 platform was the first available new generation sequencing technique 
and to date the most widely used, with over 300 peer-reviewed articles 
(www.454.com. January 2009) and the principle is shown in Figures 5-3 and 5-4. 
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Light ry IUCI ~in 
Figure 5-3. Chemistry of 454 sequencing. A single-stranded DNA library is prepared and short 
adaptors are attached to the 3' and 5' ends of each fragment, these are used for attachment to 
beads, primer-binding and purification. One unique fragment is bound to each bead and 
amplification takes place in separate microreactors (PeR-mixture droplets in an oil emulsion) 
resulting in several millions of copies of identical DNA fragments on each bead. The beads are 
deposited in microwells, containing one bead each and luciferase-Iabelled nucleotides are flushed 
sequentially over the wells . Each bead gives a separate read detected by a camera, which converts 
opt ical brightness to electrical amplitude signals . The picture and information was retrieved from the 
454 website (www.454.com) . 
FlowOrdel 
n CTGCG 
Figure 5-4. Reads from a single bead in 454 sequencing. As a control measure, all sequences start 
with a key sequence incorporated in the adaptors (the use of different adaptors enables the 
differentia t ion between multiple samples run in the same reaction), thereafter the actual sequence 
follows. The nucleotides follows a set flow order, and when incorporated the light emitted results in 
a signal proportional to the number of bases in a row. The picture and information was retrieved 
from th e 454 website (www.454.com). 
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The 454 technique is based on pyrosequencing (Nyren et aI., 1993), where 
fluorescent nucleotides are added and detected as they are incorporated. The high-
throughput format amplifies template DNA on beads that are deposited in 
individual wells and the incorporation of new nucleotides, which are sequentially 
flushed over the wells, are registered as emitted fluorescent light that is detected 
by a high resolution camera. This technique was first described in an article 
published in Nature in 2005 (Margulies et aI., 2005), and it highlights the immensely 
increased throughput and reduced costs compared with traditional sequencing, and 
proves the feasibility of assembling a de novo sequence from short reads, without 
the need for cloning and scaffold building. Obviously, this is possible only because 
the computer capacity and bioinformatics software have developed rapidly as well, 
and the capacity of these methods is continuously increasing. The possibility of 
ultra-deep coverage of small genomes and the capacity to use bioinformatics to 
assemble separate genomes even from closely related species present in the same 
sample have opened up completely new research fields like metagenomics - the 
investigation of all microbial species present in a certain niche such as soil, sea 
water or the human gut (Hall, 2007). Furthermore, the quantitative ability also 
enables the detection of rare species or rare mutations within a sample. For 
example, 454 deep sequencing of human HIV-samples has been able to detect 
minor drug-resistant variants leading to treatment failure, which would have been 
missed using conventional sequencing (Wang et aI., 2007). A coverage 20x is 
recommended by the 454 official website for de novo genome assemblies. With a 
throughput of around 100 million base pairs in each run, this can be achieved for 
most prokaryotic genomes using only one or a few runs, while the cost can still be 
prohibitively high for eukaryotic organisms. However, when a reference sequence is 
available, the reads can be mapped to this and even low sequencing depths can 
provide a good coverage. 
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5.1.4 Aims 
The aim of the final study of this thesis was to sequence and analyze the 
genome of the TgCkUg2 strain using the 454-platform, and this was the first T. 
gondii sequencing project to target a recombinant strain and one of the first whole 
genome sequencing projects of eukaryote pathogens employing one of the new 
generation sequencing technologies. Through alignment and comparison with the 
previously sequenced T. gondii reference strains, the goal was to unravel the 
genetic constitution of TgCkUg2, and to look for novel allelic variants and genes 
under selection in this recombinant T. gondii strain from Uganda. 
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5.2 Materials and Methods 
5.2.1 Parasite strain 
The parasite strain chosen for whole genome sequencing, TgCkUg2, was 
isolated from chicken number 2 (see Chapters 3 and 4 for more information). This 
chicken was a male, around 1.5 years of age and originated from Wakiso in the 
Gayaza area north of Kampala. The chicken was killed on Sep 4th 2006 and the 
Toxoplasma strain had been through three passages in mice, including 
cryopreservation for four months, and ten passages in cell culture when DNA was 
extracted in January 2008. 
Parasites were grown in six T75 flasks and allowed to eat through the 
fibroblast monolayer. The total quantity of medium was 150 ml and the density of 
parasites in the medium was counted in a haematocytometer and found to be 
3.45*106 per ml, which gave a total harvest from all flasks of at least 5*108 
parasites. Only a small proportion of human cells were visible under the microscope 
but due to their large DNA-content, additional efforts were taken to reduce their 
number. Three PBS-washes (3,500 rpm, 5 min) was used to get rid of cell debris and 
was followed by the release of intracellular T. gondii by passage through 26g 
needles. Thereafter two more washes were performed at a lower speed (2000 rpm, 
5 min) in order to collect only the dense parasites, but excluding the fibroblasts. 
Pellets were suspended in two aliquots of 1 ml PBS and new counts were 
performed. The total harvest was around 4*108 parasites. 
5.2.2 DNA extraction and quality control 
Serial DNA extractions were performed using the QIAgen DNA extraction kit 
(see 2.2.4), using approximately 2*107 purified parasites per reaction. The 
concentration and purity of the extractions were measured using a Nanodrop 1000 
machine (Thermo Scientific). The DNA samples contained between 25 and 80 ngfl.d 
and only extracts with a 260/280 > 1.8 and 260/230 > 1 were used in order to avoid 
protein and solvent contaminations. DNA from several extractions, which met the 
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required standard, were mixed and concentrated in a DNA concentrator to a 
volume of 50 ~I and a total DNA content of 5 ~g. 
Two T. gondii genes (BTUB and SAG3) and one human gene (~-globin), all 
single-copy, were used to estimate the DNA contributions from the respective 
organisms to the final extracts, through amplification of serial dilutions (primers and 
conditions for these PCR-reactions are described in chapter 3.2.9), and there were 
around 100 parasite genomes per human copy. In addition, the BTUB and SAG3 
amplicons were sequenced, and the type II result for BTUB and type'" for SAG3 
confirmed that this was indeed the recombinant strain. 
5.2.3 4s4-sequencing, creation of output files and bioinformatic 
analysis 
The whole genome sequencing including creation of the genomic library, 
annotation with other genomes and assembly of FASTA and Artemis files described 
in this section was performed by Prof. Neil Hall and Dr. Kevin Ashelford at the 
University of Liverpool. First, a DNA library with fragments of around 250 bp was 
created through nebulization and enzymatic attachment of the adaptors needed for 
amplification and sequencing. Thereafter, three runs were performed on the 454 
platform described in section 5.1.3. Reads were assembled into contigs using the 
Newbler software (Roche) and the sequence from TgCkUg2 was aligned with the 
published sequences for the type II (Me49) and'" (VEG) reference strains retrieved 
from ToxoDB. Sequences of human origin were filtered away. Since the strain was a 
type II/III recombinant, the 454 sequence was not aligned to the ToxoDB type I 
strain (GT1) as this would have increased the complexity of the analysis, while 
adding little useful information. 
The output files were FASTA text files containing all contigs (their length, 
number of reads, location (mapped to Me49) and sequence, (see Appendix 9 for a 
sample) and FASTA text files with details of all the SNP calls (location, number of 
reads, nucleotide present in each strain, per cent of concordant reads and the 
actual reads shown. SNPs were considered valid if three or more reads, of which at 
least one in the forward and one in the reverse direction, were in agreement. If 
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there were additional reads not in agreement, or if a SNP could be mapped to 
several locations in the genome they were not taken into account. These strict 
criteria prohibited the detection of all existing SNPs, but those that were called can 
be assumed to be correct with a high level of confidence (see Appendix 10 for 
examples of valid and invalid SNPs). 
Furthermore, files were prepared for analysis in Artemis 
(http://www.sanger.ac.uk/Software/ Artemis /v10/) which made it easy to 
distinguish between the features that could be properly mapped and those that 
were in repeat regions or had insufficient reliability. Three different types of SNPs 
were called for TgCkUg2 : novel SNPs, where the TgCkUg2 allele was different from 
both Me49 and VEG (orange), type II SNPs, where TgCkUg2 is identical to Me49, but 
different from VEG (green), and type III SNPs, where TgCkUg2 was identical to VEG, 
but different from Me49 (blue). In some cases, SNPs were called against one of the 
reference strains, while the relationship to the other could not be determined 
according to the strict criteria employed. In these instances a conservative 
interpretation was chosen, where TgCkUg2 was assumed to be identical to the 
other strain, rather than having a novel allele. In addition, SNPs between Me49 and 
VEG where the affiliation of TgCkUg2 could not be ascertained (yellow), and SNPs 
which had ambiguous mapping positions in the genome (white), were available in 
the Artemis file, but these were not included in the subsequent analysis. The SNP 
types and the colour codes are listed in Table 5-2. 
Table 5-2. SNP colour scheme 
TgCkUg2 vs. Me49a TgCkUg2 vs. VEG a Total number of SNPs b Colour c 
different different 1,252 Orange 
different same 29,056 
different NA 735 Blue 
same ·different 41,153 
NA different 550 Green 
SNPs between Me49 and VEG 165,225 Yellow 
Repeat regions 11,483 White 
aResult from comparisons between TgCkUg2 and either Me49 or VEG, where "same" means that the 
strains had the same allele, "different" means that they had different alleles and "NA" indicates that 
the comparison did not yield a definite answer. In these cases a conservative approach were chosen 
and these SNPs were assumed to be similar to one of the parental strains rather than being a novel 
SNP. 
bSNPs of each type detected across the genome. 
cThis colour scheme was used to differentiate between SNPs in all the subsequent analyses, but the 
yellow and white SNPs were not included. 
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Additional features implemented in the Artemis files were genes, exons, 
introns, mRNA, tRNA, coding sequence (CDS), and information for each SNP on 
whether it was non-coding, synonymous or non-synonymous. A screenshot from 
Artemis with some of these features is shown in Figure 5-5. 
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Figure 5-5. Artemis screenshot showing SNP features. The Me49 sequence from chromosome II is 
imported in embl format, wh ich includes the gene annotations from ToxoDB, and then a feature file 
is overlaid, which includes the SNPs between Me49, VEG and TgCkUg2 (1). The sequence and six-
frame translation, position and features are shown in detail (2) and in larger scale (3), both panels 
are zoomable. It is possible to show a range of features that Artemis reads from the sequence, here 
stop codons are displayed as vertical black lines in all reading frames in (3), and one can see how the 
gene 41.m02360 (4) is encoded within several open reading frames (exons are shown as boxes, 
introns as lines and th e whole mRNA is shown as a dark grey box) . The selected feature here (5) is a 
non-coding SNP situated in an intron, at position 215695. All blue-coloured SNPs are shared between 
VEG (three-II) and TgCkUg2 (454), but different from Me49 (two-II). The colour codes (0 0 255 for 
blue) were used to retrieve all SNPs of the same type and export these to Excel for creation of graphs 
and other analyses. 
Selected features were retrieved from Artemis and imported into Microsoft 
Excel, where calculations were performed and graphs made. To enable quantitative 
analysis of the FASTA files all contig information, except the actual sequences, were 
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imported to Excel where calculations regarding average contig length, distance 
between contigs, percent mapped etc could be easily performed. All contig, SNP 
and mapping data generated for TgCkUg2 has been submitted to ToxoDB and the 
inclusion of this data into the main database is currently in progress. 
5.2.4 Divergence time estimate 
The type II and type III derived chromosomes of TgCkUg2 were used in parallel 
to calculate the MRCA of the Ugandan type II (UglI) and Me49 and the Ugandan 
type III (UglIl) and VEG respectively. These time points are referred to as T2 and T3 
(Figure 5-6) . 
x MRCA a. j3 & II 
MRCA 
A. B. 
Figure 5-6. Schematics of the cross yielding types I, II, III, and the MRCA time estimates. A. A 
simpl ified overview of the crossing events between three ancestral strains (a, ~ and II) that resulted 
in the three modern lineages I, II and III (adapted from Boyle, 2006. Also see section 4.1.2). Ug2 
stands for TgCkUg2, which is a recent recombinant between modern type II and III from Uganda. The 
type II chromosomes from this strain are used to represent Ugandan type II strains (UglI) and the 
type III chromosom es represent Ugandan type III strains (UgllI) . B. The time point of the MRCA to 
strains a ~ and II is called T1 and is estimated at 150,000 years ago (Morrison, 2005). T2 is the MRCA 
of Me49 and Ugil and T3 is the MRCA of VEG and Ugili. 
Two different methods were used to calculate T2 and T3. The first was based 
on the T. gondii intron mutation rate, calculated by Su et al (2003). Intronic SNPs 
were defined as SNPs present in the mRNA, but not in the CDS, and the lengths of 
introns were calculated analogously. The intron minor SNP count divided by the 
intron length (the SNP density per nucleotide) was divided by the T. gondii intron 
mutation rate of 1.94*10-8 SNPs per nucleotide per year (Su et aI., 2003) . In 
addition, an estimate of the divergence time between type II and III (T1) was 
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calculated using the calculated estimates for T2 and T3 and relating these to the 
major SNP type found in introns (see Table 5-7 in the results section). 
For the second set of calculations, the relation between major and minor SNPs 
was assumed to be directly proportional to the relation in time between the MRCA 
of all type II and III strains (Tl) and the more recent MRCAs of Me49/Ugll (T2) and 
VEG/UgllI (T3) (Figure 5-6 B), meaning that the mutation rate was assumed to be 
constant over time, in accordance with the 'molecular clock' principle (Zuckerkandl 
and Pauling, 1965). Minor SNPs were defined as SNPs against the background (i.e. 
against Me49 on type II chromosomes and against VEG on type III chromosomes) 
and included the unique (orange) SNPs. Major SNPs were defined as SNPs against 
the non-background type (but excluding unique SNPs). Here, T1 was assumed to be 
150,000 years, as estimated by Morrison (2005). Regions dominated by type I SNPs 
were excluded since they are practically lacking major SNPs and, consequently, the 
whole of chromosomes la and IX and regions from several other chromosomes 
(detailed in Table 5-8) were excluded from the analysis. The T. gondii mutation rate 
at the whole genome level (including, introns, exons and intergenic regions) was 
calculated based on these results, by dividing the result of the minor SNP count over 
the sequence length with the new time estimates (Table 5-8). 
5.2.5 Targeted sequencing and phylogeny. 
Sanger sequencing was used to verify SNPs discovered by the 454 sequencing 
of TgCkUg2 and to look at the genetic relationship between the eight Ugandan 
isolates (see Chapter 4). Thirty-two new primer pairs were designed across the 
genome (Table 5-3), around loci with a high prevalence of unique SNPs as well as 
more conserved loci (see 4.2.9 for more details on primer design, sequence analysis 
and tree building methodology). All primers were designed with a similar melting 
temperature (60-65·C) and all but the X-27 locus (which was not further used) were 
readily amplified using the same 25 \ll mix (17.5 \ll water, 1.25 \ll of each primer (10 
\lM), 1.25 \ll dNTPs (4 mM), 5 \ll buffer and 0.125 GoTaq (Promega) plus 1 III DNA 
(10 ng)) and touchdown PCR program (94"C 5 minutes; 10 cycles of 94·C 30s, 60·C 
30s, 72·C 90s; 25 cycles of 94"C 30s, 56·C 30s, 72"C 90s; and finally 72"C for 7 
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minutes). PeR-products were purified and sequenced as described in 3.2.10. All loci 
were first sequenced in four strains (TgCkUg2, 5, 6, 8), and when informative 
polymorphisms were found, TgCkUg1, 3, 7 and 9 were also sequenced. A total of 
230 sequences, including those generated previously (see section 4.3.5) were 
submitted to GenBank (Accession numbers: FI274744-FI274973). 
Table 5-3. Primers used for complementary sequencing of additional Ugandan isolates 
Locus Chrom Start pos. Forward primer Reverse primer 
la-1 la 6169 CTTGAACATGCTGCCCATC AACGAGACAATGCTCCAACA 
Ib-2 Ib 188452 GAGGAATGGCAAGGTCTTCA GTTGTACATCTCCGCCATCA 
Ib-3 Ib 1638147 TCCAGGTCCAGCACTTCTTC GTTCTTCGGCAGGGAAGTCT 
11-4 II 74885 AGAAGCTCCTGTGAACGATGA TGACGCAAACTCTACAAAAACG 
11-5 II 1460420 TCCAGCAGTCCTTGACAATG TCACAGTTCACTACGACAAAG 
111-6 III 3650 CTGTCCCGACTGTTTCAGTG CGTCTGATCCTAAGTACGCAGT 
111-7 III 2457553 ATCAGAATTGTGCGAACACG TGCATCGTGATAGCGAAGAC 
IV-8 IV 8518 AGGGGATGCTGTCCAGTTTA GAATTCGCCTGAACAAGCAG 
IV-9 IV 1096127 GAGAAAGCATGGCGACAAAC AGGAAAGCGAAATGCGTGT 
V-10 V 2692201 TTGCTGCCTTATCACACAGG ATAACTGGCCAGGCATCTCA 
V-ll V 1466 CGAGAATGCGAACATGGAC CACCACTACATCACTGGACGA 
V-12 V 2500 TCATCGATATGCTGGTCTGC TAATTACCGCGCTTCCAAGA 
VI-13 VI 266750 GCCTGCTGCACGAATTAAG TCTCGCTCCTGACCCTTG 
VI-14 VI 2222524 CAAGCGATGTTGAGGGAACT ATGTTTGCATGCCTTTTTGT 
Vlla-15 Vila 4388405 GAAACCTACCAGGCCACACT CTCTCTCAGTTCCCGTGGTC 
Vlla-16 Vila 1061357 GGGAGCTTTTTCATTGTTGC CCAGACAATTGTATCCGTCCT 
Vllb-17 Vllb 4210302 CGCATTGTCCAGCCTTTC AGAAGCAGCCACTGATCCAT 
Vllb-18 Vllb 1506358 AAGCCTCCTGTGGGCATAC GCGTCGAAAACAAGCAGAG 
VIII-19 VIII 904801 CGCGAAACTTTCTTTTGGAT CTCCCACTGAGTGCTTTCGT 
VIII-20 VIII 2074625 GCAACTTTCAGACGGGAATC CGAAGTGACACGTGGAGTTG 
VIII-21 VIII 5857660 GACGACCGCAGAATTTTTGT GCATCATGTGTGCGTCATTA 
IX-22 IX 96023 AACAAGGCGAGGTGAAAGTG GGCGTCGGTAGAAGCACATA 
IX-23 IX 105770 GCCCACACCTTCTCAGTGAT AGCGAGGTGCTGTTTTGAAC 
IX-24 IX 5634308 CCGGCAAGAAAAGAAGTGAC TCTGTCTCGTGAGAGCTTCG 
X-25 X 30863 CGGTTTCCGTGTCACACTC GAGCAGGCAAGGACAGAACT 
X-26 X 4139809 CGCAGTCGCGTTGTAAAAAT CTGGGATCCTTCTTGGCATA 
X-27 X 7275823 CACATCGTAGGTGCTGTGCT CGAAACGTGTGAGTACACAT 
XI-28 XI 727 GCCAGACTCGAACTGGACTT CGACGCAGCTGTCACTACAT 
XI-29 XI 235815 GTACGGAGCCAGGGGATT CATCGTGCTTGCGTCTCTAC 
XI-30 XI 4244028 CTGTCAACCAAGCTGCTGAA TACTTATGTTGGGCGCTGCT 
XII-31 XII 72111 AAAGCAAGACAGAGGGTCGT CTCGGTTCCCCTGTCTCTC 
XII-32 XII 5851643 GACCGGACTGGTTCTATGCT GCAACTTTAAGCGCGGTATC 
Primers were designed for complementary sequencing of all the Ugandan isolates. The selected 
regions were distributed over all chromosomes and included loci with a high prevalence of unique 
SNPs as well as more conserved sections. 
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5.3 Results 
5.3.1 Coverage and contig metrics 
Three runs at the 454 GSFlX (Roche) generated approximately 4x coverage of 
the 61.6 Mb T. gondii genome. Human DNA contamination was unavoidable, but 
those reads could be removed bioinformatically. In total, 673,878 reads from 
TgCkUg2 were assembled into 67,013 contigs, ranging from 95 to 12,769 bp. The 
total contig length was 51.8 Mb, spanning over 84% of the genomic sequence. The 
average contig length was 774 bp, while the mean distance between contigs was 
148 bp, and these figures were similar over all chromosomes (Table 5-4), thus there 
does not appear to be any coverage bias. Many of the gaps are due to the fact that 
regions that could not be unambiguously mapped, for example repeat regions, and 
deeper sequencing would be needed for accurate mapping of the remaining 
sequence. 
Table 5-4. Contig and coverage summary for all chromosomes and the apicoplast. 
Percent Average 
Number Total covered distance Average Median 
Chromo Number of contig by Read between contig contig 
length of reads contigs length contigs density" contigs length length 
la 1,896,408 20,649 1,988 1,585,140 83.59% 13.03 155 797 
Ib 1,956,324 20,583 2,127 1,639,876 83.82% 12.55 147 771 
II 2,302,931 24,968 2,478 1,939,495 84.22% 12.87 147 783 
III 2,470,845 26,771 2,730 2,060,909 83.41% 12.99 149 755 
IV 2,576,468 27,510 2,885 2,150,897 83.48% 12.79 148 746 
V 3,147,601 33,619 3,433 2,582,080 82.03% 13.02 163 752 
VI 3,600,655 39,723 3,850 3,042,491 84.50% 13.06 146 790 
Vila 4,502,211 48,365 4,884 3,797,608 84.35% 12.74 145 778 
Vllb 5,023,822 53,768 5,469 4,231,651 84.23% 12.71 144 774 
VIII 6,923,375 75,308 7,501 5,851,305 84.52% 12.87 143 780 
IX 6,384,456 72,298 7,039 5,337,365 83.60% 13.55 150 758 
X 7,418,475 85,205 8,056 6,298,377 84.90% 13.53 140 782 
XI 6,570,290 70,653 7,222 5,549,592 84.46% 12.73 142 768 
XII 6,871,637 74,458 7,351 5,770,139 83.97% 12.90 150 785 
Total 61,645,498 673,878 67,013 51,836,925 84.09% 13.00 148 774 
Apico 34,996 3,055 1 25,117 71.77% 121.47 
- -
a Reads per kb over the contigs. 
The read density, contig lengths, distance between contigs and proportion covered by contigs 
showed little variance between the 14 chromosomes. However, most of the apicoplast was 
represented by a single long contig with a read density over nine times higher than that for any of 
the chromosomes, indicating multiple copies of the apicoplast genome in each parasite. 
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5.3.2 SNP distribution 
To determine the relative contribution of type II and type III regions to the 
recombinant isolate, the sequence generated for TgCkUg2 was aligned with 
published data for the reference strains Me49 (type II) and VEG (type III), and 
mapped to the 14 chromosomes. The total number of unambiguous SNPs identified, 
excluding repeat regions mapping to several locations, were 72,746. This number 
corresponds to about a quarter of the >300,000 known polymorphisms between 
Me49 and VEG (ToxoDB). The distribution of SNPs called against the two reference 
strains was highly disproportionate and indicated that each one of the 
chromosomes was inherited in its entirety from a single parental strain, without 
evidence of recombination events. Chromosomes II, IV, VI, Vila, IX and X originated 
from a type II strain while chromosomes la, Ib, III, V, Vllb, VIII and XII originated 
from a type III parent, see Table 5-5. 
Table 5-5. SNP summary for all chromosomes. 
Average distance Density / kb 
SNPs: SNPs: SNPs: 
Length TgCkUg2 TgCkUg2 Unique to Unique Major Minor 
(Mb) Type vs. Me49 vs. VEG TgCkUg2 All SNPs SNPs SNPs· SNPsb 
la 1.9 III 128 2 7 13,842 270,915 0.067 0.005 
Ib 2.0 III 1,483 1 10 1,309 195,632 0.758 0.006 
II 2.3 II 73 4,370 52 512 44,287 1.898 0.057 
III 2.5 III 4,224 27 73 571 33,847 1.710 0.040 
IV 2.6 II 176 4,731 60 519 42,941 1.836 0.038 
V 3.1 III 5,725 54 26 542 121,062 1.819 0.025 
VI 3.6 II 168 1,985 99 1,599 36,370 0.551 0.043 
Vila 4.5 II 79 8,663 56 512 80,397 1.924 0.017 
Vllb 5.0 III 5,530 62 41 892 122,532 1.101 0.021 
VIII 6.9 III 6,775 123 158 981 43,819 0.979 0.041 
IX 6.4 II 325 8,119 269 733 23,734 1.272 0.047 
X 7.4 II 236 13,459 209 534 35,495 1.814 0.033 
XI 6.6 NO 60 49 117 29,072 56,156 - -
XII 6.9 III 4,809 58 75 1,390 91,622 0.7 0.005 
Total 61.6 II/III 29,791 41,703 1,252 847 49,238 1.264 0.023 
• Major SNPs = The dominant SNP type: SNPs against Me49 on type III chromosomes and against VEG 
on type II chromosomes. 
b Minor SNPs = All SNPs where TgCkUg2 differs from the background type, for example on 
chromosome V this is the sum of SNPs against VEG (54) and unique SNPs (26), since all these 
represent nucleotides where TgCkUg2 is different from VEG. 
The density of major SNPs was in the order of 0.5-2 SNPs per kb, while the minor SNP density was 
around 0.005-0.05 per kb. Also note the extremely low total SNP density on chromosomes la and XI 
(see Figures 5-7 and 5-8 for more on this). 
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Most SNPs were mapped against either Me49 or VEG, i.e. TgCkUg2 was 
identical to one of the reference strains but different from the other. Dissimilarities 
to Me49 are marked in blue and to VEG in green (see Table 5-2 and Figures 5-7 and 
5-8), which means that a type II background is shown in green and regions inherited 
from type III in blue, and this corresponds to the SNP type colours in ToxoDB. In 
addition to these SNP types, 1,252 unique polymorph isms were found where 
TgCkUg2 was different from both Me49 and VEG, these SNPs are coloured in orange 
and are discussed in more detail in section 5.3.5. Due to the extreme scarcity of 
SNPs between types II and III on chromosome XI, which is dominated by type I SNPs 
(Figure 5-9), it has not been possible to ascertain the source of origin of this 
chromosome. In total, 226 SNPs were called over its length of >6.5 Mb, averaging 
one SNP per 29 kb. Over half ofthese (117 SNPs) were unique to TgCkUg2, while 49 
positions were identical to Me49 and 60 to VEG. There was no obvious separation 
between the SNP types on this chromosome and therefore no evidence of a cross-
over (Figure 5-7 (XI)). 
Some chromosomes were completely dominated by one SNP type over the full 
length (Figure 5-7 (II)), but several chromosomes showed dramatic changes in major 
SNP density (Figure 5-7 (VIII)). The major SNPs correspond to the divergence 
between the type II and III lineages, and were therefore scarce in regions where 
these two lineages are highly similar, that is regions inherited from closely related 
parental strains in the original cross (see section 4.1.2). These drastic changes in 
SNP density were observed in chromosomes Ib, III, VI, Vllb, VIII, IX and XII, but in all 
cases this coincided with type I dominance and is thus consistent with a uniparental 
origin in TgCkUg2. Detailed graphs of the SNP densities in all chromosomes are 
provided in Appendix 11. Altogether, there were six type II and seven type III 
chromosomes encompassing 26.8 Mb and 28.3 Mb respectively, and in addition 
there was one chromosome (XI) which might be either II or III. This nearly equal 
contribution from both parental strains to the genome of TgCkUg2 is consistent 
with a single event of sexual recombination. An overview of the SNPs found in 
TgCkUg2 when aligned with Me49 and VEG is shown in Figure 5-8. 
-148 -
60 
50 -
-;) 
~ 40 
~ 
.. 
0.. 
Z 
~ 30 
i!: 
Wi 
c 
co 
." 
0.. 20 
z 
CI) 
10 
0 
0 
70 
60 
-;)50 
... 
C> 
'i !i 40 
!!? 
>-~ 30 
.. 
." 
0.. 
~ 20 
10 
0 
0 
30 
25 
:il 
~ 20 
... 
0.. 
Z 
!!? 15 
i!: 
~ 
GO 
." 
"- 10 z 
CI) 
5 
50 
Chromosome II 
100 
Chromosome VIII 
150 200 
50 100 150 200 250 300 350 400 450 500 550 600 650 
Chromosome XI 
50 100 150 200 250 300 350 400 450 500 550 600 650 
Chromosome length ("10 kb) 
Figure 5-7. SNP density graphs of chromosomes II, VIII and XI. The X-axis represents the 
chromosome length *10 kb and the V-axis shows the density of the different SNP types per 10 kb. 
Chromosome II has a type II background, (the major SNP type is green, i.e. TgCkUg2 vs. VEG) and VIII 
is a type III chromosome (dominated by blue SNPs (TgCkUg2 vs . Me49)) . Note the radical change in 
SNP density on VIII and the co nstant low SNP density on XI, which can be explained by the low level 
of genetic difference between type II and III over these regions (as indicated by a predominance of 
type I SNPs in Figure 5-9). The SNP density graphs for all chromosomes were created in Excel and are 
shown in Appendix 11. 
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Figure 5-8. Overview of SNP distribution in TgCkUg2. The picture was created by K. Ashelford 
(Liverpool) from Artemis screenshots and shows the SNP distribution of TgCkUg2 over the 14 
chromosomes . Green denotes a type 11 background, blue a type 111 background, orange indicates 
SNPs where TgCkUg2 differs from both the archetypal type 11 and 111, while grey shows areas where 
all three strains are identical. 
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Figure 5-9. Overview of dominant SNP types in different chromosomal regions (reproduced with 
permission from Boyle et ai, PNAS 103:10514-9). This picture was generated by Boyle et al (2006) 
through a comparison of the whole genome sequences of GTl (I), Me49 (II) and VEG (III) . Red 
indicates a dominance of type I SNPs, green type 11 and blue type II\, When compared with the 
TgCkUg2 SNP map, the type I SNP dominant areas in red correspond very well with the areas void of 
SNPs (grey) in Figure 5-8. 
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Comparisons of the TgCkUg2 454 sequence data with the data reproduced in 
Figure 5-9 showed that regions without major SNPs in TgCkUg2 coincide with the 
regions dominated by type I SNPs (except in the case of chromosome la, where all 
the three lineages are highly similar). The chromosomes in Figure 5-9 are not 
depicted at a linear scale, however, and to enable a more detailed comparison Dr. 
Jon Boyle at the University of Pittsburgh reanalyzed the original sequence 
comparison data according to a different algorithm. For each position in each 
chromosome, the program looked for SNPs, if there was a type I SNP it was marked 
at the same level, type II SNPs were "plus oneil and type III SNPs "minus oneil. Thus, 
regions dominated by type I SNPs were shown as straight lines, type II SNPs by 
ascending and type III by descending lines. An overlay of these images on the SNP 
density graphs at the same scale, revealed a perfect match between SNP scarce 
regions in TgCkUg2 and regions dominated by type I SNPs in the comparison 
between the three reference strains (Figure 5-10 and Appendix 11). This provides 
strong evidence that TgCkUg2 is the progeny of a cross between modern type II and 
III strains, where no chromosomal recombination took place. 
Chromosome IX 
- Type II 
- Type II I 
+ NevSNPs 
\. , I 
Figure 5-10. SNP density graph overlaid with SNP type graph (chromosome IX). The black line is 
straight at type I SNPs, rises +1 for every type II SNPs and falls -1 for every type III SNP (scale on the 
V-axis). However, the horizontal parts of the line (indicated by arrows)match closely to the regions 
w ith low SNP densi ty, wh ich provides robust evidence that IX was inherited in its entirety from the 
Ugil parent in the last cross. Note that the SNP density for TgCkUg2 is not affected by changes in 
major SNP type between type II and III - as long as type II and III are different TgCkUg2 differs from 
the non-parental type of each chromosome. Graphs for all chromosomes are provided in Appendix 
11. 
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5.3.3 The apicoplast genome 
The largest continuous sequence obtained in this sequencing effort was 
mapped to the apicoplast: this contig spanned over 25,000 bp which mapped to 
positions 4,871 to 29,940 of the sequenced 34,996 bp apicoplast genome from RH 
(ToxoDB). Apart from that, there was a high proportion of the apicoplast genome 
that was not mapped, which may be due to the AT-richness and presence of low 
complexity regions found in the genome of this organelle (for example poly-A 
stretches, see GenBank entry NC_001799), which complicates unambiguous 
alignments. As shown in Table 5-4, less than 72% of the apicoplast genome was 
covered by contigs, compared with 82-85% for the chromosomes. Interestingly, the 
read density of the apicoplast was considerably higher than the average read 
density for the chromosomes: 121 reads / kb for the apicoplast compared with an 
average of 13 reads / kb for the chromosomal sequences. The unbiased mechanism 
of 454 sequencing results in automatic quantification of amplified regions 
(Swaminathan et aI., 2007), and the higher read density thus implies an average 
apicoplast genome copy number of 9 or 10. 
The apicoplast genome has not been completed for any of the three fully 
sequenced reference strains, and the only sequence currently available in ToxoDB is 
from RH. Alignment of the apicoplast genomes of TgCkUg2 and RH resulted in 23 
SNP calls over 25,069 bp of sequence. The sequence surrounding each of the 23 
SNPs from TgCkUg2 was therefore compared with the fragmented sequence data 
from Me49, VEG and GTl in the NCBI Trace Archive, using the BLAST tooll. Out of 23 
high-confidence SNPs detected between TgCkUg2 and RH, all positions where 
matching data was available were confirmed to be identical in TgCkUg2 and Me49 
and VEG, thus it was not possible to deduce the origin of the apicoplast in TgCkUg2. 
Analogous comparisons using the trace archive sequences for GTl showed that for 
20 of these 23 positions GTl and TgCkUg2 were identical, while GTl had the same 
allele as RH at the three remaining bases (Table 5-6). 
http://blast.ncbi.nlm.ni h .gov /BI ast.cgi?P AG E= N ucleotides& P ROGRAM=blastn& BLAST _SP EC= 
TraceArchive&BLAST_PROGRAMS=megaBlast&PAGE_TYPE=BlastSearch 
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Table 5-6. Details of SNPs in the Apicoplast genome. 
Position RH TgCkUg2 Me49 VEG GTl 
5442 G T T T T 
7848 C T T T T 
7969 G A A A A 
8864 G T T T T 
11253 - A not found not found A 
12858 C T T T T 
14396 C T T T T 
14918 G T T T T 
18101 C T T T C 
18506 T C C C T 
18669 C A A A A 
18675 C A A A A 
18701 C T T T T 
19606 G A A A A 
19959 G A not found A A 
22554 G A A A A 
24528 C A A A A 
24794 A G G G A 
25468 A T not found T T 
25508 C T T T T 
25962 C T T T T 
26380 A T T T T 
29819 G TT TT TT TT 
Details of the 23 SNPs detected between TgCkUg2 and RH, and their counterparts in the Me49, VEG 
and GTl strains. 
5.3.4 Divergence time estimates 
SNP data from TgCkUg2 was used to determine the time of the most recent 
common ancestor of the Ugandan types II and III (Ugli and UglIl) and their 
respective reference strains. The divergence time for Me49/Ugli is called T2 and 
that for VEG/UgIII is called T3 (see Figure 5-6). The calculations were made for all 
chromosomes separately and also for all chromosomes of the same genotype 
together and the two starting points were the T. gondii intron mutation rate of 
1.94*10.8 mutations per nucleotide per year (Su et aI., 2003), and an estimate ofTl 
of 150,000 years (Morrison, 2005). 
For the first method all minor SNPs found in introns were retrieved for each 
chromosome, since the mutation rate used was calculated for T. gondii intronic 
regions. From the introns of the type II chromosomes (II, IV, VI, Vila, IX and X) all 
SNPs where TgCkUg2 was different from Me49 were retrieved and for the type III 
chromosomes (la, Ib, III, V, Vllb, VIII and XII) the SNPs where TgCkUg2 differed from 
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VEG were used. In total, the type II intronic regions contained 381 SNPs over 1.13 
Mb, compared with 229 SNPs over 1.28 Mb for type III, corresponding to SNP 
densities of 3.38*10-4 and 1.79*10-4 SNPs per base pair. Division of the SNP density 
with the intron mutation rate resulted in overall estimates of T2 and T3 of around 
17,400 and 9,200 years, which implies that the Ugandan type II strains are older 
than their type III counterparts. The obtained results were used for calculation of 
the MRCA of the parental strains to all lineages (T1), and the estimates in both cases 
were much higher than the 150,000 years calculated by Morrison (2005). 
Calculations based on the data from the type II chromosomes of TgCkUg2 landed at 
around 1 million years, while calculations based on the type III parts gave an 
estimate of around half a million years. The results of these calculations are shown 
in Table 5-7. 
Table 5·7. Divergence time estimates based on the T. gondii intron mutation rate. 
All intronic regions Regions with a major SNP type-
Intron Minor Minor Intron 
Type" length SNPs in MRCAb SNPs in Major SNPs length MRCAc 
chrom (bp) introns years (T2) introns in introns (bp) years (Tl) 
II 89,003 34 19,691 34 1,800 89,003 973,654 
IV 85,471 58 34,979 58 1,758 85,471 1,700,620 
VI 152,385 65 21,987 21 656 46,869 1,570,910 
Vila 198,902 28 7,256 28 3,264 198,902 442,187 
IX 266,876 117 22,598 65 2,667 175,224 1,484,722 
X 334,181 79 12,186 79 5,044 334,181 807,328 
Total II 1,126,818 381 17,429 285 15,189 929,650 1,066,743 
Intron Minor Minor Intron 
Type III length SNPs in MRCAb SNPs in MajorSNPs length MRCAc 
chrom (bp) introns years (T3) introns in introns (bp) years (Tl) 
lad 80,522 2 1,280 ... NA ... NA 
Ib 85,805 8 4,806 6 466 38,069 392,610 
III 82,660 9 5,612 6 1,381 66,453 270,064 
V 119,536 15 6,468 15 2,015 119,536 383,720 
Vllb 220,517 39 9,116 16 2,052 115,228 511,919 
VIII 337,557 78 11,911 25 2,296 138,216 717,022 
XII 352,605 78 11,403 25 1,394 78,096 638,808 
Total III 1,279,202 229 9,228 93 9,604 555,598 533,830 
·Whole chromosomes for II, IV, Vila, X, V. No part of la. Ib >1.2 Mb, III < 1.9 Mb, VI >2.6 Mb, Vllb < 
2.5 Mb, VIII> 4 Mb, IX 0.5-4 Mb, XII , 1.5 Mb. Only regions with a major SNP type can be used for this 
calculation since Tl is based on the number of major SNPs. 
b (Minor SNPs in introns / Intron length) / 1.94 *10-8 
C (Region with major SNP type intron length * MRCA T2 or 13) / Major SNPs in introns. 
d Since there are no major SNPs in chromosome la, T1 could not be calculated 
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The second approach related the number of 'major SNPs' to the number of 
'minor SNPs', where the former type was assumed to represent the divergence 
between the type II and III lineages (beginning at T1), and the latter type the 
divergence between Ugandan strains and the reference strains (starting at time 
points T2 and T3), see Figure 5-6. This method is not applicable to regions without 
major SNPs, since the recombination events between the ancestral strains that gave 
rise to the present lineages occurred much more recently then did the MRCA of all 
the present strains, and types II and III have had much less time to acquire 
mutations in the regions they inherited jointly in this cross. Therefore, 
chromosomes la, XI and other chromosomal regions where type I SNPs are 
predominant (see Boyle 2006 and Figure 5-9) were excluded. All chromosomal 
regions included are listed in Table 5-8. These calculations resulted in considerably 
more recent divergence time estimates of 4,600 years for type II and 1,600 years for 
type III, which would correspond to an overall genomic mutation rate of 
approximately 1.29*10-8 per year. 
Table 5-8. Divergence time estimate based on the relation between major and minor SNPs. 
Genomic 
M RCAb years mutation 
Type II chrom Length- MinorSNPs Major SNPs (T2) rate C 
II 2,302,931 125 4,370 4,291 1.27E-08 
IV 2,576,468 236 4,731 7,483 1.22E-08 
VI >2.6 Mb 1,000,655 70 1,913 5,489 1.27E-08 
Vila 4,502,211 135 8,663 2,338 1.28E-08 
IX 0.5-4 Mb 3,500,000 205 6,349 4,843 1.21E-08 
X 7,418,475 445 13,459 4,960 1.2lE-08 
Total II 21,300,740 1,216 39,845 4,578 1.25E-08 
Genomic 
MRCA b years mutation 
Type III chrom Length- (bp) MinorSNPs Major SNPs (T3) rate C 
Ib >1.2 Mb 756,324 6 1,375 655 1.21E-08 
III <1.9 Mb 1,900,000 33 3,953 1,252 1.39E-08 
V 3,147,601 80 5,725 2,096 1.21E-08 
Vllb <2.5 Mb 2,500,000 43 5,069 1,272 1.3SE-08 
VIII >4 Mb 2,923,375 49 6,268 1,173 1.43E-08 
XII <1.5 Mb 1,500,000 69 3,259 3,176 1.45E-08 
Total III 12,727,300 280 25,648 1,638 1.34E-08 
aOnly chromosomal regions that were not jointly inherited by type II and type III in the lineage cross, 
i.e. regions that have a major SNP type, were included in this analysis. The length is in base pairs. 
b (Minor SNPs • 150,000) / Major SNPs. C (Minor SNPs / Length) / MRCA 
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As with the intron mutation rate method, substantial differences among 
chromosomes of the same genotype were observed. However, with the exception 
of chromosome Vila, all estimates of T2 were higher than those of T3. 
5.3.5 Novel SNPs and genes under selection 
In the alignments of TgCkUg2 with Me49 and VEG, 1,252 positions were found 
where the two reference strains were identical but the Ugandan strain TgCkUg2 had 
a different base (marked in orange in Figures 5-7,5-8,5-10 and Appendix 11). These 
novel SNPs were dispersed all over the genome with an average distance between 
them of about 50 kb. Based on the SNP discovery rate with the coverage and cut-off 
criteria used, the real density of novel SNPs is however likely to be around four 
times higher (see 5.3.2). Novel SNPs were often found towards the chromosomal 
ends, in the subtelomeric regions. The proportion of all SNPs located in the 
outermost 20% of each chromosome (10% on each end) was 21.4%, close to the 
expected value, but a significantly higher proportion (38%) of the unique SNPs were 
found in these regions (P«O.OOl). Several chromosomes had one or a few "hot-
spots" with a high level of new mutations, see Figure 5-11. 
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Figure 5-11. Distribution of novel SNPs in TgCkUg2. The graph shows the number of unique SNPs 
per 100 kb of sequence over the 14 chromosomes (separated by dashed lines). Several hot-spots 
with a high SNP density are seen and these were often located near the chromosomal ends, most 
prominently for chromosomes IX, X and III. Large peaks were also seen in central regions of 
chromosomes VI and VIII. 
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The highest concentrations of new SNPs were found in the subtelomeric 
regions of III, IX and X, and in more central regions of VI and VIII, but smaller 
clusters were found on all chromosomes except la. The majority of the novel SNPs 
(N=l,086, 86.7% of the total 1,252) were non-coding mutations in intergenic or 
intronic regions, but among the coding SNPs there were twice as many non-
synonymous (N=111) as synonymous (N=55) mutations. 
Fifteen genes, which had at least two new SNPs in the coding sequence, were 
identified and these are listed in Table 5-9. 
Table 5-9. Genes with ~2 novel 5NPs in the coding region of TgCkUg2. 
Novel SNPs in SNPs between the 
TgCkUg2 b three lineages b 
Gene lOa Chromo Syn Non-syn Syn Non-syn Protein description a 
641.m01S62 IV 1 1 12 86 SRS16B 
641.m02553 IV 1 1 6 1 
WO-40 repeat protein, 
putative 
49.m03276 VI 1 1 0 4 ROP29 
49.m03279 VI 2 8 1 13 Hypothetical 
49.m03372 VI 1 1 13 3 Long chain fatty acid CoA ligase 
SS.m04829 Vllb 1 3 1 2 SRS26A 
44.m02583 VIII 0 2 9 11 Hypothetical 
44.mOS903 VIII 0 2 7 8 Hypothetical 
S7.m0176S IX 0 2 143 231 Protein kinase domain 
containing 
2.mOOO67 IX 3 7 0 0 Hypothetical 
57.m01732 IX 0 2 7 8 Hypothetical 
80.m02252 IX 1 1 4 2 Phosphoenolpyruvate 
carboxykinase, putative 
42.m07434 X 0 2 0 0 Hypothetical 
S51.mOO238 XII 3 6 8 44 ROP5 
65.mOOOOl XII 4 0 9 6 NTPase I 
-rhe GenelO is from ToxoOB 4.3, but the product description was updated from the more recent 
annotation in v.5.0. 
bAli listed genes have at two or more novel SNPs in TgCkUg2. The number of SNPs between the three 
lineages for each gene (data from ToxoDB) is listed for comparison. For example 57.m01765 is highly 
polymorphic, while 2.m00067 has a lot of novel SNPs but no divergence at all between the three 
archetypal strains. 
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Ten of the genes with novel SNPs in the CDS, including two SRS genes, had 
more non-synonymous than synonymous SNPs. Many of these genes, which appear 
to be under positive selection, have a high number of coding SNPs between all the 
lineages, but two of the hypothetical genes listed in Table 5-9 (57.m01765 and 
42.m07434) did not have any previously identified SNPs (ToxoDB search). Three 
genes contained six or more amino acid changing mutations: hypothetical proteins 
2.m00067 (IX), 49.m03279 (VI) and the rhoptry protein ROP5 (551.m00238, XII). 
5.3.6 Local allelic variants and relationship between strains 
In order to assess the level of divergence between all the eight Ugandan 
isolates and to investigate whether the novel SNPs in TgCkUg2 were conserved in 
the other strains as well, 32 new primer pairs were designed (see 5.2.6). These were 
distributed over all 14 chromosomes and while some of them were targeting novel 
SNP containing loci, others were simply distributed across the genome to provide an 
estimate of the overall divergence. Amplifications were primarily done in four 
strains: the recombinant (TgCkUg2), the type III (TgCkUg6) and two type II strains 
(TgCkUg5 and 8), and if informative polymorphisms were detected, the remaining 
type II strains were also amplified. 
A high level of sequence homology was seen between the novel isolates from 
Uganda and the reference strains. The type III strain, TgCkUg6, was very closely 
related to the type'" reference strain VEG as well as to the type III regions of 
TgCkUg2. In comparison to VEG, TgCkUg6 had 39 SNPs over 20.9 kb and most of 
these SNPs were concentrated to two loci: 11-4 (10 SNPs over 598 bp) and VI-13 (18 
SNPs over 368 bp). Apart from these regions the sequence identity between the 
type "I strains was >99.9%. Locus 11-4 consisted of non-coding sequence in the 
subtelomeric region of chromosome II, where TgCkUg6 shared some alleles with 
strains of genotype II (including Me49). The second locus, VI-13, included 220 bp of 
coding sequence from a SRS-gene (SRS22H, 49.m03110), where several new, non-
synonymous SNPs were found for TgCkUg6, TgCkUg2 and three of the Ugandan 
type II strains. Interestingly, most new SNPs found within coding regions, including 
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SRS22H, Toxofilin (33.m02185) and SRS16B (641.m01562), resulted in amino acid 
changes, suggesting positive selection (Table 5-10). 
Table 5-10. Amino acids at three polymorphic loci for Ugandan and reference strains. 
Locus SRS22H (VI-13) Toxofilin SRS16B 
aa position 111 113 138 139 140 141 143 144 146 150 147 168 176 77 
Me49 (II) E E K P S A H R T D L E K A 
TgCkUgS • G • G • • • • • • • • R • 
TgCkUg9 • • • • • • • • • V • D R • 
TgCkUg7 • • • • • • • • • • Q 0 R E 
TgCkUgl • • • • • • • • • • Q • • E 
TgCkUg8 • • • • • • • • • • Q • • E 
TgCkUg3 • • • • • • • • • V Q • • E 
TgCkUg2 D G T G T G R • P V Q • • E 
TgCkUg6 D G N G • G R S P V E • • T 
VEG (III) • • • • • • * • • * E * * T 
GTl (I) • G S A T E R S D G Q * R A 
Identities to the reference sequence shown at the top are indicated by asterisks (.). 
The Ugandan type II isolates, including the type II regions of TgCkUg2, were 
closely related to Me49 (>99.5% sequence identity), but with some allelic variation. 
The new SNPs were largely concentrated at a few loci and many were shared 
among several Ugandan isolates, suggesting that these are local allelic variants. At 
one locus on chromosome IV (IV-8), several of the Ugandan type II strains shared 
sequence homology with GT1 (Table 5-11). This was only seen for a short stretch 
near the chromosomal end (positions 8805-8907), and this was the only instance 
where a high level of similarity with the type I reference strain was detected. 
Table 5-11. Sequence similarity between Ugandan type II strains and the reference type I. 
Locus IV-8 
Me49 (II) T C T A T T G G A G G G A A G T 
VEG (III) • • • • * * • • * * • * • • * * 
TgCkUg6 • • • • • • • • • • • • • • • • 
TgCkUgS • • • • • • • • • • • • • • • * 
TgCkUg9 • • • • • • • • * • • • • • • • 
TgCkUg7 • • A T C C C • • T • • G C C • 
TgCkUgl C A A T C C C C C T A A G C C A 
TgCkUg2 C A A T C C C C C T A A G C C A 
TgCkUg3 C A A T C C C C C T A A G C C A 
TgCkUg8 C A A T C C C C C T A A G C C A 
GTl (I) C A A T C C C C C T A A G C C A 
Identities to the reference sequence shown at the top are indicated by asterisks (.). 
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Complementary Sanger sequencing confirmed the assignment of TgCkUg2 
chromosomes according to the 454 SNP analysis, but possible cross-over events 
were detected in two regions without major SNPs. Chromosome VIII was identified 
as derived from type III, based on the major SNP density in the second half of the 
chromosome (Figure 5-7). However, for loci VIII-19 and VIII-20 (located at 
approximately 0.9 and 2.1 Mb) TgCkUg2 was more similar to Me49 than VEG and 
even contained four allelic variants, which were present in the Ugandan type II 
isolate TgCkUg8 as well. However, locus VIII-21 located around 5.8 Mb on the same 
chromosome identified TgCkUg2 as a type III strain. Similarly, comparison of 
TgCkUg2 and TgCkUg6 sequence for the VI-13 locus, located around 0.3 Mb, 
indicated the presence of a type III region in the otherwise type II derived 
chromosome VI. These results provide indications of chromosomal recombination in 
TgCkUg2 (Table 5-12). 
Table 5-12. Different 5NP types on TgCkUg2 chromosome VIII suggests recombination. 
Locus VIII-19 VIII-20 VIJI-21 
Position O.9Mb 2.1Mb 5.8Mb 
Me49 (II) A T G C T T T C T G A G C G 
TgUgCkS • • • • • • • • • • • • • • 
TgUgCk8 • • • • A C * T * A * • • • 
TgUgCk2 * • * * A C * T • A • A A T 
TgUgCk6 T • C G • • C • C * T A A T 
VEG (III) T C C G • • C * C * T A A T 
Identities to the reference sequence shown at the top are indicated by asterisks (*). 
Few informative SNPs were detected on chromosome XI, but one unique allele 
within locus XI-28 was present in the recombinant as well as all of the type II 
Ugandan strains, but not in Me49, VEG or TgCkUg6. The fact that all of the Ugandan 
type II strains had this mutation implies that chromosome XI in TgCkUg2 was 
inherited from the type II parent. 
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Based on the sequence divergence over all amplified loci (including those 
described in Chapter 4), it was possible to resolve that TgCkUg5 and TgCkUg9 were 
the isolates most similar to Me49 and that TgCkUg3 was the strain most similar to 
the type II component of the recombinant TgCkUg2 (Figure 5-12). 
TgCkUg1 A 
TgCkUg8 
TgCkUg3 
TgCkUg2 
TgCkUg7 
TgCkUg9 
TgCkUgS 
Me.49 
GTl 
TgCkUg6 
VEG 
0.01 
~ TgCldJgJ B 
~TgCkUg8 
~TgCkUgl 
--TgCkUg2 
TgCkUgG 
.... VEG 
GT1 
-TgCkUg7 
Me49 
TgCkUgS 
---
TgCkUg9 
--------- 0.01 
Figure S-12. Phylogenetic trees of the relationship between Ugandan and reference strains. Trees 
based on sequence from chromosomes where TgCkUg2 were type II (A) and III (8). The type II part of 
the recombinant TgCkUg2 is most similar to TgCkUg3 and this strain can therefore be considered the 
putative type II parent in the cross. The slow-growing TgCkUgS and 9 associate with Me49, while 
TgCkUg7 showed a higher level of similarity with non-type II strains. The methodology is described in 
section 4.2.9. 
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5.4 Discussion 
5.4.1 Recombination through chromosome sorting 
The first whole genome sequencing of a recombinant T. gondii strain revealed 
a nearly equal contribution of type II and III a"eles, and the TgCkUg2 strain is likely 
to have arisen through a single recombination event between modern type II and 11\ 
strains. The origin of most chromosomes could easily be deduced from the SNP 
density, since TgCkUg2 was either similar to VEG (type III origin) or Me49 (type II 
origin). However, extended sections with an apparent paucity of SNPs were 
observed, and these were found to be consistent with the type I SNP dominated 
regions in the comparison between the three archetypal lineages (Boyle et aL, 
2006). Even though novel SNPs were observed in the Ugandan strains, the whole 
genome sequence of TgCkUg2 showed almost perfect synteny with either Me49 or 
VEG for any given region. Thus, the sequencing of this recombinant isolate does not 
provide evidence of exotic or ancient strains in Uganda, but demonstrates 
recombination between two strains that are closely related to the lineages in 
Europe and North America. 
Analysis of recombinant progeny from experimental crosses have shown that 
recombination can occur on a" T. gondii chromosomes and that the frequency is 
related to the physical size (Khan et aL, 200Sb). The genetic map unit was estimated 
at around 104 kb/cM (Khan et aL, 200Sb), which is high compared with the human 
genome 1000 kb/cM (Sved et aI., 2008) but represent a considerably lower 
recombination rate compared with the related apicomplexan P. Jalciparum, which 
has an estimated cross-over frequency of 17 kb/cM (Su et aL, 1999). The study by 
Khan et al also detected an unexpectedly high prevalence of closely spaced 
crossovers, which may be due to gene conversions as seen in other protozoa (Le 
Blancq et aL, 1988; Su et aL, 1999; Palmer and Brayton, 2007). For TgCkUg2, no 
chromosomal crossovers were detected by whole genome SNP analysis. However, 
complementary sequencing of regions that had an unusually high number of minor 
SNPs showed that two loci on the otherwise type 11\ derived chromosome VIII had a 
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high similarity to type II strains. This could indicate a regular crossover event, but 
the limited extension of the peaks (Figure 5-13) suggests that these may represent 
gene conversion events. Similarly, the identity of several Ugandan type II strains to 
the type I reference strain in the subtelomeric sequence of chromosome IV (Table 
5-11), was limited to around 0.1 kb, and is likely to have arisen through one double 
cross-over rather than two separate events. 
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Figure S-13. SNP density graph of chromosome VIII, with polymorphic loci suggestive of 
recombination. The area around the two polymorphic loci at 0.9 Mb and 2.1 Mb were sequenced for 
four Ugandan strains and showed that TgCkUg2 was identical to TgCkUg8 (a type II strain) for these 
loci, while it was clearly similar to type III for the region after 3.7 Mb, as shown by the predominance 
of blue SNPs. 
Clonal propagation of non-archetypal genotypes has been observed in South 
America (Pena et aI., 2008) and Asia (Dubey et aI., 2007a; Dubey et aI., 2007d), but 
comparison of the ten loci used in these studies showed that TgCkUg2 had a unique 
genotype, which has not been observed in any of the >900 strains analyzed to date 
(Dr. Chunlei Su, personal communication). However, apart from locus c22-8 on 
chromosome Ib, TgCkUg2 was highly similar to one strain from Ghana (Table 5-13) . 
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Table 5-13. TgCkUg2 compared with circulating non-archetypal lineages and African strains. 
Vietnam, 
China + 
Locus· TgCkUg2 S. Amer. Brl Brll Brill BrlV Nigeria Ghanal Ghana 2 
c22-8 (Ib) III II u-l I II u-l III II II 
c29-2 (III) III III I III III I I III III 
L358 (V) III II I I III I I II III 
PKl (VI) II II I II III III III III II 
SAGl (VIII) III u-l I I I u-l u-l u-l II or III 
SAG2 (VIII) III II I I III I I II III 
BTUB (IX) II III I III III III III III II 
GRA6(X) II II II III III III III II II 
SAG3 (XII) III III III III III III III III III 
Apico II or III I I III III I I I III 
·loci used In the worldwide population study by J.P. Dubey and C. Suo 
Comparative strains were chosen because they are widely dispersed non-archetypal clonal lineages, 
found in Asia and South America (Dubey et aI., 2007a, d) or different regions of Brazil (Sri-IV, Pena et 
aI., 2008). In addition three African strains were used for the comparison (Velmurugan, 2008). 
5.4.2 Apicoplast genome copy number 
The quantitative nature of the 454 sequencing technology revealed that the 
read density of the apicoplast genome was more than nine times higher than the 
average for chromosomal contigs, which implies an average apicoplast genome 
copy number of 9.3 in this strain of T. gondii. This result is higher than the average 
apicoplast genome copy number of 5-6 reported in an early study using DNA 
hybridization (Fichera and Roos, 1997), but significantly lower than the average of 
25 copies (occasionally up to 80) detected by microscope photon counting 
(Matsuzaki et aI., 2001). These differences could be due to inherent differences 
between strains or methodological discrepancies, but the genome copy number 
may also vary over the different life cycle stages (Matsuzaki et aI., 2001). 
5.4.3 Level of divergence and relatedness to other strains 
The estimated time of the most recent ancestors relies on the theory of the 
molecular clock: that the mutation rate in a species remains relatively constant over 
time (Zuckerkandl and Pauling, 1965; Bromham and Penny, 2003). Since there are 
no fossil records for T. gondii, calibration of the clock is difficult, and furthermore it 
is reasonable to assume that the accumulation of mutations in an organism with a 
life cycle that includes rapid division as well as prolonged periods of latency 
depends heavily on factors such as the transmission frequency and life span of 
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infected hosts. For the first calculations of the MRCA of the TgCkUg2 parental 
strains (UglI and UgllI) and their respective reference strains (Me49 and VEG), the 
density of minor SNPs was divided by the T. gondii intron mutation rate and the 
estimates for the two splits landed at around 17,400 and 9,200 years ago, and using 
these estimates of T2 and T3 resulted in an estimate of T1 of 500,000-1,000,000 
years. Interestingly, these figures correspond relatively well with the estimates 
calculated by the Sibley group who suggest a MRCA for the clonal lineages around 
104 years ago and of all T. gondii strains around 106 years ago (Khan et aI., 2007). In 
the second approach, we used a previous estimate of the MRCA of all present T. 
gondii strains, which represents the time when the divergence between the 
different strains through mutations began (Tl). It would not be possible to 
substitute this for the time estimates for the crossings which have given rise to the 
clonal types, since much of the nucleotide divergence had occurred previously in 
the ancestral strains, before participating in the cross. The resulting approximations 
of 4,600 for type II and 1,600 years for type III correspond to an overall genomic 
mutation rate of 1.29*10.8 SNPs per bp per year, which is about 68% of the rate 
calculated for introns. The two methods, which partly use different data sets, end 
up with noticeably different results, and until we have better tools for calibration of 
the clock it is difficult to tell when these strains began their divergence from their 
common ancestor. However, the relative timing is fairly consistent and it is clear 
that the type II split (T2) preceded that of type III (T3). Comparisons of the density 
of major and minor SNPs between the chromosomes derived from type II and III 
(Table 5-7) showed significant differences between the groups, where the level of 
major SNPs was significantly higher in the type III derived chromosomes, while the 
minor SNP density was higher in the type II chromosomes (Figure 5-14). 
Furthermore, the difference between the minor SNP density in introns was 
significantly higher (P<O.Ol) compared with the overall minor SNP density, for type 
II as well as for type III derived chromosomes (not shown in graph). This is 
consistent with the calculations which showed that the genomic mutation rate was 
lower compared with the intron mutation rate. 
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Figure 5-14. Average SNP density in type II and type III derived chromosomes. Average values and 
standard deviations for major and minor SNPs and minor SNPs in introns are shown for the type II 
and type III derived parts ofTgCkUg2. These SNP densities were the basis for calculations of the 
divergence time estimates, and the real numbers are listed in Table 5-7 in section 5.3.4. 
Sequencing of selected polymorphic regions in all the Ugandan strains made it 
possible to look at the relationship between the type II component of TgCkUg2 and 
the other type II strains. From this it was inferred that the closest relative to the 
type II parent of the recombinant strain was the fast-growing TgCkUg3. The original 
chicken host of TgCkUg3, Ch17, had the highest antibody titre of all chickens from 
which isolates were retrieved (1:160 compared with 1:80 for Ch1/TgCkUg1 and 1:40 
for all the others) and the parasite DNA was readily amplified directly from the 
chicken tissues (Chapter 3). All this points towards a relatively high parasite burden 
in the chicken, and this may have increased the likelihood of recombination. 
Chickens 2 and 17, the hosts of TgCkUg2 and 3, both originated from the same 
district (Gayaza) as did the host of TgCkUgl. All the other isolates were obtained 
from chickens from Mulago and, as might be expected, there was a closer genetic 
relationship between T. gondii strains from chickens living in the vicinity of each 
other. The relatedness between TgCkUg1 and TgCkUg3 was also confirmed by the 
RAPD analysis, as was the closeness betweenTgCkUgS and TgCkUg9: These latter 
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ones were the slowest growing strains in cell culture and the targeted sequencing 
showed that these were the Ugandan type II strains most genetically similar to 
Me49. 
5.4.4 Genes under selection 
Although the Ugandan strains are very similar to the clonal lineages, we 
detected over 1,200 new SNPs in TgCkUg2, many of which were found in the 
subtelomeric regions (here defined as the outermost 10% on each chromosomal 
end). It is well known that other parasitic protozoa like Trypanosoma and 
Plasmodium spp. use the higher recombination and mutation rate of the 
subtelomeres to produce a variety of antigens in order to escape host immunity 
(Barry et aI., 2003; Carlton et aL, 2005; EI-Sayed et aI., 2005), and it is possible that 
similar mechanisms drives the adaptation of T. gondii to different hosts. There are 
clusters of genes encoding surface antigens and other proteins important in the 
host-pathogen interaction towards the chromosomal ends of T. gondii (Jung et aL, 
2004 and ToxoDB), and future gene annotations and functional studies of 
hypothetical proteins and regulatory factors may appoint a biological meaning to 
the clusters of novel SNPs detected in TgCkUg2. 
Pathogenicity in T. gondii is a multigenic trait and even though all the 
contributing genes have not yet been identified, a genome scale sequence analysis 
of recombinant and atypical isolates is a powerful tool for mapping genes important 
for survival and transmission in different natural environments. Early genetic 
linkage analysis of 6 RFLP markers in five strains showed that T. gondii virulence in 
mice was associated with the SAG1 gene on chromosome VIII (Howe et aL, 1996). 
This analysis has later been followed up by experimental gene knockouts as well as 
large-scale bioinformatic analyses, and it is now clear that several surface antigens 
and secretory proteins affect the virulence of T. gondii. Knockout of the GRA2 gene 
led to attenuation of the virulent RH strain, while still allowing for chronic infection 
(Mercier et aI., 1998), and a similar reduction in virulence was seen in SAG3 
deficient mutants (Dzierszinski et aI., 2000). linkage analysis of recombinant 
progeny from an experimental cross led to the first identification of a major 
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virulence locus of the then called chromosome VII (Su et aI., 2002), which has later 
been the focus of much attention under its new designation Vila. In 2006, there was 
one report showing that knockout of MIC2 (located on Vila) resulted in severely 
restrained attachment and invasion, completely eliminating the virulence in mice 
(Huynh and Carruthers, 2006), and later the same year two studies published in the 
same issue of Science revealed a major virulence locus on Vila and proved through 
knockout experiments that the introduction of a virulent ROP18 allele in an 
avirulent strain increased the mouse mortality rate by 4-5 logs (Saeij et aI., 2006; 
Taylor et aI., 2006). Although novel SNPs were not present in the ROP18 gene 
(20.m03896) in our Ugandan isolates, positive selection was detected for several 
other genes active in the interface with the host, including two rhoptry antigens and 
two SRS genes (Table 5-9). In the study by Saeij and others, a total of four distinct 
virulence loci were identified in an experimental cross between types II and III, and 
these were located on chromosomes Vila, Vllb, X and XII (Saeij et aI., 2006). The 
TgCkUg2 strain possessed the avirulent allele for two of these loci: type III on Vllb 
and type II on X, and the virulent allele for two: type lion Vila and type III on XII. 
The candidate virulence gene at the Vila locus was ROP18, where genotype II is 
associated with virulence (Saeij et aI., 2006), but no polymorphisms were seen for 
ROP18 in TgCkUg2, it was identical to Me49 and the Ugandan type II strains. SAG3 
and ROPS were the candidate genes on XII, where genotype III is the virulent type, 
and while no new SNPs were found for TgCkUg2 in the SAG3 gene, ROPS was one of 
the genes with the highest number of novel SNPs (Table 5-9). The presence of six 
non-synonymous and three synonymous new SNPs suggests that ROPS may be 
under diversifying selection in TgCkUg2. 
While it is currently not possible to determine which loci are responsible for 
the intermediate phenotype of this recombinant strain the high density of SNP data 
from the current study could provide the basis for closer mapping of genotype-
phenotype associations and genes under selection for niche adaptation within 
African isolates. 
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5.5 Conclusions 
Whole genome sequencing of the recombinant TgCkUg2 revealed a nearly 
equal contribution from the type II and III parental strains. Recombination had 
mainly occurred through chromosome sorting and although indication of gene 
conversion events were recognized these were in regions where type II and III are 
highly similar and is probably of little biological significance. In experimental crosses 
intrachromosomal recombination is frequent and it is possible that the successful 
propagation in nature for this strain is due to the conservation of entire 
chromosomes, which may contain advantageous gene combinations. 
The amount of data generated in this study proved that the T. gondii strains 
present in Uganda are indeed highly similar to the archetypal lineages, and they 
were calculated to have diverged from the North American reference strains around 
104 years ago, with the type III divergence being more recent than type II. Novel 
SNPs were detected throughout the genome, but with a non-random distribution. A 
higher mutation frequency was detected in subtelomeric regions, but also in the 
coding sequence of a handful of genes. Interestingly, one of the genes indicated to 
be under positive selection (ROPS) have previously been indicated to be important 
for T. gondii virulence, and the alternate possession of virulent and avirulent alleles 
at different loci may explain the intermediate in vivo phenotype detected for this 
recombinant strain. 
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Chapter 6 General discussion and final conclusions 
Infectious and parasitic diseases kill around ten million people globally every 
year, and approximately half of these cases occur in Africa making communicable 
diseases the most important cause of death on the continent (WHO, 2004). In 
addition, many infections confer a substantial level of disability, with enormous 
social and economic consequences. The economic impact of malaria alone has been 
estimated to decrease the gross national income in many African countries by 
around 10% (Sachs and Malaney, 2002) and HIV/AIDS adds another 2-4% growth 
reduction (Dixon et aI., 2001). Research on infectious diseases is thus important in 
order to reduce morbidity and mortality as well as for fighting poverty, and a 
thorough understanding of the disease-causing microorganisms is crucial for the 
development of effective diagnostic, prevention and treatment strategies. 
A microbe is considered a pathogen if it is capable of causing damage in its 
host (Casadevall and Pirofski, 1999), but the level of virulence depends on a 
combination of factors including the host immune response, concurrent infections 
and the genetic make-up of the microorganisms. Host-pathogen interactions 
represent very complex systems, where the same infectious agents can give rise to 
completely different outcomes, highlighting the importance of factors encountered 
by the microbe in the host upon infection. For instance, while most Epstein-Barr 
virus infections are asymptomatic, some otherwise healthy people develop 
infectious mononucleosis, while oral hairy leukoplakia is a common complication in 
severely immunocompromised patients (Greenspan et aI., 1985) and 
Iymphoproliferative cancers may develop upon co-infections with Epstein-Barr virus 
and malaria parasites (Chene et aI., 2007). The recent spread of HIV has lead to a 
massive increase in diseases rarely seen before, caused by a number of viral, 
bacterial, protozoal and fungal pathogens which normally do not cause disease in 
immunocompetent hosts. In the pre-AIDS era T. gondii was recognised as an 
important veterinary pathogen and causative agent of severe congenital infections, 
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but cases of clinically important post-natally acquired toxoplasmosis were unusual 
before HIV-induced immunosuppressions became widespread (Moskowitz et aL, 
1983). High levels of T. gondii reactivation were seen in AIDS-patients in high-
income countries before the introduction of HMRT, but nowadays toxoplasmic 
encephalitis is uncommon in countries where appropriate antiretroviral treatment 
is provided (Miro et aL, 2006). It is clear that the immune status of the host is highly 
important for the development of T. gondii, and this was confirmed through the 
investigation of latent and active toxoplasmosis in Ugandan HIV-patients described 
in Chapter 2 of this thesis, where nearly one out of five HIV-patients were shown to 
have active T. gondii infections. The affected patients had reached a more advanced 
stage of immunosuppression compared with the patients who had managed to 
keep their infections in the latent state, and these seropositive, PCR-negative 
individuals are at risk of reactivation at a later stage of AIDS. The seroprevalence 
rates of T. gondii exceed 50% in many countries in East-, West-, and Central Africa 
(Figure 2-1), and previous autopsy studies have shown that TE is an important cause 
of death in AIDS-patients in this part of the world (Byanyima, 1998; lucas et aL, 
1993). Until efficient HIV-treatment is widely available in Africa opportunistic 
diseases including TE will continue to cause significant morbidity and mortality, 
unless they are properly diagnosed and treated. To achieve disease control, we 
must know the enemy. The major aim of the work presented in this thesis was 
therefore to investigate the genotypic and phenotypic properties of T. gondii strains 
from Africa, where the problem with HIV-associated toxoplasmosis is worst. 
The success of an invasive microorganism is dependent of its capacity to evade 
the host immune response and pharmaceutic treatments, and different types of 
organisms use different approaches to meet the challenge of a changing 
environment. HIV-viruses are adaptation specialists that can escape from immune 
defence mechanisms as well as antiviral drugs through very high reproduction and 
mutation rates; every possible mutation in the genome can be generated on a daily 
basis in a single viremic patient (Richman et aL, 2004). In bacteria, large blocks of 
genes, 'pathogenicity islands', can be transmitted horizontally through conjugation 
or with bacteriophages, and these may confer dramatic phenotype alterations such 
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as adaptations to an intracellular lifestyle (Gal-Mor and Finlay, 2006). Eukaryotic 
organisms typically have a slower mutation and replication rate compared with 
viruses and bacteria, and only rarely acquire genes through horizontal uptake 
(Opperdoes and Michels, 2007). Sexual recombination provides an opportunity of 
extensive genetic exchange and is the driving force of evolution in metazoa, 
however many protozoan parasites appear to use this option sparingly. A clonal 
population structure was first discovered in Trypanosoma cruzi, where isozyme 
analysis of 121 samples revealed clonal strains without evidence of mating, 
although some clones derived from the same individual or even the same insect 
vector (Tibayrenc et aL, 1986). Different levels of clonality were later detected in 
several other organisms including Leishmania, Giardia, Trypanosoma brucei, 
Entamoeba, Plasmodium and Toxoplasma (Tibayrenc et aL, 1990, 1991). The 
observed clonality could be due to inherent properties of the parasites favouring 
asexual transmission or self-fertilization over recombination, or it might be the 
result of downstream purifying selection of non-recombinant progeny (Tibayrenc, 
2002). These explanations may not be mutually exclusive and could vary between 
species, for example Plasmodium goes through an obligatory sexual stage in the 
mosquito, while Toxoplasma can be transmitted directly between intermediate 
hosts, which enable prolonged transmission of true clones. It is noteworthy that a 
predominantly clonal population structure does not exclude sexual recombination. 
In the case of T. gondii, a limited number of clonal lineages are found over vast 
geographic areas, but a high level of non-clonal strains have been found in South 
America (Pena et aL, 2008), which may be due to increased mating opportunities or 
selection of a diversity of strains. As more areas and host species are being 
investigated, more diversity has been unravelled, and the work described in this 
thesis provides the first characterization of an African T. gondii population. The 
focus of this work was on strains present in the domestic cycle, since these are most 
relevant for HIV-associated toxoplasmosis. 
The discovery of multiple infections in five Ugandan chickens gave the first 
indication that mating opportunities between genetically distinct genotypes may be 
more frequent in the human I domestic animal cycle in Africa compared with 
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Europe or North America. Small scale rearing of animals like goats and chickens 
around the houses is commonplace and the transmission between these animals 
and domestic cats can easily take place. The subsequent isolation of a recombinant 
strain confirmed that sexually derived strains were present in Uganda. 
Recombination is difficult to detect if it occurs between strains with a similar 
genetic background, such as two type II strains. However, the deep sequencing 
performed on TgCkUg2 revealed different levels of novel SNPs among the 
chromosomes derived from the same lineage. For example, the MRCA of the 
Ugandan type II and Me49 was estimated to be 3-5 times higher based on 
chromosome IV compared with Vila, using the two different methods (Tables 5-7 
and 5-8) and this may be an indication of a previous chromosome sorting event 
between two type II strains. Furthermore, the gene conversion event where several 
(but not all) Ugandan type II strains shared SNPs with GT1 indicate that this 
recombination occurred at a time point prior to the type II/III cross that gave rise to 
TgCkUg2. Thus, lack of opportunity for sexual recombination, which has been 
suggested to be an important explanation for the dominance of three clonal types 
in Europe and North America (Sibley and Boothroyd, 1992, Darde, 1996, Ajzenberg, 
et aI., 2002), does not appear to hold true for Africa. 
Nevertheless, the whole genome analysis of this strain and sequencing of >20 
kb from each of the eight additional Ugandan strains showed a remarkable level of 
similarity with the reference strains isolated decades ago in North America. Unlike 
the findings from South America, the Ugandan strains were highly conserved and 
although the recombinant strain provided evidence of the sexual cycle, all the 14 
chromosomes were nearly identical to either type II or III, and virtually no mixing of 
genes from different origin was seen on the same chromosome. Indications of 
recombinatory events were detected for small regions located on chromosomes VI 
and VIII, but these occurred in type I dominated regions where type II and III share a 
high level of similarity and did therefore not alter the overall gene composition of 
the chromosomes. Although diverse genotypes are likely to be generated through 
sexual recombination in this setting, the environment does not seem to favour the 
persistence of mUltiple diverse genotypes. A prerequisite for recombinant strains to 
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be found is their ability to survive and propagate, and in order to persist in nature 
they must be able to compete with the established lineages. T. gondii is known to 
undergo sexual recombination given the chance, and the average map unit size has 
been calculated to 104 kb/cM (Khan et aL, 200Sb). The data from TgCkUg2 shows 
evidence of at least three past recombination events, but the gene content on each 
chromosome has remained intact. A single cross yields countless genetically distinct 
progeny, but only a handful may survive in nature, where the predominant strain 
type in a defined environment can be assumed to be the one that is best adapted to 
the prevailing conditions. Thus, in contrast to the upstream inhibition of sexual 
recombination proposed previously (Ferguson, 2002) the data obtained in this study 
favour the model of downstream selection through environmental pressure rather 
than absence of opportunity for sexual recombination. This conclusion is in 
agreement with a recent review on the subject, where the population structure is 
described as "punctuated by clonal sweeps" when a new recombinant happens to 
be superiorly adapted to the prevailing conditions (Grigg and Sundar, 2009). 
The research presented in this thesis revealed that the T. gondii strains 
present in humans and domestic animals in Uganda are closely related to the clonal 
lineages, and began diverging from these approximately 10,000 years ago. Although 
recombination occurs the selective pressures appear to favour conservation of the 
genetic make-up of the clonal strains, but some genetic drift inevitably occurs over 
time. But are these good representatives for African strains? The strains were 
isolated from the area in and around Kampala, and they are likely to be 
representative of the strain population important for the HIV-associated 
toxoplasmosis in this region. However, it is possible that other strains are present 
elsewhere in Africa. A recent serotyping study reported a predominance of non-
type II strains in West Africa (Ivory Coast, Congo, Angola, Cameroon and Gabon) 
and several samples reacted with both peptides, which may indicate multiple 
infection in human patients (Sousa et aL, 2008). Furthermore, a recent case report 
found a type 1/111 recombinant strain causing severe toxoplasmic encephalitis and 
chorioretinitis in a HIV-patient from Ghana (Genot et aL, 2007). None of these 
studies provide much detail on the genetic composition of the strains involved, but 
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the latter emphasize the clinical importance of the T. gondii genotype, and the 
disease severity often associated with atypical strains. No study has yet looked 
further afield into the African sylvatic cycle, where different selective pressures may 
shape the population structure and transmission may be driven by other feline 
species. 
The studies presented in this thesis extend the understanding of the T. gondii 
population structure and provides the first in depth characterization of African 
strains. The whole genome sequencing project was one of the first to utilize a new 
generation sequencing platform for a protozoan genome, and it was the first large 
scale sequencing of any T. gondii strain apart from the three clonal references. 
Evidence of recombination through chromosome sorting, in an organism where 
meiotic recombination is frequent in experimental crosses, was a significant result, 
and furthermore the novel African alleles and genes under selection provide clues 
to the selective pressures acting in this environment. The unique situation with a 
fully sequenced genome from a natural recombinant strain and the isolation of its 
putative parents provide excellent opportunities for further studies of the genetic 
basis for virulence and transmission of T. gondii. 
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Appendix 1: T. gondii genotypes in different regions and host species 
Abbreviations for genotyping methods are: RFlP = restriction fragment length polymorphisms, MS = microsatellites, Z = zymodemes, SNP = 
single nucleotide polymorph isms, seq = sequencing. 
Recombinant strains are strains which show alleles typical for different genotypes on different loci, and atypical are strains with non-archetypal 
alleles on at least one locus. Mixed means co-infection with two or more strains in the same host. 
No of 
Host Origin N Method(s) markers Type I Type II Type III Recomb. Atypical Mixed Reference 
Cats Brazil 38 RFLP 1 15 23 Dubey et aI., 2004d 
Chickens Argentina 9 RFLP 1 1 1 7 Dubey et aI., 2003d 
Chickens Argentina 17 RFLP 1 4 3 10 Dubey et aI., 2005g 
Chickens Austria 67 RFLP 1 67 Dubey et aI., 2005a 
Chickens Brazil 48 RFLP 1 34 13 1 Dubey et aI., 2003a 
Chickens Chile 22 RFLP ~5 17 4 1 Dubey et aI., 2006a 
Chickens Colombia 24 RFLP 1 7 17 Dubey et aI., 2005b 
Chickens Costa Rica 32 RFLP ~5 5 1 26 Dubey et aI., 2006b 
DRC, Mali, Burkina 
Chickens Faso, Kenya 17 RFLP 1 1 4 12 Dubey et aI., 2005d 
Chickens Grenada 36 RFLP 1 5 1 29 1 Dubey et aI., 2005i 
Chickens Guatemala 8 RFLP 1 3 5 Dubey et aI., 2005t 
Chickens India 7 RFLP, MS ~5 2 5 Sreekumar et al., 2003 
Chickens Israel 19 RFLP 1 17 2 Dubey et aI., 2004f 
Chickens Mexico 6 RFLP 1 1 5 Dubey et aI., 2004c 
Chickens Peru 10 RFLP 1 7 3 Dubey et aI., 2004b 
Chickens Sri Lanka 12 RFLP 1 6 6 Dubey et aI., 2005h 
Chickens USA 19 RFLP 1 5 14 Dubey et aI., 2003c 
Chickens Venezuela 13 RFLP 1 3 10 Dubey et aI., 200Se 
Chickens, duck Egypt 20 RFLP 1 3 17 Dubey et aI., 2003b 
Dogs Brazil 9 RFLP 1 4 5 da Silva et aI., 2005 
Domestic 
animals Brazil 16 RFLP ~S 16 Ferreira Ade et al., 2006 
Noof 
Host Origin N Method(s) markers Type I Type II Type III Recomb. Atypical Mixed Reference 
Domestic 
animals Colombia 19 RFlP 1 19 Gallego et aI., 2006 
Domestic 
animals Europe, USA 5 SNP+ MS ~5 2 1 2 Ajzenberg et aI., 2004 
Domestic Sibley and Boothroyd, 
animals Europe, USA 9 RFlP 3 2 4 1 2 1992 
Domestic 
animals Europe, USA 10 Z, MS 1 1 5 4 Costa et aI., 1997 
Domestic 
animals Europe, USA 23 MS, Z, RFlP ~5 1 14 4 4 Ajzenberg et al., 2002a 
Domestic 
animals Uruguay, Barbados 3 SNP + MS ~5 2 1 Ajzenberg et aI., 2004 
Domestic 
animals USA, Canada, U.K 4 RFlP, seq t!S 1 2 1 lehmann et aI., 2000 
Humans Africa 3 SNP+ MS t!S 1 1 1 Ajzenberg et aI., 2004 
Sibley and Boothroyd, 
Humans Australia 1 RFlP 3 1 1992 
Sibley and Boothroyd, 
Humans Brazil 1 RFlP 3 1 1992 
Humans Brazil 4 RFlP t!5 4 Ferreira Ade et aI., 2006 
Humans Colombia 14 RFlP 1 12 1 1 Gallego et aI., 2006 
Humans Europe, USA 14 SNP+ MS ~5 2 1 3 1 7 Ajzenberg et aI., 2004 
Sibley and Boothroyd, 
Humans Europe, USA 14 RFLP 3 6 1 2 5 1992 
Humans Europe, USA 24 Z,MS 1 6 17 1 Costa et aI., 1997 
Humans Europe, USA 60 MS, Z, RFlP t!5 15 37 4 4 Ajzenberg et aI., 2002a 
Humans France 37 MS 1 37 Costa et aI., 1997 
Humans France 68 RFlP 1 7 SS 6 Howe et aI., 1997 
Humans France 86 MS t!S 7 73 2 4 Ajzenberg et aI., 2002b 
Humans France 90 RFlP 1 14 69 7 Honore et aI., 2000 
Humans French Guyana 16 MS ~S 16 Carme et aI., 2002 
Noof 
Host Origin N Method(s) markers Type I Type II Type III Recomb. Atypical Mixed Reference 
Sibley and Boothroyd, 
Humans Japan 1 RFLP 3 1 1992 
Humans Spain 25 RFLP 1 10 10 5 Fuentes et aI., 2001 
Humans U.K. 32 RFLP 1 10 11 1 10 Aspinall et aI., 2003 
Uruguay, 
Guadeloupe, 
Reunion, French 
Humans Guyana 13 SNP+ MS t!5 1 1 11 Ajzenberg et aI., 2004 
Humans USA 12 RFLP t!5 3 3 1 5 Grigg et aI., 2001 
Humans USA, Canada, U.K 9 RFLP, seq ~5 3 2 3 1 Lehmann et aL, 2000 
Sibley and Boothroyd, 
Pigs Brazil 1 RFlP 3 1 1992 
Pigs Brazil 7 RFlP 1 2 5 dos Santos et aI., 2005 
Sibley and Boothroyd, 
Pigs Japan 1 RFlP 3 1 1992 
Pigs Portugal 15 RFLP, MS ~5 10 4 1 de Sousa et aL, 2006 
Pigs USA 7 RFLP, MS 1 2 3 2 Dubey et aL, 2005c 
Pigs USA 25 RFLP, MS ~5 20 5 Lehmann et aL, 2003 
Pigs USA 43 RFLP 1 36 7 Mondragon et aI., 1998 
Pork, beef, lamb UK 27 RFLP 1 21 6 Aspinall et aI., 2002 
Sea otters USA 13 RFlP 2 6 7 Cole et aL, 2000 
Sea otters USA 35 RFlP, RAPD t!5 14 21 Conrad et al., 2005 
Sea otters USA 35 RFLP, seq ~5 14 21 Miller et aL, 2004 
Sheep U.K. 15 RFLP 1 15 Owen and Trees, 1999 
Wildlife Europe, USA 3 SNP+ MS t!5 2 1 Ajzenberg et aI., 2004 
Wildlife USA 10 RFlP 1 2 8 Dubey et aL, 2004e 
Wildlife USA 43 RFLP 1 3 35 5 Dubey et aL, 2004a 
Wildlife USA, Canada, U.K 3 RFlP, seq t!5 1 2 Lehmann et aI., 2000 
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Appendix 2: T. gondii-seroprevalence in adult Africans 
Country N Seroprev. (%) Reference 
Benin 211 54 Rodier et aL, 1995 
Burkina Faso 1828 25 Millogo et aL, 2000 
Burkina Faso 336 25 Simpore et aL, 2006 
Burkina-Faso 148 50 Ledru et aL, 1995 
Burundi 622 44 Excler et aL, 1988 
Cameroon 421 48.5 Marty et aL, 1985 
Cameroon 192 77 Ndumbe et aL, 1992 
Central African Republic 814 40 (overall) 
25 (pre-desert) Dumas et aL, 1990b 
Central African Republic 1953 51 Morvan et aL, 1999 
Perez-Rendon Gonzalez and 
Ceuta (Morocco) 100 51 lopez Caminero, 1992 
Comoros 871 84 Julvez et aL, 1994 
Congo-Brazzaville 2500 40 Dumas et aL, 1990a 
Congo-Brazzaville 310 42 Candolfi et aL, 1993 
DRC 50-65% Dumas et aL, 1990c 
Egypt 150 43 el-Nawawy et aL, 1996 
Egypt 700 15 Hamadto et aL, 1997 
Egypt 152 58 Hussein et aL, 2001 
Ethiopia 144 34 Flatau et aL, 1993 
Ethiopia 1016 75 Guebre-Xabier et aL, 1993 
Ethiopia 170 80 Woldemichael et aL, 1998 
Gabon 268 61 Billiault et aL, 1987 
Gabon 1178 68 Duong et aL, 1992 
Gabon 767 71 Nabias et aL, 1998 
Ghana 364 57 Anteson et aL, 1978 
Ivory Coast 2000 37 (pre-desert) 
56-70 (humid) Dumas et aL, 1989 
Ivory Coast 1025 60 Adou-Bryn et aI., 2004 
Kenya 322 54 Griffin and Williams, 1983 
Kenya 180 54 Brindle et aL, 1991 
liberia 133 70 Negro Ponzi et aL, 1976 
liberia 390 58 Omland et aL, 1977 
libya 2300 50.5 Khadre and el Nageh, 1987 
libya 369 47 Kassem and Morsy, 1991 
Madagascar 599 84 Lelong et aL, 1995 
Madagascar 2354 52 Dromigny et aL, 1996 
Mali 100 34 Maiga et aL, 1984 
Niger 400 18.2 Develoux et aI., 1988 
Niger 218 15 Develoux et aL, 1989 
Niger 371 18 Julvez et aL, 1996 
Nigeria 352 78 Onadeko et aL, 1992 
Nigeria 162 68 Ekweozor et aL, 1994 
Nigeria 363 32 Uneke et aL, 2005 
Nigeria 1650 59 Arene, 1986 
country N Seroprev. (%) Reference 
Rwanda 50 Gascon et aL, 1989 
Senegal 415 25 (dry) 
58 (humid) 
33 (Dakar) Dumas et aL, 1990d 
Senegal 720 40 Diallo et aL, 1996 
Senegal 353 40 Faye et aL, 1998 
Somalia 356 53 Zardi et aL, 1980 
Somalia 40-56% Ahmed et aL, 1988 
South Africa 600 10 Brink et aL, 1975 
South Africa, Namibia, 
Botswana 3379 20 Jacobs and Mason, 1978 
Sudan 386 42 Abdel-Hameed, 1991 
Sudan 487 34 Elnahas et aL, 2003 
Tanzania 357 48 Gill and Mtimavalye, 1982 
Tanzania 450 4 Gille et aL, 1992 
32 47 Doehring et aL, 1995 
Tanzania 849 35 Agbo et aL, 1991 
Togo 819 59 Deniau et aL, 1991 
Togo 618 62-88% Bouratbine et aL, 2001 
Tunisia 1421 58 Zumla et aL, 1991 
Uganda 279 33 This study 
Uganda 677 56 Zumla et aL, 1991 
Zambia 376 7 Dumas et aI., 1990d 
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Appendix 3. Result table, Ugandan HIV-patients 
All HIV·samples used in the study, listed by group and sample 10. HA=headache, 
PP=photophobia, MCF=mental confusion, CV=convulsions, F=fever, W=weakness or 
paresis, V=vomiting. '+' indicates a positive test result or the presence of a 
symptom, '.' indicates a negative test result or the absence of a symptom. Blanks 
show that the information was not obtained. 
Group Sample Age Sex CD4 HA pp MCF CV F W V IgG peR Type 
Gl HOS-l 40 F + + + 
Gl HOS-2 S6 F + + + + 
Gl HOS-3 3S M + + + 
Gl HOS-4 34 F + + + + 
Gl HOS-S 31 F + + + 
Gl HOS-6 4S M + + + 
Gl HOS-7 36 F + + 
Gl HOS-8 + 
Gl HOS-9 29 M + + + 
Gl HOS-IO 28 F + + + + 
Gl HOS-ll 23 F + + + 
Gl HOS-12 + 
Gl HOS-13 
Gl HOS-14 + 
Gl HOS-lS 32 M + + + + 
Gl HOS-16 
Gl HOS-17 44 M + + + 
Gl HOS-18 
Gl HOS-19 37 F + + + + + II 
Gl HOS-20 32 F + + + + + 1/11 
Gl HOS-21 36 F + + + + III 
Gl HOS-22 M + + 
Gl HOS-23 27 F + + + 
Gl HOS-24 F + + + 
Gl HOS-2S M + + 
Gl HOS-26 M + + + II 
Gl HOS-27 39 M + 
Gl HOS-28 40 F + + + 
Gl HOS-29 
Gl HOS-30 27 F + 
Gl HOS-31 + II 
Gl HOS-32 43 M + 
Gl HOS-33 
Gl HOS-34 40 M + 
Gl HOS-3S + + II 
Gl HOS-36 M + + 
Gl HOS-37 + II 
Gl HOS-38 + 
Gl HOS-39 + 
Gl HOS-40 
Gl HOS-41 + 
Gl HOS-42 M + + 
Gl HOS-43 + + II 
Gl HOS-44 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G1 HOS-4S + II 
G1 HOS-46 
G1 HOS-47 + 
G1 HOS-48 
G1 HOS-49 
G1 HaS-SO 
G1 HOS-S1 + + 
G1 HOS-S2 + + 
G1 HOS-S3 + 
G1 HOS-S4 
Gl HOS-SS + 
Gl HaS-56 
Gl HOS-S7 + 
Gl HOS-S8 + 
Gl HOS-S9 + 
Gl HOS-60 + + II 
G1 HOS-61 
G1 HOS-62 
G1 HOS-63 
G1 HOS-64 + + I 
G1 HOS-6S + + 1/11 
G1 HOS-66 
G1 HOS-67 + + II 
G1 HOS-68 + II 
Gl HOS-69 F 
G1 HOS-70 42 M 
G1 HOS-71 S4 M + II 
Gl HOS-72 
Gl HOS-73 60 M 
Gl HOS-74 
Gl HOS-7S F 
Gl HOS-76 M + + 
Gl HOS-77 22 M + + + 
G1 HOS-78 M + + + + 
Gl HOS-79 + + 
Gl HOS-80 30 F + 
Gl HOS-8l + + + + II 
Gl HOS-82 35 M + + + + II 
G1 HOS-83 37 M + 
Gl HOS-84 M + + + + 
G1 HOS-8S 2S M + + + 
G1 HOS-86 + + 
Gl HOS-87 + 
Gl H05-88 + + + 
Gl H05-89 25 F + 
G1 HOS-90 27 M + + + + III 
G1 HOS-91 + + + 
G1 HOS-92 39 M 
G1 HOS-93 + 
G1 HOS-94 + + 
Gl H05-9S + 
Gl H05-96 M + 
Gl HOS-97 + + + + 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
Gl HOS-98 M 
- - - - - - - + -
Gl HOS-99 F - - + - - + - - -
Gl HOS-lOO F - - - - - - - + -
Gl HOS-lOl F 
- - - - - - - - -
Gl HOS-l02 46 M - - - - - - - + -
Gl HOS-l23 F + - - - - + - + + II 
Gl HOS-l24 F + + - - - - - - -
Gl HOS-l2S + - - - + - - + + II 
Gl HOS-l26 - - + - - - - + + II 
Gl HOS-l27 23 F + - - - - - - + + I 
Gl HOS-l28 F + + + - - - - - -
Gl HOS-129 - - - - - + - + -
Gl HOS-130 F - - - + + - - + -
G1 HOS-131 SO F - - + - - - - + -
Gl HOS-132 + - - - - - - - + II 
G1 HOS-133 + - + - - - - + -
Gl HOS-134 
- - + - - - - - -
Gl HOS-13S 42 F + - - - - - - + -
G1 HOS-136 31 F - - - - - + - + -
Gl HOS-137 3S F + - + - - - - + + 1/11 
Gl HOS-138 48 M + - - - - - - + + II 
Gl HOS-139 32 M + + + - - - - + -
G1 HOS-140 38 M - - + - - - - - -
Gl HOS-14l 38 F + - - + - - - + -
Gl H05-142 25 M + - - - + - - + -
Gl H05-143 M - - - - - - - - -
Gl HOS-144 41 M - - + - - - - + -
Gl H05-145 35 F - - - - - - - + + I 
Gl HOS-146 F - - + - - - - - -
Gl HOS-l47 F + - + - - - - - -
Gl H05-148 35 F + + - - - - - + + III 
G1 H05-149 F - - + - - - - + -
G1 HOS-1S0 F + - - - + + - - -
G1 H05-1S1 43 F - - + - - - - - -
G2 H06-1 34 M 2G3 - -
G2 H06-2 17 F - + 
G2 H06-3 40 F + -
G2 H06-4 1 F - + 
G2 H06-5 37 M 234 - -
G2 H06-6 45 M + -
G2 H06-7 2S M - -
G2 H06-8 28 F + -
G2 H06-9 20 F 
- + 
G2 H06-10 19 F 600 + -
G2 H06-11 36 F 175 + + 
G2 HOG-12 22 M 22 + -
G2 H06-13 27 F + -
G2 H06-14 4S M + -
G2 H06-1S S F - + 
G2 H06-1G 32 F + -
G2 HOG-17 40 F 344 - -
G2 HOG-18 25 F 150 - -
G2 HOG-19 18 F + -
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G2 HOG-20 30 F 
G2 H06-21 30 F + 
G2 H06-22 17 M 
G2 HOG-23 42 F 
G2 H06-24 17 F + 
G2 H06-25 25 F + 
G2 H06-2G 43 M + 
G2 H06-27 50 F 
G2 H06-28 26 F + 
G2 H06-29 55 F + 
G2 H06-30 35 F + 
G2 H06-31 2G F 
G2 H06-32 30 F 
G2 HOG-33 30 M 
G2 H06-34 30 F 68 + 
G2 H06-35 40 F 142 
G2 HOG-3G 31 F + 
G2 HOG-37 24 F 
G2 HOG-38 34 M + 
G2 HOG-39 30 F + + 
G2 HOG-40 29 F 
G2 HOG-41 28 M 
G2 H06-42 38 F + 
G2 HOG-43 42 F 71 
G2 H06-44 25 F G48 
G2 HOG-45 45 
G2 HOG-4G 46 M 323 
G2 HOG-47 2G F 
G2 H06-48 47 F 143 + 
G2 H06-49 45 F 244 + 
G2 HOG-SO 30 M 
G2 HOG-51 M 
G2 HOG-52 49 F + + 
G2 H06-53 F 
G2 HOG-54 M + 
G2 HOG-55 M + + 
G2 HOG-5G 44 F + 
G2 H06-57 F + 
G2 HOG-58 F + + 
G2 HOG-GO 24 M + + 
G2 HOG-G1 37 M 
G2 HOG-62 22 F + + 
G2 H06-63 19 F 
G2 HOG-G4 30 F + 
G2 H06-65 33 F + + 
G2 HOG-6G 41 M + 
G2 HOG-67 37 F 502 + 
G2 HOG-68 38 M + + 
G2 HOG-69 24 M + 
G2 H06-70 18 F + + 
G2 HOG-71 42 F + + 
G2 HOG-72 25 M 
G2 HOG-73 36 M 70 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G2 HOG-74 4G F 103 + 
G2 HOG-7S 30 F + + 
G2 HOG-7G 3G M 
G2 HOG-77 31 F + 
G2 HOG-78 23 F 
G2 HOG-79 27 F + 
G2 HOG-80 20 F 
G2 HOG-81 3S F + + 
G2 HOG-82 44 F + 
G2 HOG-83 30 M 
G2 HOG-84 38 M + + 
G2 HOG-8S 23 F 1837 + 
G2 HOG-8G 47 M 
G2 HOG-87 35 M + 
G2 HOG-88 23 F 
G2 HOG-89 27 M 
G2 HOG-90 30 F 329 
G2 HOG-91 25 M + 
G2 HOG-92 32 M + 
G2 HOG-93 32 F + 
G2 HOG-94 2G F + 
G2 HOG-9S 23 F 
G2 HOG-96 33 M 
G2 HOG-97 3G F + 
G2 HOG-98 32 F 
G2 HOG-99 34 F 
G2 HOG-100 2G F + 
G2 HOG-101 55 M + 
G2 HOG-102 37 F 
G2 HOG-103 29 F 
G2 HOG-104 25 M + 
G2 HOG-lOS 40 M 
G2 HOG-lOG 25 F 
G2 HOG-107 24 M + 
G2 HOG-108 40 M + 
G2 HOG-109 2S F + 
G2 HOG-ll0 40 F 
G2 HOG-lll 45 M + 
G2 HOG-112 2G M 
G2 HOG-113 30 M 
G2 HOG-114 33 F + 
G2 HOG-llS 30 F 
G2 HOG-llG 24 F 
G2 HOG-117 34 M 
G2 HOG-llS 40 M + 
G2 HOG-119 21 F 
G2 HOG-l20 33 F + 
G2 HOG-l21 27 F + 
G2 HOG-122 30 F 
G2 HOG-l23 41 F + 
G2 HOG-124 33 F 
G2 HOG-12S 35 F + 
G2 HOG-126 21 F + 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G2 H06-127 39 F + -
G2 H06-128 30 F - -
G2 H06-129 45 M + -
G2 H06-130 34 F + -
G2 H06-131 26 F + -
G3 H07-1 35 M - - - - -
G3 H07-2 45 M - + - + -
G3 H07-3 35 M + - + - -
G3 H07-4 26 F + - + + + 
G3 H07-5 33 F - - - + -
G3 H07-6 43 M + - - + + 
G3 H07-7 34 M - - - - -
G3 H07-8 35 F + + - - -
G3 H07-9 42 F - - - - -
G3 H07-10 34 M - - - + -
G3 H07-11 45 F - - + - -
G3 H07-12 29 F + - + + -
G3 H07-13 32 F + - + - -
G3 H07-14 30 M + - + - -
G3 H07-15 26 M · + + - -
G3 H07·16 29 F · - + - -
G3 H07-17 21 F + - - + + 
G3 H07-18 22 F · + - + -
G3 H07-19 23 M - - + + -
G3 H07-20 40 M + - + - . 
G3 H07-21 45 F + + + + -
G3 H07-22 33 M + + + + -
G3 H07-23 32 F · + · + -
G3 H07-24 36 F + + + + -
G3 H07-25 34 F · · - + -
G3 H07-26 42 F + + - - -
G3 H07-27 23 M · · · · -
G3 H07·28 30 F · · - - -
G3 H07·29 26 F · + - + + 
G3 H07·30 38 F + · + - -
G3 H07·31 33 F + - + + + 
G3 H07-32 38 F + - + - -
G3 H07-33 39 F + + · + · 
G3 H07·34 30 M + + + + -
G3 H07·35 36 M · · + · -
G3 H07·36 28 F + + + - -
G3 H07-37 23 F + + + + -
G3 H07·38 25 F · · + - -
G3 H07-39 24 F + - + · · 
G3 H07-40 30 F + · + - -
G3 H07-41 37 F + · + · -
G3 H07·42 27 M + - - + + 
G3 H07-43 30 F + · + · -
G3 H07-44 + · 
G3 H07-45 · · 
G4 E06-1 26 F 19 + - - - + . - + -
G4 E06·2 31 F 152 + · - - + + . + -
G4 E06-3 45 F 37 + - . + + . - + -
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G4 E06-4 30 M 5 + + + - - - - + -
G4 E06-5 34 M 42 + - + + - - - + -
G4 E06-6 31 M 33 + + + - - - - - -
G4 E06-7 28 F 0 + - + - + - - - + 
G4 E06-8 33 F 397 + - - - + - - + -
G4 E06-9 43 M 73 + - - - + - - - + 
G4 E06-10 39 M 182 + - + + + + - + -
G4 E06-11 30 F 336 + - + - + - - + + 
G4 E06-12 30 M 17 + + - - + - - + -
G4 E06-13 36 M 15 + - - - + - + - -
G4 E06-14 45 M 16 - - - - - - + + -
G4 E06-15 47 M 49 + + - - - - + - -
G4 E06-16 38 M 49 + - + - + - - - -
G4 E06-17 40 M 13 + - - - + - - + -
G4 E06-18 20 F 235 + - + - + - - - -
G4 E06-19 54 F 31 + - - - + - - + -
G4 E06-20 38 M 9 + - - - + - - + -
G4 E06-21 29 F 611 + - - - + - + + -
G4 E06-22 41 F 97 + + + + - - + - -
G4 E06-23 21 F 20 + - - - + - + + -
G4 E06-24 42 F 128 + + + + + - + + -
G4 E06-25 43 F 6 + + + - + + - - -
G4 E06-26 53 M 26 + + + - + - - - -
G4 E06-27 50 F 22 + - + - + - - - -
G4 E06-28 30 F 89 - + - - + - - - -
G4 E06-29 35 F 166 + + + - + - + + + 
G4 E06-30 35 F 4 + + - - + - - + -
G4 E06-31 30 M 226 + - + - + - - + -
G4 E06-32 35 F 524 - + - - + - - - -
G4 E06-33 20 M 292 + - - - + - - + -
G4 E06-34 43 F 68 - + + + + - + - -
G4 E06-35 38 M 6 - - - - + - - + -
G4 E06-36 35 F 1 - + - - + + - + -
G4 E06-37 20 F 71 + + - - + - + + -
G4 E06-38 35 M 354 + - - - + - + + -
G4 E06-39 30 M 164 + - - - + - - - -
G4 E06-40 23 M 44 + - + - + - - + -
G4 E06-41 33 M 46 + + - - + - - + -
G4 E06-42 25 M 248 + - - - + - + - -
G4 E06-43 45 M 9 + + + - + - + - -
G4 E06-44 33 M 689 + - - - + - - + -
G4 E06-45 27 F 47 + + - - + - + + -
G4 E06-46 35 F 150 + - - - + - + + -
G4 E06-47 21 F 61 + - - - - - + + -
G4 E06-48 34 M 11 - + - - + - - + -
G4 E06-49 45 M 4 + - - - + - - + -
G4 E06-50 43 M 45 + - - - + - - + + 
G4 E06-51 28 F 8 + - - - - - - + -
G4 E06-52 25 F 93 + - - - + - + + -
G4 E06-53 30 F 240 + - - - + - - - -
G4 E06-54 32 M 210 + - - - + - - + -
G4 E06-55 47 F 353 - - - - - - - + -
G4 E06-56 36 M 75 + - - - + - + + + 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G4 E06-57 29 M 48 + - + - + - + - -
G4 E06-58 19 F 304 + - - - + - - + -
G4 E06-59 30 F 1 + - - - + - + - -
G4 E06-60 25 F 83 + - - - + - + - -
G4 E06-61 25 F 23 + - - - + - - + -
G4 E06-62 45 F 78 + - - - + - - + -
G4 E06-63 55 F 3 + - + - + - + - -
G4 E06-64 28 F 94 + - - - + - + + + 
G4 E06-65 25 F 19 + - - + + - + + -
G4 E06-66 22 F 419 
- - - - + - - + -
G4 E06-67 60 F 442 
- - - - + - + + -
G4 E06-68 28 F 1361 + - - - + - + + -
G4 E06-69 35 F 18 + - - - + - + + -
G4 E06-70 36 M 532 + - - - + - + + + 
G4 E06-71 35 M 303 + - - - + - - - -
G4 E06-72 33 M 26 + + + - + - + + -
G4 E06-73 15 M 4 + - - - + - + - -
G4 E06-74 27 M 429 + - - - + - - - -
G4 E06-75 28 F 33 + - - - + - + - -
G4 E06-76 27 F 16 + + + - + - + + -
G4 E06-77 30 F 20 + - - - + - + - -
G4 E06-78 22 F 100 + - + - + - - + -
G4 E06-79 40 M 15 + - + - + - - + -
G4 E06-80 38 F 67 + - + - + + - + -
G4 E06-81 60 F 463 + - - - + - + + -
G4 E06-82 23 F 181 + - - - + - + + -
G4 E06-83 37 M 356 + + - - + - + + -
G4 E06-84 22 F 111 + - - - + - + + -
G4 E06-85 34 M 9 + - - - + + - + -
G4 E06-86 24 M 3 + - - - + - + + -
G4 E06-87 40 M 81 + - + - + - - + -
G4 E06-88 44 M 143 + + + - + - + + -
G4 E06-89 42 M 456 + - + + + - + + -
G4 E06-90 32 M 240 + + + - + - - + -
G4 E06-91 29 M 1 + - + - + - - + -
G4 E06-92 41 M 181 + - - - + - - + -
G4 E06-93 38 M 48 + - + - + - + - -
G4 E06-94 35 F 16 + + + - + - + + -
G4 E06-95 28 F 493 + + + + + + + - -
G4 E06-96 26 F 208 + + + + + - + - -
G4 E06-97 28 F 7 + - - - + - + + + 
G4 E06-98 32 F 97 + - - - + - + - -
G4 E06-99 20 M 129 + - - - + - + - -
G4 E06-100 28 F 70 + - - - + - + + -
G4 E06-101 22 F 403 + - - - + - - - -
G4 E06-102 44 F 5 + - - - + - + + -
G4 E06-103 45 M 162 . 
- -
. + - + + -
G4 E06-104 25 F 312 + - - - + - + + -
G4 E06-105 36 M 10 + - - - + - + + -
G4 E06-106 50 F 46 + - - - + - - + -
G4 E06-107 32 F 141 + - - . + + + - -
G4 E06-108 26 F 82 + - + + + - - + -
G4 E06-109 55 F 9 + - - - + - + + -
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G4 E06-110 49 M 39 + + - + + - - + -
G4 E06-111 40 F 240 
- - - - + - + + -
G4 E06-112 38 M 47 
- - + - + - - + -
G4 E06-113 32 F 559 + - - - + - - - -
G4 E06-114 25 F 0 + - + - + - - - -
G4 E06-115 35 F 419 + + + + + - + - -
G4 E06-116 45 F 130 + + + - + - + - -
G4 E06-117 37 M 0 + - + - + - - + -
G4 E06-118 34 F 8 + - + - + - + + -
G4 E06-119 26 F 2 + + + + + - - + -
G4 E06-120 29 F 38 + - + - + - - + -
G4 E06-121 25 F 2 + - + - + - - + -
G4 E06-122 30 M 21 + - - - + - - + -
G4 E06-123 47 M 21 + - + - + - + + -
G4 E06-124 37 M 37 + - - - + - - + -
G4 E06-125 30 F 324 + + - - + - + + -
G4 E06-126 28 M 4 + - - - + - + + -
G4 E06-127 38 F 330 
- - - - - - - + -
G4 E06-128 44 M 175 + + - - - - - - -
G4 E06-129 27 M 2 + - + - + - + + -
G4 E06-130 60 M 16 + - - - + - + + -
G4 E06-131 40 M 3 + - + - + - - - + 
G4 E06-132 28 F 28 + - - - + - + - + 
G4 E06-133 60 F 59 + - - - + - + - -
G4 E06-134 32 F 89 + - - - + - + + -
G4 E06-135 28 F 41 + 
-
+ - + - + - -
G4 E06-136 34 M 237 + - - - + - + + + 
G4 E06-137 40 M 18 + - + - + - + + -
G4 E06-138 32 M 16 + - - - + - + + -
G4 E06-139 28 F 22 + - - - + - + + 
G4 E06-140 35 F 21 + - - - + - + + 
G4 E06-141 40 M 23 + - - - + - - + 
G4 EOG-142 28 M 195 + - - - + - - + 
G4 EOG-143 40 F Gl + - - - + - - + 
G4 EOG-144 30 M 2 + + - - + - + + 
G4 EOG-145 33 F 67 + - - - + - - -
G4 E06-146 35 F 128 + - - - + - + -
G4 [06-147 52 F 41 + - - - + - + -
G4 E06-148 35 F 14 + 
-
+ - + - - -
G4 EOG-149 22 F 13 - - - - + - + -
G4 E06-1S0 58 M 1 + - + - + - - -
G4 E06-151 33 F 172 + - - - + - - -
G4 EOG-1S2 31 M 296 + - - - + - - -
G4 E06-1S3 24 F 15 + - + - + - - + 
G4 [06-154 43 M 715 - - - - + - - + 
G4 EOG-1S5 40 M 78 
- - - - + + + + 
G4 EOG-1S6 29 M 122 
- - - - + + + + 
G4 EOG-1S7 41 M 674 - - - - + + - + 
G4 EOG-1S8 30 M 515 + - - - + + + -
G4 E06-1S9 43 M 42 
- - - - + + + -
G4 E06-1GO 30 F 976 + - + - + - - + 
G4 E06-161 23 F 20 + - - - + - + + 
G4 E06-1G2 27 F 77 + - - - + - + + 
Group Sample Age Sex CD4 HA pp MCF CV F W V IgG peR Type 
G4 £06-163 45 F 507 + - - - + - + -
G4 £06-164 SO F 107 + - + - + - - + 
G4 £OG-165 37 F 16 + - - - + - - + 
G4 £06-166 28 F 3 + - - - + - - -
G4 [06-167 34 F 5 + 
- - -
+ - + + 
G4 £06-168 36 M 46 + - - - + - - + 
G4 [06-169 19 F 3 
- - - -
+ - - + 
G4 £06-170 27 F 11 
- + - - + - - + 
G4 £06-171 22 F 232 + 
- - -
+ - - + 
G4 £06-172 27 F 3 + - - - + - + -
G4 [06-173 34 F 56 + - - - + - + + 
G4 [06-174 28 F 238 + - - - + + - + 
G4 [06-175 35 F 518 + 
- - - - - -
+ 
G4 £06-176 31 M 1 + 
- - -
+ - + -
G4 £06-177 42 M 52 + 
- - -
+ - - + 
G4 £06-178 32 F 638 
· - - -
+ - - + 
G4 [06-179 35 F 635 
- · - - + - - + 
G4 [06-180 26 M 151 + - - - + - + + 
G4 [06-181 35 M 3 - · - - + - + + 
G4 [06-182 34 M 5 + 
· 
+ - + - - + 
G4 £06-183 54 M 152 + - + - - + - -
G4 [06-184 24 F 3 + 
· -
- + - - + 
G4 £06-185 45 M 115 + - . - + - - + 
G4 [06-186 38 F 13 - + + - + - - + 
G4 [06-187 36 F 143 
· - + + + - - + 
G4 [06-188 25 F 3 
· -
+ - + - + + 
G4 [06-189 28 F 0 + - - - + + + + 
G4 £06-190 34 F 2 + 
- - -
+ - + + 
G4 [06-191 26 M 619 
- - -
- + - - + 
G4 [06-192 42 M 9 + - + - + - - + 
G4 [06-193 35 M 29 + - + - + - - -
G4 [06-194 34 M 0 + - - - + - - + 
G4 [06-195 28 M 54 + - - · + - + + 
G4 [06-196 28 M 103 + - - · + - - + 
G4 £06·197 40 M 332 + - - - + - - + 
G4 £06·198 38 F 6 + - - - + - - + 
G4 [06·199 25 F 448 · · - - + - + -
G4 [06·200 32 F 34 - - - - + - - + 
G4 [06·201 21 F 1 + - - - + - + -
G4 [06·202 30 M 77 + - - - + - - + 
G4 £06-203 34 M 6 
- - - - + - + -
G4 £06-204 20 M 90 + 
- - · + - + + 
G4 £06-205 43 M 219 - - + - + + - -
G4 £06·206 29 F 41 - - - · - - - -
G4 [06·207 29 F 128 + - - - + - - -
G4 [06·208 36 M 155 + + - - - - - -
G4 [06·209 33 F 10 + - - - + - - -
G4 £06-210 35 F 2 + - - - + - + + 
G4 £06·211 25 F 305 + + + - + - - -
G4 £06·212 28 M 12 + - - - + - - -
G4 [06·213 21 M 391 + - - - + - - + 
G4 [06·214 40 F 70 
· - + · + - - -
G4 £06·215 25 F 12 + + + - + - . -
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G4 E06-216 45 F 2 + - - - + - - + 
G4 E06-217 40 F 2 
- - - - + - + -
G4 E06-218 50 F 194 + - - - + - + -
G4 E06-219 25 F 708 + - - - + - - + 
G4 E06-220 27 M 363 - - + - + - - + 
G4 E06-221 20 F 272 - - - - + - + -
G4 E06-222 44 F 52 + - - - + - - + 
G4 E06-223 24 F 3 + - + - + - - + 
G4 E06-224 32 F 95 + - - - - + + + 
G4 E06-225 32 F 111 - + + - - - + + 
G4 E06-226 40 F 101 + - - - + - + + 
G4 E06-227 55 M 290 + + - - + - - + 
G4 E06-228 35 M 62 + - + - + - - -
G4 E06-229 30 M 416 + + - - + - - + 
G4 E06-230 45 M 91 + - - - + - - + 
G4 E06-231 40 M 0 + - + - + - + -
G4 E06-232 43 F 442 
- - - - + - - -
G4 E06-233 20 F 109 + - - - + - + + 
G4 E06-234 49 F 9 - - + - + - - -
G4 E06-235 38 F 1 - - - - + - - + 
G4 E06-236 25 M 514 + + - - + - + -
G4 E06-237 34 M 612 + - + - + - - + 
G4 E06-238 25 M 7 + - - - + - + + 
G4 E06-239 68 F 96 + - - - - - + -
G4 E06-240 34 M 20 + - - - + - - -
G4 E06-241 37 F 53 + + + - - + - -
G4 E06-242 32 F 223 + + + - + + - -
G4 E06-243 27 F 60 + - - + + - - + 
G4 E06-244 23 M 11 + - + - - - - + 
G4 E06-24S 54 F 21 + + - - + - - + 
G4 E06-246 30 F 0 - - - - + + - -
G4 E06-247 24 F 16 - - + + + - - + 
G4 E06-248 52 F 0 + - - - + - - + 
G4 E06-249 45 F 608 
- - - - + - + + 
G4 E06-250 23 F 465 + - - - + - - + 
G4 E06-2S1 44 M 90 - + - - - - + + 
G4 E06-2S2 33 M 13 + - + - + - - -
G4 E06-2S3 24 F 352 
- - - - + - + -
G4 E06-254 30 M 500 + - - - - - - -
G5 E06-255 27 F 320 
- - - - - - - + 
G5 E06-256 25 F 66 
- - - - + - - + 
G5 E06-257 19 F 214 - - - - + - - -
G5 E06-258 33 F 46S - - - - - - - + 
GS E06-259 24 F 1218 - - - - - - - -
G5 E06-260 30 F 542 
- - - - - - - -
G5 E06-261 24 M 159 - - - - - - - -
GS E06-262 42 F 552 
- - - - + - - + 
GS E06-263 28 F 417 
- - - -
- - - -
G5 E06-264 35 M 33 - - - - - - - -
GS E06-265 26 F 2S0 
- - - - + - - -
G5 E06-266 32 F 7S3 
- - - - + - - -
GS E06-267 31 F 110 
- - - - + - - + 
G5 E06-268 37 M 588 
- - - - - - - -
Group 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
G5 
Sample 
E06-269 
E06-210 
E06-211 
E06-212 
E06-213 
E06-214 
E06-215 
E06-216 
E06-211 
E06-218 
E06-219 
E06-280 
E06-281 
E06-282 
E06-283 
E06-284 
E06-285 
E06-286 
E06-287 
E06-288 
E06-289 
E06-290 
E06-291 
E06-292 
E06-293 
E06-294 
E06-295 
E06-296 
E06-291 
E06-298 
E06-299 
E06-300 
E06-301 
E06-302 
E06-303 
E06-304 
E06-305 
E06-306 
E06-307 
E06-308 
E06-309 
E06-310 
E06-311 
E06-312 
E06-313 
E06-314 
E06-315 
E06-316 
E06-317 
E06-318 
E06-319 
E06-320 
E06-321 
Age Sex CD4 HA PP MCF CV F 
40 
20 
49 
32 
F 
F 
F 
M 
231 
142 
302 
358 
27 M 169 
27 F 160 
29 M 111 
30 M 42 
27 F 354 
31 M 134 
40 F 159 
20 F 121 
49 M 20 
32 M 102 
34 F 127 + 
25 M 1135 + 
27 M 355 + 
31 M 137 + 
25 M 265 + 
31 M 4 
24 M 4 
45 F 2 
35 F 57 
27 M 842 
27 F 681 + 
25 F 844 + 
30 M 42 
51 F 160 + + 
30 M 1 + 
42 F 328 + 
35 M 356 + 
28 F 423 
28 M 860 
70 M 100 + 
57 M 530 + 
28 M 90 + 
27 F 464 + 
37 M 80 
29 F 252 
47 M 518 
19 F 253 + + 
31 F 10 
34 F 110 
20 F 26 
36 F 129 + 
26 M 7 
32 F 85 
27 M 968 
27 M 520 
30 F 375 
31 F 149 
37 M 105 
43 M 136 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
w V IgG 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
PCR Type 
Group Sample Age Sex CD4 HA PP MCF CV F W V IgG PCR Type 
G5 E06-322 24 F 298 + + + 
G5 E06-323 45 F 404 + + + 
G5 E06-324 33 F 307 + + 
G5 E06-325 30 F 799 + 
G5 E06-326 24 F 397 + + 
G5 E06-327 37 M 117 
G5 E06-328 24 F 623 + 
G5 E06-329 29 F 450 + + 
G5 E06-330 SO M 585 + 
G5 E06-331 44 M 9 + 
G5 E06-332 30 F 26 
G5 E06-333 52 F 218 
G5 E06-334 25 F 655 
G5 E06-335 23 F 600 + + + 
G5 E06-336 31 M 343 + 
G5 E06-337 77 M 276 + + 
G5 E06-338 24 F 26 
G5 E06-339 46 F 263 + + 
G5 E06-340 36 F 5 + + + 
G5 E06-341 48 F 244 + + + 
G5 E06-342 25 F + 
G5 E06-343 22 F 894 
G5 E06-344 30 F 8 + + 
G5 E06-345 29 F 165 + 
G5 E06-346 27 F 481 
G5 E06-347 54 F 225 + 
G5 E06-348 27 F 769 + 
G5 E06-349 26 F 326 
G5 E06-350 35 F 438 + 
G5 E06-351 18 F 1008 + 
G5 E06-352 42 F 747 + 
G5 E06-353 23 M 602 + + 
G5 E06-354 33 F 710 
G5 E06-355 26 F 450 + + 
G5 E06-356 30 M 583 + + 
G5 E06-357 42 M 152 + 
G5 E06-358 SO F 759 + 
G5 E06-359 30 F 142 + + 
G5 E06-360 31 M 278 + + + 
G5 E06-361 45 F 378 + + 
G5 E06-362 28 F 190 + + 
G5 E06-363 30 F 522 + 
G5 E06-364 22 F 6 + 
G5 E06-365 27 M 150 
GS E06-366 28 F 126 + + 
GS E06-367 31 F 215 + 
GS E06-368 40 F 423 + 
GS E06-369 22 F 105 + 
GS E06-370 42 M 136 + 
Appendix 4. Chicken genotyping studies 
N Seropos (%) Isolates Genotyping Type I Type II Type III Atypical Multiple Reference (% markers 
Europe and USA 1284 411 (32) 114 0% 82% 16% 2% 0% 
Austria 830 302 (36) 67 SAG2 67 Dubey et al. 2005a 
Italy 80 11 (14) 3 10 RFLP 3 Dubey et al. 2008a 
Poland 20 6 (30) 2 10 RFLP 2 Dubey et al. 2008! 
Portugal 225 61 (27) 12 SAG2 8 4 Dubey et al. 2006e 
USA (Illinois) 11 11 (100) 11 11 RFLP 11 Dubey et al. 2007e 
USA (Ohio and Mass.) 118 20 (17) 19 SAG2 5 14 Dubey et al. 2003c 
Central and South America 1508 714 (47) 568 13% 7% 24% 54% 1% 
Argentina (La Plata) 29 19 (65) 9 SAG2 1 1 7 Dubey et al. 2003e 
Argentina (Santiago) 61 25 (41) 17 SAG2 4 3 10 Dubey et al. 2005t 
Brazil (Minas Gerais) 28 15 (54) 18 SAG2 17 1 Brandao et al. 2006 
Brazil (Amazon) 50 33 (66) 24 SAG2 14 10 Dubey et al. 2006! 
Brazil (Rio Grande do Sui) 50 19 (38) 19 11 RFLP 19 Dubey et al. 2007b 
Brazil (Para) 34 2059) 15 11 RFLP 15 Dubey et al. 2007b 
Brazil (Parana) 40 16 (40) 13 SAG2 7 6 Dubey et al. 2003d 
Brazil (Rio de Janeiro) 198 129 (65) 48 SAG2 34 13 1 Dubey et al. 2003a 
Brazil (Sao Paulo) 82 33 (40) 21 SAG2 13 8 Dubey et al. 2002 
Brazil 13 states, retyping 151 10 RFLP 1 5 143 2 Dubey et al. 2008b 
Chile 85 47 (55) 21 5RFLP 17 3 1 Dubey et al. 2006b 
Colombia 77 32 (42) 24 SAG2 7 17 Dubey et al. 2005b 
Costa Riea 144 60 (42) 32 5RFLP 5 1 26 Dubey et al. 2006e 
Grenada 102 53 (52) 36 SAG2 5 1 29 1 Dubey et al. 2005h 
Guatemala 50 37 (74) 8 SAG2 3 5 Dubey et al. 2005e 
Guyana 76 50 (66) 35 11 RFLP 2 33 Dubey et al. 2007a 
Mexico 208 13 (6) 6 SAG2 1 5 Dubey et al. 2004b 
Nicaragua 98 84 (86) 48 5 RFlP 6 3 6 29 4 DlJl:>ey et al. 2006d 
N Seropos (%) Isolates Genotyping Type I Type II Type III Atypical Multiple Reference (% markers 
Peru 50 13 (26) 10 SAG2 7 3 Dubey et al. 2004a 
Venezuela 46 16 (35) 13 SAG2 3 10 Dubey et al. 2005d 
Asia 524 143 (27) 13 0% 38% 46% 15% 0% 
Indonesia 94 24 (26) 1 10 RFlP 1 Dubey et al. 20081 
Sri lanka 100 39 (39) 11 SAG2 5 6 Dubey et al. 2005g 
Vietnam 330 80 (24) 1 10 RFlP 1 Dubey et al. 2008! 
North Africa/Middle East 262 117 (45) 44 0% 45% 55% 0% 0% 
Egypt 121 49 (41) 19 SAG2,10 RFlP for 7 3 16 Dubey et al. 2003b, 
samples Velmurugan, 2008 
Iran 45 23 (51) 6 GRA6 seq 6 Zia-Ali et al. 2007 
Israel 96 45 (47) 19 SAG 2 17 2 Dubey et al. 2004e 
Sub-Saharan Africa 311 75 (24) 20 5% 15% 65% 15% 0% 
Burkina Faso 40 0(0) 1 10 RFlP 1 Dubey et al. 2005e, Velmurugan, 2008 
25 (50) SAG2,10 RFlP for 5 1 8 Dubey et al. 2005, Congo 50 10 
sample 1 Velmurugan, 2008 
Ghana 64 41 (64) 2 10RFlP 2 Dubey et al. 2008a 
Kenya 30 4 (13) 1 10 RFlP 1 Dubey et al. 2005e, Velmurugan, 2008 
Mali 48 0(0) 5 SAG2,10 RFlP for 4 1 4 Dubey et al. 2005e, 
samples Velmurugan, 2008 
5 (6) 1 Velmurugan et al. Nigeria 79 1 10 RFlP 2008 
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Appendix 5. Chicken samples and serology results 
Chickens were pooled according to their serological titre. Seronegative chickens were pooled in 
groups of lS and fed to three cats, none of which shed oocysts or seroconverted. For simplicity this 
has been omitted from the table. 
Sample No Site Sex Age group MAT titre PCR+bioassay 
Ch-1 Gayaza F 3 1:80 Ch-1 
Ch-2 Gayaza M 4 1:40 Ch-2 
Ch-3 Gayaza M 3 0 
Ch-4 Gayaza M 3 0 
Ch-5 Gayaza F 4 1:5 Pool5A 
Ch-6 Gayaza F 4 1:10 Pool lOA 
Ch-7 Gayaza M 2 1:10 Pool lOA 
Ch-8 Gayaza M 2 1:5 Pool5A 
Ch-9 Gayaza M 2 0 
Ch-10 Gayaza F 1 0 
Ch-ll Gayaza M 1 1:5 Pool5A 
Ch-12 Gayaza F 2 1:5 Pool SA 
Ch-13 Gayaza F 2 0 
Ch-14 Gayaza F 1 1:10 Pool lOA 
Ch-1S Gayaza F 1 1:40 Ch-1S 
Ch-16 Gayaza M 4 0 
Ch-17 Gayaza F 2 1:160 Ch-17 
Ch-18 Gayaza M 1 0 
Ch-19 Gayaza M 3 1:5 Pool SA 
Ch-20 Gayaza F 1 1:20 Ch-20 
Ch-21 Gayaza F 3 1:10 Pool lOA 
Ch-22 Gayaza F 3 1:10 Pool lOB 
Ch-23 Gayaza M 3 0 
Ch-24 Gayaza M 4 0 
Ch-25 Gayaza F 1 1:20 Ch-25 
Ch-26 Buloba M 1 0 
Ch-27 Buloba M 1 0 
Ch-28 Buloba F 2 0 
Ch-29 Buloba M 1 0 
Ch-30 Buloba F 1 1:10 Pool lOB 
Ch-31 Buloba F 1 0 
Ch-32 Buloba M 3 0 
Ch-33 Buloba M 1 0 
Ch-34 Buloba M 1 0 
Ch-35 Buloba M 1 0 
Ch-36 Buloba M 1 0 
Ch-37 Buloba M 1 0 
Ch-38 Buloba M 1 0 
Ch-39 Buloba F 3 0 
Ch-40 Buloba M 1 0 
Ch-41 Buloba F 1 0 
Sample No Site Sex Age group MAT titre PCR+bioassay 
Ch-42 Buloba M 1 l:S PoolSB 
Ch-43 Buloba M 1 0 
Ch-44 Buloba F 1 0 
Ch-4S Buloba M 2 0 
Ch-46 Buloba F 3 0 
Ch-47 Mukono M 3 l:S PoolSB 
Ch-48 Mukono M 3 0 
Ch-49 Mukono M 3 0 
Ch-SO Mukono F 3 0 
Ch-S1 Mukono F 2 0 
Ch-S2 Mukono M 3 1:40 Ch-S2 
Ch-S3 Mukono M 4 l:S PoolSB 
Ch-S4 Mukono M 3 0 
Ch-SS Mukono F 1 1:20 Ch-SS 
Ch-56 Mukono F 4 1:10 Pool lOB 
Ch-57 Mukono F 3 0 
Ch-58 Mukono M 2 1:40 Ch-58 
Ch-S9 Mukono F 4 1:10 Pool lOB 
Ch-60 Mukono F 3 0 
Ch-61 Mukono F 4 1:40 Ch-61 
Ch-62 Mukono F 4 1:20 Ch-62 
Ch-63 Mukono F 3 0 
Ch-64 Mukono F 1 1:320 Ch-64 
Ch-65 Mukono F 3 1:5 Pool5B 
Ch-66 Mulago F 4 0 
Ch-67 Mulago F 4 0 
Ch-68 Mulago M 3 1:40 Ch-68 
Ch-69 Mulago F 2 0 
Ch-70 Mulago F 4 1:40 Ch-70 
Ch-71 Mulago M 3 0 
Ch-72 Mulago M 1 1:10 PooI10C 
Ch-73 Mulago F 1 1:40 Ch-73 
Ch-74 Mulago F 2 1:10 PooI10C 
Ch-7S Mulago F 3 1:10 PooI10C 
Ch-76 Mulago M 3 0 
Ch-77 Mulago M 2 0 
Ch-78 Mulago M 3 1:20 Ch-78 
Ch-79 Mulago M 3 1:40 Ch-79 
Ch-80 Mulago M 3 0 
Ch-81 Mulago M 3 1:40 Ch-81 
Ch-82 Mulago M 3 1:40 Ch-82 
Ch-83 Mulago M 3 1:40 Ch-83 
Ch-84 Mulago M 3 0 
Ch-85 Mulago M 3 0 
Appendix 6. Rodent samples and serology results 
Rodents were bioassayed and pooled according to their serological titre, but in 2007 no bioassay was 
performed since all samples were negative. 
Sample no Year MAT-titre PeR/bioassay 
Rat-1 2006 0 PoolRA 
Rat-2 2006 160 Rat-2 
Rat-3 2006 0 PoolRA 
Rat-4 2006 0 PoolRA 
Rat-S 2006 40 Rat-S 
Rat-6 2006 0 PoolRA 
Rat-7 2006 0 PoolRB 
Rat-8 2006 0 PoolRB 
Rat-9 2006 0 PoolRB 
Rat-10 2007 0 Serology only 
Mouse-1 2006 0 PoolM 
Mouse-2 2006 0 Pool M 
Mouse-3 2006 0 PoolM 
Mouse-4 2006 0 Pool M 
Mouse-S 2006 0 PoolM 
Mouse-6 2007 0 Serology only 
Mouse-7 2007 0 Serology only 
Mouse-8 2007 0 Serology only 
Mouse-9 2007 0 Serology only 
Appendix 7. Location 0/ new SNPs detected by direct sequencing 
Novel or unusual allelic variants detected through direct sequencing of chicken tissue samples are marked with grey boxes. In SAGl 
the parasites in Ch-70 had the u-l allele, which is similar to type I at one position and II and III at another. The Ch-2S parasites had 
one new allele for SAG!, but were otherwise like type I. Ch-83 had one new allele at SAG2-3' and Ch-70 had three novel SNPs for the 
SAG3 sequence. 
SAG! 
Ch-25 
Ch-70 
GT-1 
Me49 
VEG 
Ch-25 
Ch-70 
GT-1 
Me49 
VEG 
Ch-25 
Ch-70 
GT-1 
Me49 
VEG 
10 20 30 40 50 60 70 80 90 100 
••• • 1 •••• 1 •••• 1 •.•• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 
CAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCACTGTTCTCGGCAAGGGCCGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGTTGTGC 
CAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCGCTGTTCTCGGCAAGGGC~GACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGCTGTGC 
CAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCACTGTTCTCGGCAAGGGCCGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGTTGTGC 
CAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCGCTGTTCTCGGCAAGGGCTGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGCTGTGC 
CAATGTGCACCTGTAGGAAGCTGTAGTCACTGCTGATTCTCGCTGTTCTCGGCAAGGGCTGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGCTGTGC 
110 120 130 140 150 160 170 180 190 200 
••• • 1 •••• 1 •••• I •••• 1 •••• 1 •••• 1 •••• I •••• I •••• 1 •••• 1 •••• 1.· •• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 
AGCTTTCCGTTCTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTTT 
AGCTTTCCGTTGTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTTT 
AGCTTTCCGTTCTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTTT 
AGCTTTCCGTTGTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTTT 
AGCTTTCCGTTGTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGTATGTCGGTTTCGCTGCACCACTTCATTATTTCTTCTGGTTT 
210 220 230 240 250 260 270 280 290 300 
•••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 •••• 1 
TTTGACGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACTGATGTCGTTCTT~GATGTGGCGTTATGGCA 
TTT~CGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACTGATGTCGTTCTTGCGATGTGGCGCTATGGCA 
TTTGACGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACTGATGTCGTTCTTGCGATGTGGCGTTATGGCA 
TTTGGCGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACTGATGTCGTTCTTGCGATGTGGCGCTATGGCA 
TTTGGCGAGTATGTTTCCGAAGGCAGTGAGACGCGCCGTCACGGCAGGGGTGTTTGCCGCGCCCACACTGATGTCGTTCTTGCGATGTGGCGCTATGGCA 
Appendix B. Parasite density in mouse organs 
Mouse Brain Heart Muscle Lung 
TgCkUgl m34 27,383 78 1,911 5 
(II) m35 (tr) 354,404 160 0 38 
m36 (tr) 17,855 52 597 14 
average 133,214 97 836 19 
TgCkUg2 m6 168,779 14,594 43,914 108 
(II/III) m8 2,285,529 3,327 217,195 103 
average 1,227,154 8,960 130,554 106 
TgCkUg3 m38 12,690 16 2 0 
(II) m47 (tr) 234,607 140 67 65 
m48 (tr) 136,235 566 1 10 
average 127,844 240 23 25 
TgCkUg5 m41 92,615 39 0 0 
(II) m53 (tr) 16,242 1,150 0 27 
m54 (tr) 541,394 276 1 0 
average 216,750 488 0 9 
TgCkUg6 m40 7,697,924 306,000 0 244 
(III) m51 (tr) 4,614,821 56,553 1,006,725 487 
m52 (tr) 1,252,527 7,181 6,224 2 
average 4,521,757 123,245 337,650 244 
TgCkUg7 m42 8,007 0 146 0 
(II) m55 (tr) 444,171 853 2,122 0 
m56 (tr) 82,689 3,280 206 597 
average 178,289 1,378 825 199 
TgCkUg8 m43 15,503 0 5,703 0 
(II) m57 (tr) 51,014 86 559 2 
average 33,258 43 3,131 1 
TgCkUg9 m44 61,775 1,597 0 41 
(II) m59 (tr) 433,236 1,761 129,121 0 
m60 (tr) 60,024 483 3,548 262 
average 185,012 1,280 44,223 101 
Appendix 9. FASTA contig output example 
Sample of output file, showing data for 3 of the 67,013 contigs. 
>contig25406 VI, 3599926 .. 3600620 length=694 numreads=16 
GTTTAGGAAGAAAAAGTAGGAaCATTACTCCGTGTGTTCTATAGAGGTTGTGCGTGCATG 
GTTGCACTGGCTGAGCCATGACACGGCAGGGgACGCCTCAGTGAACGGTTCCTCCCAACG 
TCCCCGTGATCGGTGTGAGGATCTCGCGTCTTACAAAGGCCCACGAATGAGGGAACCCTG 
TGGgCGCCCATCACCAATGTAGTACTGGGGCACACTGACAAAACGTCTACGCCCGCGCAT 
GTGACGGgACGTTTTGTCCGGAAACCATCGGgCAAGTCATCAACTGTTTCCTCtCACGAA 
AAAGAAAAaGAAACGTAaTGgCTTGTTCACATGAACCAATCACCAGCGAACGCTGgTCTG 
TGTGCAGCTGCAATGTTGAAAGCGGAGGAGAATGCAGCGGCGTCTGCGCGTTGCTTGAGA 
TGGCGGCTCGGGTTCaGaGCTGGACTCCACTAATAGTATTTTTCACTCTGGTTTTTGTAT 
GTCATACGTTTCGAGAGTGCGGGTGTGTGGCTATCGCCAAACCCGTGTGTTCGCCTTGGC 
TGGCAGGATATCTCCGCTCAGCCTCGACCAGGGGCATCGATGGGCCTCTTTACCCCTTGA 
ACGAGGACCCTAATCTGTTCGGGcgcagaaggggtgttttccgtagtgccaatgcgtctg 
cgactatagctagcttggatgtcgaggagtttcg 
>contig25407 VIla, 28 .. 2058 length=2027 numreads=113 
ccgccgcctcaacagagtcgtcgtgTcTTCGCTTCCCACTCGgAGACTCAAGTCCGCACC 
CGCGCCCCGTGGATGGATGGACGACTAGCGGATCGACCGCCCGCGAACGCAGACAAACAG 
TACGCAGAACGTGCACCCGCCGTCCGACGATACACGCGAcACCTGAGCCAAGCCGCCAAA 
ACGCGACAACCAGTCGCACCACGATCCCCGACGTCGACTCCAGCGACACCCTACTCAGGA 
CGATGCCCCTCGTGTAACTCCCGATTCACCCTCCGAACCCGTCGACCAATCGTCGTGGCC 
ACTCAGGCCACGTCCCCCGACATCCTCAGACACGAGTAgCACATCGCACCGCTGCCTCCC 
GTCACGGTCTCGCGTACCGGCTCCACCTGTCGCAGACGCCACGACGTCGCCTCAAACGTA 
GGAGGGCCAGCCAGCTCGTGCCGCCGCCAATGCGTACCTGCGACCTCCGACGTCGTTCCC 
TGGCGCTCCTTCGCAACTCATGTCTGCACAGTGCATTCGCCGCCCGACCTACAAGTGGCC 
CCCCGACCTCCACATACCTCACGACCACATCTGCcTTCACTCCCATGTGCCGCGTCCATT 
CTCTGCACGTCTCCTCCTCCTCGCCGCCAACTCCCCACAGACCACCCCTCATGCAAACCA 
AACCTGACCCACTAGAAACACAACGCAACAGCCGCCCACCAGATCcATCCGTCGTCCGCA 
GGGTCACTCACCGACtGTTCaCAAaGaaaaaaCACeAAACACAGTGACGAGTCAAATCGT 
CCTCAACCCTGTCACCACCCACGCCTTCCCACGTACTTCCGACGCATTCCGCAAGCCGCG 
ACCCCCTCACCGCCATCACGCGACACCGGTCTGTGGCCGGGACACCGTCGCCCCGGCATT 
AGGCTCCCGCGCCGCTCCTGGATCACCTCCGCCGCCTCAACAGAGTCGTCGTGTCTTCGC 
TTCCCACTCGGAGACTCAAGTCCGCACCCGCGCCCCGTGGATGGATGGACGACTAGCGGA 
TCGACCGCCCGCGAACGCAGACAAACaGTACGCAGAACGTGCACCCGCCGTCCGACGATA 
CACGCGACACCTGAGCCAAGCCGCCAAAACGCGAAAACcAGTCgCACCACGATCCCCGaC 
GTCGACTCCAGCGACACCCTACTCAGGACGATGCCCCTCGTGTAACTCCCGATTCACCCT 
CCGAACCCGTCGACCAATCGTCGTGGCCACTCAGGCCACGTCCCCCGACATCCTCAGACA 
CGAGTAACACATCGCACCGCTGCCTCCCGTCACggtctcgcgtaeeggctccacctgtcg 
cagaCGCCACGACGTCGCCTCAAACGTAGGAAAGCCAGCCAGCTCGTGCCGCCGCCAATG 
CGTACCTGcgacctccgacgtcgttcectggcactccgtegcacetcatgtctgcacagt 
gcattcgecgceegacetaeaagtggccceccgacetecacataccteacgaccacatet 
gccttcacteecatgtgccgcgtceattctctgcacgtctcctccacctcgccgccaacT 
CCCCACAGaccacccctcatgcaaaccaaacctgacccactagaaacacaacgcaacagc 
cgcccaccagatccatccgtcgtccgcagggcactcaccgactgttcacaaagcaccaaa 
cacagtgacgagtcaaatcGTCCTCAACCCTGTCACCACCCACGCCTTCCCACGTACTTC 
CGACGCATTCCGCAAGCCGCGACCCCCCTCACCGCCATCACGCGACACCGGTCTGTGGCC 
GGGACACCGTCGCCCCGGCAGTAGGCTcccgcgccgctcctggatcacctccgceGCCTC 
AACAGAGTCGTCGTGTCTTCGCTTCCCACTCGGAGATACAAATCCCTACCTGCACCCCGT 
GGAGGGATAGAAGACTAGCGAGTGGACTACACGCCAACGTAGAATCGCACTatgccgtca 
cagttaccgtcgctgcgcgcgtgatctgtttgtctaagtttagtaag 
>contig25408 VIla, 2143 .. 2841 length=698 numreads=5 
cgcagctgactgaggtGGAGTCGCACAATAAACCCTCGGTGTTGCGACTGCAACGTTAAG 
ACATTCTACATCCCGCACTTACGGGAGTGTCCTGGATGATTGTCGCGACGAGACGTCAAC 
CAAACCaCGAGTCAcTGgTAgCTTGAGTGATTCTTTGCCCACTTACgTTGGGGGGTTGTT 
tAtCCCATCaTCGGTGtGAGcTgCCAACGAcGTGGCgACCCAAAGATGAGtCTTCTTeGG 
CATGAGGTTCCTGAGCTTCAAAAATTCAACACGACACTTGCAGAAGTGTTGCTCTGGTGC 
TGGATCACTCACGACGCTCTCAAACGATATGATCTGGGTCGGCCAGGCGAACCAATCAAT 
TTTTGAGTatgactgtttgtaatgtactgaatacattcagtatttegtgatacagcagca 
agcacttccgtacgcaatcacgctattAAAAACATTGacccaatcatcATTTgcttgtgg 
ctggttttgagatgttgccgagtgcggagatccatcttgtacagttggctgtctgccagt 
ctcgacatattgggcctccgtccatagaeacaccgtgtttacgccgtgtacattgttctt 
ggagaagcgcgttttggcgttatgagtcagaaaaacagcaaaatgcagcgctaccttccc 
gtttggtaccaccagaaactgcaccagtccgcctgccg 
Appendix 10. Examples 0/ valid and invalid SNP calls 
Example of a valid SNP call, where 7+7 reads are in agreement and no discordant reads were found (100% concordant reads). 
Reference 
Accno 
>Ia 
Reads with Difference: 
Ia 
E5TZWM301DILQP 
E5GlLZ402IYlOB 
E5TZWM302JFG7B 
E5GlLZ401BIFWI 
E47S0TK01CRYNG 
E5G1LZ401A4CEV (2) 
E5G1LZ402IKT4C 
E47S0TK01C6ZKR 
E5GlLZ402I1A04 
E5GlLZ401BEFOJ 
E5TZWM302FOM05 
E5G1LZ402GWVA3 
E47S0TK02GTOK7 
E5TZWM301DMQBA 
Other Reads: 
Variation 
Start End Seq 
Pos Pos 
34 34 G 
Seq 
A 
Frequency 
#fwd #rev #Var #Tot (%) 
7 7 14 14 100 
7+ GCA-CTGTATTGA-GTACGAGTG-AATCTT-GCA-TGT-GCGTGCGACGATGACGCG-AGTG 61 
** 
120- GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 66 
139- GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 85 
116+ GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 170 
148- GCA-CTGTATT-AAGTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 94 
13+ GCAACTGTATTGA-GTACGAGTGCA-TCTTA-CA-TGTA-CGTGCGACGATGACGCGG-GTG 68 
66+ GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 120 
44+ GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 98 
219- GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 165 
219- GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 165 
21+ GCA-CTGTATTGA-GTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 75 
227- GCA-CTGTATTGA-GTACGAGTGCA-TCTTA-CA-TGTA-CGTGCGACGATGACGCGG-GTG 173 
5+ GCA-CTGTATT-AAGTACGAGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 59 
1+ AGTG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 38 
254- TG-AATCTTA-CAC-GTA-CGTGCGACGATGACGCGG-GTG 219 
** 
Example of an invalid SNP call, where 3+2 reads are in agreement, but 15 discordant reads were found (25% concordance). 
Reference 
Accno 
>Ia 
Reads with Difference: 
Ia 
E5GlLZ401BIFWI 
E5GlLZ402GWVA3 
E47S0TK02F8I7D 
E5TZWM302FFMOQ 
E5TZWM302GJ291 
Other Reads: 
E5TZWM301DILQP 
E5GlLZ402IYlOB 
E5TZWM302JFG7B 
E47S0TK01CRYNG 
E5G1LZ401A4CEV (2) 
E5GlLZ402IKT4C 
E47S0TK01C6ZKR 
E5G1LZ402I1A04 
E5GlLZ401BEFOJ 
E5TZWM302FOM05 
E47S0TK02GTOK7 
E5TZWM301DMQBA 
E47S0TK02G69A6 
E5TZWM301BHM51 
E47S0TK01DOE4H 
Variation 
Start End Seq 
Pas Pas 
85 85 G 
Seq 
C 
Frequency 
'fwd frev 'Var 'Tot (%) 
3 2 5 20 25 
55+ GCG-AGTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATCGA-CTC-GTCTATT 115 
******* 
100- GCGG-GTGCGGGAGAGCAAAGCTCTACCATGCGGG--AC-AAAACAAAGCATC-AACTC-GTCTATT 40 
53+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATGCGGG--AC-AAAACAAAGCATC-AACTC-GTCTATT 113 
23+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATGCGGG--AC-AAAACAAAGCATCGA-CTCC-TCTATT 83 
254- CTCTACCATGCGGG--AC-AAAACAAAGCATC-AACTC-GTCTATT 214 
1+ TACCATGCGGG--AC-AAAACAAAGCATC-AACTC-GTCTATT 38 
******* 
******* 
72- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 12 
91- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 31 
164+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 224 
62+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 122 
114+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 174 
92+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 152 
171- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 111 
171- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GACGAAAACAAAGCATC-AACTC-GTCTATT 110 
69+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 129 
179- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 119 
32+ GCGG-GTGCGGGAGAGCAA-GCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 91 
225- GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 165 
4+ GCGG-GTGCGGGAGAGCAAAGCTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 64 
252- CTCTACCATG-GGG-GAC-AAAACAAAGCATC-AACTC-GTCTATT 212 
248- TACCATG-GG-NGACGAAAACAAAGCATC-AACTC-GTCTATT 210 
******* 
Appendix 11. SNP distribution and correlation with SNPs in the three reference strains 
Overlay pictures for all chromosomes showing the match between SNP data forTgCkUg2 and the dominant SNP type from the comparison 
between GTl (I), Me49 (II) and VEG (III) . The underlying figures show SNPs for TgCkUg2 against Me49 (a type II strain) and/o r VEG (a type III 
strain). Green depicts a type II background genotype in TgCkUg2 (TgCkUg2 = Me49, but different from VEG), a type III background is shown in 
blue (TgCkUg2 = VEG, but different from Me49) and novel SNPs are orange (TgCkUg2 is different from both Me49 and VEG) . The overlying grey 
lines were created by looking for SNPs between GT1, Me49 and VEG at each position along the chromosome length . There is no change on the 
Y-axis for type I SNPs (where GT1 has the divergent base), but the line rises (+1) for every type II SNP and falls (-1) for type III SNPs (this scale is 
not shown in these graphs, but is depicted in Figure 5-10). These graph show a clear correlation between type I dominated areas (flat lines) and 
regions scarce in SNPs in TgCkUg2. 
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